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The immunoreceptor NKG2D recognizes ligands that are upregulated 
on infected cells and tumor cells. The expression of NKG2D ligands is 
induced by the DNA damage response (DDR), which is often constitutively 
active in tumor cells. We found that DDR-induced NKG2D ligand expression 
depends on the DNA sensor pathway initiated by STING, TBK1 and IRF3. 
Cytoplasmic DNA accumulated in response to DNA damage and was also 
detected in tumor cell lines that constitutively express NKG2D ligands. 
Transfection of DNA into ligand-negative cells was sufficient to induce 
NKG2D ligand expression. Our results suggest that genomic damage in tumor 
cells results in the activation of Sting-dependent nucleic acid sensor pathways, 
leading to expression of NKG2D ligands, and enabling tumor 
immunosurveillance. To investigate the exact DNA sensor that might be 
involved, we cross mice deficient in Zbp1 (Z-DNA-binding protein 1), which 
is a type I IFN-inducible candidate cytosolic DNA sensor, to the Eµ-Myc 
mice. Surprisingly, the survival of Eµ-Myc mice was increased in absence of 
ZBP1. The DDR response was enhanced in tumor cells of Zbp1-deficient Eµ-
Myc mice, resulting to an increase in apoptosis. Our data suggest a novel 
function for ZBP1 in Eµ-Myc mouse model. 	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Chapter 1: Introduction 
 2 
1. Introduction  
In addition to cell intrinsic barriers to tumor formation mediated by 
tumor suppressors such as p53, the immune system has also been implicated in 
tumor surveillance in several settings. The various modes of tumor cell 
recognition by the immune system are topics of intense interest. Optimal 
immune responses to autologous cells generally only occur when the cells are 
first exposed to pathogen-associated molecular patterns, or when the cells are 
subjected to disease related stress. In infections, such signals often emanate 
from various pattern recognition receptors (PRR) such as toll-like receptors 
(TLRs) and numerous intracellular sensors that detect viral or microbial DNA 
and RNA in the cytoplasm. The initial recognition of cancer cells, on the other 
hand, is thought to require the activation of pathways triggered by disease-
associated stress. This study examines interactions between these modes of 
signaling. 
1.1 DNA damage response (DDR) 
1.1.1 Overview of the DNA damage response (DDR) 
The DNA damage response (DDR) is a signal-transduction pathway 
that directs cell-cycle transitions, DNA replication, DNA repair and apoptosis. 
The major regulators of the DDR are the phosphoinositide 3-kinase (PI3K)-
related protein kinases (PIKKs), including ataxia-telangiectasia mutated 
(ATM) and ATM and RAD3-related (ATR). ATM and ATR have similar 
biochemical and functional characteristics. Both are large kinases with 
significant sequence homology and tend to phosphorylate Ser or Thr residues 
that are followed by Gln. Both phosphorylate an overlapping set of substrates 
that results in cell-cycle arrest and DNA repair. 
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The ATM and ATR kinase are activated by different genomic insults. 
ATM kinase is preferentially activated by DNA double strand breaks (DSB) 
while ATR kinase, is generally activated by stalled replication forks that occur 
during DNA replication. In addition, it has been demonstrated that ATR 
kinase is activated by ultraviolet light, single strand DNA breaks, and 
chemical agents that interrupt DNA replication and give rise to stalled 
replication forks. 
 The DNA damage sensors, the MRE11–RAD50–NBS1 (MRN) 
complex that detects DNA double-strand breaks (DSBs) or replication protein 
A (RPA) and the RAD9–RAD1–HUS1 (9-1-1) complex that detects exposed 
regions of single-stranded DNA, enlist ATM (through the MRN complex) and 
ATR (through RPA and the 9-1-1 complex), which is bound by ATR-
interacting protein (ATRIP) upon sensing damaged DNA (Figure 1.1).These 
would then phosphorylate (P) the histone variant H2AX on Ser139 (known as 
γH2AX) in the region proximal to the DNA lesion (Stiff et al., 2004; Ward 
and Chen, 2001). γH2AX is crucial to recruit mediator of DNA damage 
checkpoint 1 (MDC1) that further maintains and amplifies DDR signalling by 
promoting further build up of the MRN complex and activation of ATM. 
BRCA1 is recruited at sites of DNA damage on phosphorylation by ATM and 
ATR. Many of the recruited proteins as well as the core histones at the 
position of the breaks, undergo extensive post-translational modifications 
(PTMs; including phosphorylation, ubiquitylation, sumoylation, acetylation, 
methylation and poly (ADP)-ribosylation) (Polo and Jackson, 2011).  Finally, 
DDR signalling would move away from the damaged locus due to the 
activation of diffusible kinases CHK2 (which is mainly phosphorylated by 
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ATM) and CHK1 (which is mainly phosphorylated by ATR) with converging 
signalling on downstream effectors such as p53 and the cell division cycle 25 
(CDC25) phosphatases. Depending on the extent of genomic damage, DDR-
mediated cellular outcomes may be cell death by apoptosis; transient cell cycle 
arrest followed by repair of DNA damage and continuation of proliferation; or 
cellular senescence caused by the persistence of unrepaired DNA damage.  
 
Figure 1.1 Overview of the DNA damage response (DDR). 
The DDR pathway consists of two main DNA damage sensors that would 
recruit the apical kinases ataxia-telangiectasia mutated (ATM) and ataxia 
telangiectasia and RAD3-related (ATR), which is bound by ATR-interacting 
protein (ATRIP) in response to genomic insults. These in turn phosphorylate 
(P) the histone variant H2AX on the chromatin surrounding the DNA breaks. 
ATM and ATR would phosphorylate the downstream kinases such as CHK2 
and CHK1, which would in turn activate downstream effectors such as p53 
and the cell division cycle 25 (CDC25) phosphatases. DDR-mediated cellular 
outcomes may be cell death by apoptosis; cell cycle arrest followed by repair 
of DNA damage; or cellular senescence. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Cancer publication(Sulli et al., 




1.1.2 Overview of ataxia-telangiectasia mutated (ATM) 
ATM is a large protein with a molecular weight of 350 kDa and 
consists of 3,056 residues. The carboxy-terminal active site of ATM contains a 
PI3K domain, which constitutes about 10% of this large protein. The rest of it 
most probably contains regulatory and interaction domains that determine its 
modes of activation and broad substrate specificity. Other important sites are 
those that undergo posttranslational modifications during ATM activation 
(Figure 1.2). The lack of structural data due to technical challenges in ATM 
crystallization is currently obstructing the understanding of the functional 
significance of ATM domains. 
 
The  
The physiological consequences of loss of ATM as opposed to having 
inactive ATM may not be the same from evidence using mice with different 
Atm mutations (Choi et al., 2010). Atm-knockout mice display characteristic 
traits of ataxia-telangiectasia with the exception of neurodegeneration and 
hence portray a relatively moderate phenotype (Barlow et al., 1996; 
Borghesani et al., 2000; Elson et al., 1996; Xu et al., 1996). Strikingly, mice 
Figure 1.2 Schematic representation of ATM with its major domains.  
The sites of posttranslational modifications link to ATM activation in various 
situations and the proteins responsible for these modifications, including ATM 
itself (see text for details), are indicated. Ac, acetylation; FATC, FAT 
carboxy-terminal; NLS, nuclear localization sequence; P, phosphorylation; 
ROS, reactive oxygen species; S-S, disulphide bridge. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular 
Biology (Shiloh and Ziv, 2013), copyright 2013. 
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producing physiological levels of catalytically inactive (kinase-dead) ATM 
were embryonic lethal and conditional expression of the mutant protein in the 
immune system caused significant genomic instability in lymphoid cells 
(Daniel et al., 2012; Yamamoto et al., 2012). The mechanistic explanations are 
not available, but one hypothesis could be that as kinase-dead ATM was 
recruited to DSB sites, the presence of catalytically inactive ATM within the 
DDR network proximal to these sites harshly affects the damage response 
pathway. These studies clearly show that the presence of the inactive form of 
ATM severely affects the cellular response to genotoxic stress more than its 
loss. 
ATM assembles and coordinates the huge array of DSB response 
proteins in response to induction of acute DNA damage. ATM phosphorylates 
and thus regulates the activity of several protein kinases, which in turn 
phosphorylate their own substrates. A map containing the functional links of 
ATM to effectors that have been documented in detail are shown in (Shiloh 
and Ziv, 2013). However, proteomic screens point to hundreds more potential 
ATM substrates (Bensimon et al., 2010; Matsuoka et al., 2007; Mu et al., 
2007). This huge array of downstream effectors is not common when 
compared with the most diversified protein kinases and questions whether 
ATM is a promiscuous or specific protein kinase.  
1.1.3 Overview of the DNA repair pathways 
Damage to DNA could trigger specific repair pathways depending on 
the type of lesions and the stage of the cell cycle (Figure 1.3).  
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Figure 1.3 Overview of the DNA repair pathways.  
DNA can undergo various lesions, from single-strand breaks (SSBs) to base 
alkylation events, which would be repair by specific repair factors. The important 
proteins involved in each DDR mechanism, the tumour types usually characterized by 
DDR defects and the drugs that target these defects are shown. BER, base excision 
repair; NER, nucleotide excision repair; NHEJ, non-homologous end-joining. 
Reprinted by permission from Macmillan Publishers Ltd: Nature(Lord and Ashworth, 
2012) ,copyright 2012. 
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1.1.3.1 Base Excision Repair (BER) 
Most of the slight changes to DNA, such as oxidative lesions, 
alkylation products and single-strand breaks (SSBs), are repaired through a 
series of processes that is known as base excision repair (BER). In BER, 
damaged bases are first cut out from the double helix, and the damaged region 
of the DNA backbone is then cleaved and substituted with newly synthesized 
DNA (Figure 1.4) (David et al., 2007; Sancar et al., 2004b). DNA glycosylase 
is responsible for recognizing oxidized/reduced bases, alkylated (usually 
methylated) bases, deaminated bases (e.g., uracil, xanthine), or base 
mismatches and plays an important role in initiating BER (Sancar et al., 
2004b). Organisms usually contain enzymes recognizing uracil (uracil-DNA 
glycosylase), alkylated purines (methyl-purine glycosylase), oxidized/reduced 
pyrimidines (homologues of E. coliendonuclease III), or oxidized purines 
(homologs of E. coli Fapy glycosylase or 8-oxoguanine glycosylase) (Sancar 
et al., 2004b). The enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP1 
and PARP2), which act as sensors and signal transducers for lesions, such as 
SSBs, also play a role in BER(Lord and Ashworth, 2012).  
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Figure 1.4 Base excision repair mechanisms in mammalian cells. 
A damaged base is removed by a DNA glycosylase to generate an  abasic 
(AP) site. The repair patch may be a single nucleotide (short patch) or 2–10 
nucleotides (long patch). In the short patch pathway, the base damage is 
removed by a glycosylase/AP lyase  that cleaves the phosphodiester bond 3’ to 
the AP site.  APE1 endonuclease then cleaves the 5’!bond to the site and 
recruits Polβ"to fill the 1-nt gap that is ligated by Lig3/XRCC1 complex. The 
long patch pathway usually occurs when the AP site is generated by hydrolytic 
glycosylases or by spontaneous hydrolysis, repair. APE1 cleaves the 5’! 
phosphodiester bond, and the RFC/PCNA-Polδ/ε#complex is responsbile for 
repair synthesis and nick translation, displacing several nucleotides. The 
overhang is cleaved off by FEN1 endonuclease and the long-repair patch is 
ligated by Ligase 1. Reprinted from (Sancar et al., 2004b) with permission 
from the Annual Review of Biochemistry, Volume 73 © 2004 by Annual 
Reviews, http://www.annualreviews.org. 
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1.1.3.2 Nucleotide Excision Repair (NER) 
The bulkier single-strand lesions that changes the DNA helical 
structure, such as those caused by ultraviolet light, are repaired by nucleotide 
excision repair (NER) (Cleaver et al., 2009). NER is often further divided into 
transcription-coupled NER (TC-NER), which happens where the lesion 
blocks, and is detected by elongating RNA polymerase; and global-genome 
NER (GGR), in which the lesion affects base pairing and distorts the DNA 
helix. Although these processes identify lesions using distinct processes, the 
repair processes are quite similar. DNA surrounding the lesion is cut out and 
then replaced using the normal DNA replication machinery. Excision repair 
cross-complementing protein 1 (ERCC1) is crucial to this excision step. On 
GGR, XPC-RAD23B-Centrin2 complex detects the damage while in TC-NER 
damage is recognized through the stalling of RNA polymerase II on the 
actively transcribed strand of a gene. Xeroderma pigmentosum, 
complementation group A (XPA), RPA, xeroderma pigmentosum, 
complementation group B (XPB) and xeroderma pigmentosum, 
complementation group D (XPD) stabilize the damaged DNA and xeroderma 
pigmentosum, complementation group G (XPG) and ERCC1XPF structure-
specific endonucleases cleave the 3’ and 5’side of the nucleotide fragment 
containing the damaged DNA (Figure 1.5). DNA polymerases will fill in the 
missing nucleotides and the newly synthesized DNA fragment is ligated by 
DNA ligaseIII-XRCC1 and DNA ligase I (Figure 1.5). 
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Figure 1.5 Overview of human nucleotide excision pathway.  
The four repair factors, RPA, XPA, XPC-TFIIH, recognize the damage and form 
a complex at site. If the site contains a lesion, ATP hydrolysis by the XPB and 
XPD helicases unwinds the duplex around the lesion, making a stable preincision 
complex 1 (PIC1) at the damage site. XPG then replaces XPC in the complex to 
form a more stable preincision complex 2 (PIC2). Finally, XPFERCC1 is 
recruited to the damage site to form preincision complex 3 (PIC3). The damaged 
strand is incised by XPG and XPFERCC1, releasing the oligomer containing the 
damaged strand. Polδ/ε will fill up the gap with the help of replication accessory 
proteins PCNA and RFC.  Reprinted from (Sancar et al., 2004b) with permission 




 1.1.3.3 Repair of double-strand breaks (DSB) 
The repair of double strand breaks (DSB) is mediated by non-
homologous end joining (NHEJ) or homologous recombination repair (HRR; 
also known as homology-directed repair (HDR)). HRR is a high fidelity repair 
pathway that usually occurs in the S and G2 phases of the cell cycle and it 
would reinstate the original DNA sequence to the site of damage. A portion of 
the DNA sequence around the DSB is deleted (known as resection) and the 
DNA sequence on a homologous sister chromatid is used as a template for the 
synthesis of new DNA at the DSB site (Lord and Ashworth, 2012). HR repairs 
DNADSBs through the double-strand break repair (DSBR) or the 
synthesisdependent strand-annealing repair (SDSA) (Figure 1.6). In both 
scenarios, the MRN complex is needed to detect DSBs. After incision, the 3' 
end single-stranded DNA coated with RPA and RAD51 invades into a 
homologous recipient DNA duplex. During DSBR, two Holliday junctions are 
created, each between four strands of DNA that are then converted into 
recombination products while SDSA results in non-crossover products. DNA 
polymerases would fill in missing nucleotides at the end of the invading 3' 
DNA strand. BRCA1, BRCA2, RAD51 and partner and localizer of BRCA2 
(PALB2) are important proteins involved in HRR. 
  In NHEJ, the two ends of a DNA DSB are connected and resealed 
without the need for sequence homology between the ends (Helleday et al., 
2008). NHEJ acts throughout the cell cycle. Sometimes this process can result 
in deletion or mutation of DNA sequences at or around the DSB area. The 
heterodimer of the 70 and 80 kDa Ku autoantigens (KU70 and KU80) 
recognize the broken DNA ends and forms the DNA-binding component of 
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DNA-dependent protein kinase (DNA-PK) (Figure 1.6). Ku aligns the DNA 
ends followed by DNA polymerases or nucleases that fill in or removes the 
DNA single-stranded overhangs, respectively to produce the two DNA blunt 
ends (Figure 1.6). The XRCC4/DNA ligase IV ligation complex then joins the 
DNA ends together (Figure 1.6). Compared with HRR, NHEJ, although 
mechanistically simpler, have a higher mutation rate. 
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Figure 1.6 Mechanisms of homologous recombination and non-homologous end joining. 
Double-strand breaks are repaired by either homologous recombination or by nonhomologous 
end-joining. An important intermediate in homologous recombination is the Holliday 
intermediate, in which the two recombining duplexes are joined covalently by single-strand 
crossovers. Resolvases such as MUS81-MMS4 cleave the Holliday junctions to separate the 
two duplexes. In the single-strand annealing (SSA) mechanism, the duplex is digested by a 5’ 
to 3’ exonuclease to reveal microhomology regions that promote pairing, trimming, and 
ligation.  Reprinted from (Sancar et al., 2004b) with permission from the Annual Review of 
Biochemistry, Volume 73 © 2004 by Annual Reviews, http://www.annualreviews.org. 
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1.1.3.4 Mismatch Repair 
Mismatch repair is important to the DDR and it focuses mainly with 
dNTP misincorporation and formation of ‘insertion and deletion’ loops that 
form during DNA replication. These errors cause base ‘mismatches’ in the 
DNA sequence that change the helical structure of DNA. The heterodimers, 
MUTSα or MUTSβ recognize AG or TC mismatches between the old and the 
newly synthesized strand, and trigger a cascade of events to remove the 
mismatched nucleotide and allow the replication machinery to use the original 
DNA template to restore the damaged DNA strand back to its original form 
(Figure 1.7). The proteins encoded by the mutS and mutL homologue genes, 




 Figure 1.7 Human mismatch-repair system. 
The mismatch (red triangle)-bound MutSα (orMutSβ) recruits MutLα, which 
undergoes an ATP-driven conformational switch, releasing the sliding clamp from the 
mismatch site. a | Clamps that diffuse upstream meet replication factor C (RFC) that 
is bound at the 5′ terminus of the strand break and replacing it with exonuclease-1 ( 
EXO1) which would degrade the strand in a 5′→3′ direction. The single-stranded gap 
is stabilized by replication protein A (RPA). b | Clamps that move downstream meet 
a PCNA molecule that is bound at the 3′ terminus of the strand break. The recruitment 
and the activation of EXO1 lead to the degradation of the region between the original 
discontinuity and the mismatch. In both scenarious, after the mismatch is removed, 
MutLα inhibits EXO1 activity. A complex consisting of DNA polymerase δ (Pol δ) 
and proliferating cell nuclear antigen (PCNA) fills the gap and DNA ligase I seals the 
remaining nick to complete the repair process. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology (Jiricny, 2006), 
copyright 2006. 
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1.1.4 Role of DDR in tumorigenesis 
 Genomic instability is one of the hallmarks of cancer (Stratton et al., 
2009). Although the specific DDR defects are unknown in most cancers, there 
is an indisputable connection between a particular DDR defect and the 
neoplastic phenotype in several cases. For example, 15% of sporadic 
colorectal tumours show abnormal shortening or lengthening of dinucleotide 
repeat sequences characteristic of microsatellite instability, which may be due 
to defective mismatch repair that results in an inability to repair DNA 
replication errors. Microsatellite instability is also found in the familial form 
of the disease known as hereditary non-polyposis colorectal cancer (HNPCC), 
which is linked with loss-of-function mutations in mismatch repair genes, such 
as MSH2 and MLH1. Mutations in ATM increase the susceptibility of carriers 
to cancer and are found in approximately 0.5–1.0% of the population 
(Renwick et al., 2006; Swift et al., 1987). People with mutations in both 
alleles of ATM would be diagnosed with the neurodegenerative and cancer 
predisposition disorder ataxia-telangiectasia (Savitsky et al., 1995). Mutations 
in ATR are uncommon and probably only result in viability when they are 
heterozygous or hypomorphic.  
DDR has been proposed to represent an important barrier to 
tumorigenesis (Bartek et al., 2001; Bartkova et al., 2005; Gorgoulis et al., 
2005a). Uncontrolled cell proliferation, caused by oncogene activation or 
inactivation of certain tumour suppressors, results in DNA-replication stress 
and persistent DNA-damage, leading to activation of the ATR/ATM-mediated 
signaling. This would cause cell death or senescence in cell-culture models 
and during tumorigenesis in vivo (Bartkova et al., 2005; Campisi and D'adda 
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Di Fagagna, 2007; Gorgoulis et al., 2005b; Halazonetis et al., 2008b). The 
DDR is activated in early neo-plastic lesions and acts as a barrier against 
malignancy (Bartkova et al., 2006; Gorgoulis et al., 2005b). Inactivation of 
this barrier, arising through mutational or epigenetic inactivation of DDR 
components, is then selected for during tumour development, which would 
promote tumorigenesis. This model for the DDR as an anticancer barrier 
provides explanation for the high frequency of DDR defects in human cancers 
(Halazonetis et al., 2008b). 
1.2 NKG2D ligands 
The activating receptor NKG2D is a C-type lectin-like molecule that is 
expressed on NK cells, activated mouse CD8+ T cells, a subset of mouse 
TCRγδ+ T cells, and all human CD8+ and TCRγδ+ T cells (Mistry and 
O'Callaghan, 2007). NKG2D is a homodimeric type II transmembrane 
glycoprotein present on human chromosome 12, within the NK gene complex, 
and in a syntenic position on mouse chromosome 6 (Coudert and Held, 2006).  
NKG2D recognizes ligands that are distant homologues of major 
histocompatibility complex (MHC) class I proteins (Raulet, 2003). One arm of 
innate immune recognition, important in the context of both cancer and 
infection, is the NKG2D-NKG2D-ligand system (Gasser and Raulet, 2006c; 
Raulet, 2003).This is a critical arm of innate immunity, in which transformed 
or infected cells increase their expression of various cell surface ligands for 
NKG2D. Engagement of the NKG2D receptor on natural killer cells or certain 
T cell subsets stimulates these effector cells to kill tumor cells and/or provoke 
an inflammatory response that aids in tumor control (Guerra et al., 2008; 
Raulet and Guerra, 2009). 
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 Multiple NKG2D ligands have been identified in humans and mice 
(Figure 1.8). In humans, the NKG2D ligands include MICA and MICB (MHC 
class I chain–related proteins A and B), both encoded by genes in the MHC, 
and up to six different proteins called ULBPs (UL16- binding proteins), also 
known as RAET1 proteins (Raulet et al., 2013). In mice, the NKG2D ligands 
is divided into three subgroups, including five different isoforms of RAE-1 
(retinoic acid early inducible-1) proteins, one MULT1 (murine UL16-binding 
protein-like transcript 1) protein, and three different isoforms of H60 proteins 
(though not all mouse strains express all the isoforms) (Raulet et al., 2013). 
Figure 1.8 Domain structures and affinities of various NKG2D ligands.  
The affinities of the various ligands for NKG2D, represented as the 
equilibrium dissociation constant (KD), are shown above each ligands. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Immunology (Raulet, 2003), copyright 2003. 
 NKG2D ligands are usually not expressed on healthy cells but are up 
regulated during cellular stress. NKG2D ligands can be regulated at several 
stages of biogenesis, including transcription, RNA stabilization, protein 
stabilization, and cleavage from the cell membrane by several distinct 
pathways (Figure 1.9).  
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Figure 1.9 Regulation of NKG2D ligands at different stages of ligand 
biogenesis and degradation.  
The regulatory signals and pathways that regulate NKG2D ligands are shown, 
together with information on whether they act transcriptionally, by stabilizing 
or targeting ligand mRNAs, by stabilizing ligand proteins, or by cleavage of 
the ligand from the cell surface. Reprinted from (Raulet et al., 2013) with 
permission from the Annual Review of Immunology, Volume 31 © 2013 by 
Annual Reviews, http://www.annualreviews.org. 
 	  
1.2.1 Regulation of NKG2D ligands by the DDR 	  
The link between NKG2D ligands and DDR was initially observed 
through in vitro cell culture. Drugs or irradiation that damaged DNA 
consistently induced several NKG2D ligands in mouse in vitro cell lines, 
including RAE-1, MULT1, and H60 (Gasser et al., 2005; Gasser and Raulet, 
2006b). In the case of human cell lines, DNA-damaging agents induced the 
expression of ULBP1, 2, and 3 and, in some cases, MICA and MICB (Cerboni 
et al., 2007; Gasser et al., 2005; Soriani et al., 2009).  Depending on the nature 
and severity of DNA damage, the DDR would induce cell cycle arrest, DNA 
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repair or apoptosis and is proposed to represent an important barrier to 
tumorigenesis (Bartek et al., 2001; Bartkova et al., 2005; Gorgoulis et al., 
2005a). Previously we demonstrated that the DDR molecules ATR , ATM  
and CHK1 , but not p53, are required for inducing NKG2D ligand expression 
in response to DNA damage (Gasser et al., 2005). Inhibition of these 
molecules in tumor cell lines inhibited NKG2D ligand expression, indicating 
that a sustained DDR is essential for maintaining expression of NKG2D 
ligands. To add to the significance, tumor cells in situ, including precancerous 
lesions, exhibit constitutive activation of ATM and other components of the 
DDR (Bartkova et al., 2005; Popa et al., 2011). The DDR has also been 
implicated in the induction of p53, apoptosis and senescence, which constitute 
intrinsic modes of tumor suppression (Halazonetis et al., 2008a; Mallette and 
Ferbeyre, 2007).  
In addition to transformed cells, the DDR can also be activated in 
rapidly proliferating cells because of DNA replication stress. Stimulation of 
cultured human T cells with mitogens, super-antigens, or antigens were shown 
to induce NKG2D ligands in vitro, and the expression of the ligands could be 
decrease by treating the cells using drugs or siRNAs that inhibit the DDR 
(Cerboni et al., 2007). However, mouse T cells that are stimulated to 
proliferate in vitro do not induce NKG2D ligands (Diefenbach et al., 2000; 
Gasser et al., 2005). 
The DDR can be induced during infection to enable NK cells and T 
cells to eliminate infected cells. In one study, pre-B cells infected with 
Abelson murine leukemia virus increases the expression of activation- induced 
cytidine deaminase (AID), which deaminates bases in DNA, thereby inflicting 
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DNA damage and resulting in NKG2D upregulation in the infected pre-B cells 
(Gourzi et al., 2006). Studies showed that HIV infection of cells in culture 
results in induction of ULBP1 and 2 (Ward et al., 2009). This process is 
dependent on the Vpr protein encoded by HIV, which would activate the ATR 
kinase and thereby activates the DDR. A subsequent study showed that the 
HIV Vif protein also impacts NKG2D ligand expression by inhibiting it 
(Norman et al., 2011). Vif targets the degradation of the antiviral host protein 
APOBEC3G that would deaminate cytosine residues in the HIV genome, 
causing mutations that inactivate the viral genome. A study suggested that 
DNA damage created while repairing these mutations induces the DDR and 
hence the expression of NKG2D ligands on infected cells (Norman et al., 
2011). HIV Vif partially offsets this effect by reducing the amounts of 
APOBEC3G in infected cells. 
1.2.2 Regulation of NKG2D ligands by other pathways 
MICA and MICB expression can be upregulated in response to heat 
shock (Groh et al., 1996). The heat shock transcription factor (HSF1) was 
found to bind to heat shock response elements (HSE) in the MICA promoter in 
response to heat shock (Fionda et al., 2009). Optimal induction of NKG2D 
ligands in response to heat shock was found to require binding sites for Sp-
family transcription factors (Venkataraman et al., 2007b). No heat shock 
elements have been described for mouse NKG2D ligand genes.  
Proliferative signals could activate the NKG2D ligands. Activating 
E2F family of transcription factors were shown to regulate the transcription of 
mouse Raet1, but not H60 or Mult1 family members (Jung H, 2012). In a 
human cell line, expression of MICA, MICB, ULBP2, ULBP3 and possibly 
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ULBP1 was associated with proliferation and increased activity of the MICA 
and MICB promoters (Jung H, 2012; Rabinovich et al., 2003; Venkataraman et 
al., 2007a).  
NKG2D ligands can be regulated by oncogene activation. 
Overexpression of the adenovirus E1A oncogene upregulated NKG2D ligands 
on mouse and human cells (Routes et al., 2005) and inhibition of BCR/ABL 
activity downregulated MICA and MICB cell surface expression in the K562 
chronic myelogenous leukaemia cell line (Boissel et al., 2006). However, the 
expression of MICA and MICB expression in breast cancer cell lines was 
regulated by HER2/HER3 mediated activation of the PI3K/AKT pathway, but 
not the DDR (Okita et al., 2012). Similarly, we found that oncogenic H-RAS 
induced the expression of RAET1 in a PI3K-dependent, but DNA damage 
independent manner (Liu et al., 2012).  
NKG2D ligands can be regulated by miRNAs. The function of p53 
was dispensable for induction of NKG2D ligand expression in response to 
DNA damage, but p53 was found to induce the expression of ULBP1 and 
ULPB2. Paradoxically, p53 was also shown to downregulate ULBP2 by 
inducing the expression of microRNAs that target ULBP2 transcripts 
suggesting a complex regulation of NKG2D ligands by p53 (Gasser et al., 
2005; Gasser and Raulet, 2006a; Heinemann and Paschen, 2012). In addition 
to p53-induced microRNAs, a group of endogenous, ubiquitously expressed 
cellular miRNAs control MICA and MICB expression by binding to the 3’ 
UTR sites of MICA and MICB in various human tissues and in cell lines 
(Heinemann et al., 2012; Stern-Ginossar et al., 2008; Tsukerman et al., 2012). 
MICA is also targeted by an IFN-γ-induced miRNA (Yadav et al., 2009).  
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1.2.3 Role of NKG2D ligands in tumourigenesis 
The expression of NKG2D ligands by tumour cell lines has been 
shown to make the cells more prone to NK-cell killing. In addition, NKG2D 
was found to be important in tumour surveillance in spontaneous cancer 
models in vivo. Mice deficient in NKG2D were crossed with the TRAMP 
(transgenic adenocarcinoma of the mouse prostate) mice and they developed 
spontaneous prostate tumours at a higher frequency (Guerra et al., 2008). The 
authors also assessed the role of NKG2D in a model of lymphoid 
tumorigenesis using transgenic mice in which the oncogene Myc is 
constitutively expressed in B cells and they found that B-cell lymphomas 
arose significantly earlier in the NKG2D deficient transgenic mice. These 
observations provides genetic evidence of a role for NKG2D in early tumour 
surveillance of prostate and lymphoid malignancies in vivo, which would 
provide potential cancer immunotherapy by manipulation of NKG2D-
dependent tumour surveillance. 
Many independent pathways that are activated in cancer cells are likely 
to act together in the induction of NKG2D ligands (Figure 1.10). In the early 
stages of tumorigenesis, the cell undergoes a hyperproliferative in association 
with the activation of oncogenes or the loss of gatekeeper tumor suppressors. 
Cell cycle entry usually needs active E2F transcription factors, which also 
transcriptionally activate various NKG2D ligands. Proliferation is also linked 
to the induction of MICA, MICB, and several ULBPs in human cells (Jung et 
al., 2012; Venkataraman et al., 2007a).  In addition, several oncogenes have 
been proposed to transcriptionally activate NKG2D ligand genes (Raulet et al., 
2013). 
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The hyperproliferative state usually results in activation of p19ARF 
and/or the DDR, both of which activate the p53 tumor suppressor, which act 
as a key barrier to tumorigenesis. Activated p53 can promote transcription of 
certain NKG2D ligands, such as ULBP1 and 2 (Li et al., 2011; Textor et al., 
2011) in human cells. Finally, the heat shock stress response, which is 
commonly activated in tumor cells (Garrido et al., 2006), has been linked to 
transcription of MICA and MICB ligands in human cells. 
Figure 1.10 Regulation of NKG2D ligands in the multistep process of 
tumorigenesis.  
The figure shows various regulators of NKG2D ligand expression in the multistep 
process of tumorigenesis. Tumorigenesis may initiate with loss of gatekeeper 
tumor suppressors and activation of oncogenes, resulting in hyperproliferation. 
Reprinted from (Raulet et al., 2013) with permission from the Annual Review of 
Immunology, Volume 31 © 2013 by Annual Reviews, 
http://www.annualreviews.org. 
 26 
1.3 Nucleic acid sensing 
The cellular innate immune system consists of different groups of 
cellular sensors, to sense and eliminate microbes rapidly in a non-specific 
manner. They include the Toll-like receptors (TLRs), retinoid acid-inducible 
gene I (RIG-I)-like receptors (RLRs) and other cytosolic nucleic acid sensors, 
and nucleotide-binding and oligomerization domain (NOD)-like receptors 
(NLRs) (Figure 1.11). 
The importance of these sensors in protecting against pathogens is 
shown by their ubiquitous distribution, diversity, strategic positions as 
sentinels (both on cell surfaces and within intracellular compartments), and the 
increased risks infections in humans and mice carrying loss-of-function 
mutations that affect these receptors or their signaling partners. They function 
mainly to detect various pathogen-associated molecular patterns (PAMPs) 
such as lipopolysaccharide (LPS), lipopeptides, RNA and DNA or damage-
associated molecular patterns (DAMPs) released from stressed or dying cells. 
Excessive activation might lead to autoimmune disease. An example is 
systemic lupus erythematosus (SLE), which has been linked to aberrant DNA 
recognition Although SLE is a multifactorial disease, several causes of SLE-
like diseases have been identified such as mutations in deoxyribonuclease I, II 
and III (Hornung and Latz, 2010).    
Many PRRs, including some of the TLRs and cytoplasmic RNA/DNA 
sensors, trigger a TANK-binding kinase 1 (TBK1) and interferon regulator 
factors 3 (IRF3)-dependent type I interferon and cytokine response (Figure 
1.7). Recently identified candidate cytosolic DNA sensors include ZBP1 (Z-
DNA-binding protein 1); AIM2 (absent in melanoma 2); IFI16 (interferon, 
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gamma inducible protein 16) and its mouse ortholog p204; HMGB1 (high 
mobility group box protein 1); LRRFIP1 (leucine rich repeat (in FLII) 
interacting protein 1); DDX41 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 
41) and cyclic guanosine monophosphate-adenosine monophosphate synthase 
(cGAS) (Hornung et al., 2009; Sun et al., 2013; Takaoka et al., 2007; 
Unterholzner et al., 2010a; Yanai et al., 2009a; Yang et al., 2010; Zhang et al., 
2011b). With the exception of AIM2, upon recognizing DNA these sensors 
activate TBK1 and/or the related serine threonine kinase IKK-related kinase 
epsilon (IKKε). Activated TBK1 or IKKε directly phosphorylate IRF3, 
which is translocated to the nucleus and stimulates transcription of numerous 
genes that are critical in the immune response, including Ifnb (Fitzgerald et al., 
2003; Pomerantz and Baltimore, 1999; Sharma et al., 2003; Shimada et al., 
1999). Although TBK1 and IKKε appear to be partially functionally 
redundant, IKKε is preferentially expressed in lymphocytes, whereas TBK1 
is constitutively expressed in embryonic and adult fibroblasts (Perry et al., 
2004) and our own unpublished data) and is required in these cells for normal 
IRF3 activation and IFN-β production induced by dsRNA (Hemmi et al., 
2004). In response to activation, cytoplasmic IRF3 is phosphorylated, 
undergoes dimerization and translocates into the nucleus (Hiscott et al., 2003; 
Honda and Taniguchi, 2006; Takeda and Akira, 2005; Taniguchi et al., 2001). 
Nuclear IRF3 binds to the IFN-stimulated response element (ISRE) in the 
promoter regions of IFN-β, chemokine (C-C motif) 5(Ccl5) and other target 
genes, thereby upregulating their transcriptional activities (Kim et al., 2000; 
Parekh and Maniatis, 1999).	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Figure 1.11 Overview of the nucleic acid sensing machinery.  
Endosomal Toll-like receptor 7 (TLR7), TLR8 and TLR9 signal via the 
adaptor protein myeloid differentiation primary-response protein 88 (MYD88) 
in the cytosol, leading to the activation of mitogen-activated protein kinases 
(MAPKs) and the IκB kinase (IKK) complex subsequent activation of the 
transcription factors activator protein 1 (AP1) and nuclear factor-κB (NF-κB). 
Endosomal TLR3 signals through TIR-domain-containing adaptor protein 
inducing IFNβ (TRIF), which may activate IRF3 through TANK-binding 
kinase 1 (TBK1) and IKKε, resulting in the expression of type I IFNs. Various 
cytosolic receptors — including nucleotide-binding oligomerization domain 
protein 2 (NOD2), the RIG-I-like receptors (RLRs) retinoic acid-inducible 
gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), 
and some other DExD/H-box helicases — may promote the expression of pro-
inflammatory cytokines and type I IFNs through the IFNB-promoter 
stimulator 1 (IPS1)-mediated activation of TBK1 and IKKε or through the 
activation of the IKK complex. The proposed cytosolic DNA receptors 
DDX41, IFNγ-inducible protein 16 (IFI16) and possibly Z-DNA-binding 
protein 1 (ZBP1) interact with stimulator of IFN genes (STING) to activate 
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TBK1, IKKε and the IKK complex. The helicases DDX1, DDX21 and 
DHX36 have been thought to form a TRIF-interacting complex, and LRRFIP1 
(leucine-rich repeat flightless-interacting protein 1) was suggested to enhance 
IRF3 transcriptional activity through β-catenin. In pDCs, DHX36 and DHX9 
activate TRIF-dependent and MYD88-dependent signalling, respectively. 
RIG-I and absent in melanoma 2 (AIM2) may increase inflammasome 
formation and caspase 1 activation through the adaptor protein ASC, leading 
to the release of mature interleukin-1β (IL-1β). dsRNA, double-stranded 
RNA; ER, endoplasmic reticulum; ssRNA, single-stranded RNA. Reprinted 
by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 
(Desmet and Ishii, 2012), copyright 2012. 	  
1.3.1 Role of cytosolic DNA sensors in tumorigenesis 
Both IFI16 and AIM2, which are cytosolic DNA sensors belonging to 
the PYHIN family, have been proposed to function as tumour suppressor. The 
PYHIN (pyrin and HIN200 domain-containing proteins) family consists of the 
mouse IFN-inducible genes Ifi200, p202a, p202b, p203, p204, myeloid cell 
nuclear differentiation antigen 1 (Mnda1), and Aim2, and the human HIN-200 
genes IFI16, MNDA, AIM2 and PYHIN1 (Gariglio et al., 2011). Many PYHIN 
family members were also shown to modulate proliferation, differentiation, 
and transcriptional regulation (Asefa et al., 2004; Cresswell et al., 2005; 
Johnstone and Trapani, 1999).  
Increased expression of IFI16 protein in normal human diploid 
fibroblasts and prostate epithelial cells had been linked to cellular senescence-
associated permanent cell growth arrest (Choubey et al., 2008). In line with 
this finding, expression of IFI16 was downregulated in breast cancer tissue 
(Fujiuchi et al., 2004) and transcriptional silencing of IFI16 via histone 
deacetylase (HDAC) was found in human prostate cancer cell lines (Alimirah 
et al., 2007). IFI16 could negatively regulate p53 as inhibition of endogenous 
IFI16 expression by small interfering RNA (siRNA) induces p21Waf1 mRNA 
and protein expression through p53 but does not induce pro-apoptotic p53 
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target genes (Kwak et al., 2003). Overexpression of IFI16 in cells inhibits cell 
proliferation by promoting the p53/p21- and RB/E2F-mediated inhibition of 
cell-cycle progression, and downregulation of IFI16 contributes to 
oncogenesis (Liao et al., 2011; Ludlow et al., 2005). IFI16 had been found to 
have in vivo anti-tumoral activity by promoting apoptosis of tumor cells, by 
inhibiting neo-vascularisation, and by increasing the recruitment of 
macrophages through the release of chemotactic factors through xenografts 
experiments using cell lines derived from head and neck squamous cell 
carcinoma (Mazibrada et al., 2010). 
AIM2 was originally cloned in a functional screen to identify putative 
tumor suppressor genes present on chromosome 6, which is often mutated in 
human melanomas, colorectal carcinomas, gastric and endometrial cancers 
(DeYoung et al., 1997; Michel et al., 2010; Ray et al., 1996; Woerner et al., 
2003; Woerner et al., 2005; Woerner et al., 2007). Extensive studies had been 
done on how overexpression of AIM2 suppressed proliferation and increased 
the rate of apoptosis of several cells ,similar to the effects of other members of 
the HIN-200 family of proteins (Asefa et al., 2006; Asefa et al., 2004; Chen et 
al., 2006; Choubey et al., 2000; Ding et al., 2004; Johnstone and Trapani, 
1999; Landolfo et al., 1998; Patsos et al., 2010; Trapani et al., 1992). 
Restoration of AIM2 expression in AIM2-deficient colon cancer cells 
increased the mestastic potential of colorectal cancer (Chen et al., 2006; Patsos 
et al., 2010). Inhibition of AIM2 expression in human diploid fibroblasts leads 
to the activation of the DDR,thus implicating a role of AIM2 in the 
maintenance of genomic stability in cells which is one of the hallmarks of 
cancer (Duan et al., 2011). In addition, expression of AIM2 innibits cell 
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proliferation and mammory tumour growth in a mouse model (Chen et al., 
2006). AIM2 are over-expressed in Epstein-Barr virus (EBV)-associated 
nasopharyngeal carcinoma (NPC), and the expression levels correlate with 
patient’s survival (Chen et al., 2012). AIM2 is necessary for production of IL-
1β induction by EBV genomic DNA and EBV-encoded small RNAs in 
tumour cells, and this tumour-derived IL-1β would inhibit tumour growth 
and promote survival through host responses (Chen et al., 2012).  
LRRFIP1 recognize both cytosolic dsDNA and dsRNA in 
macrophages infected by Listeria monocytogenes and vesicular stomatitis 
virus (Yang et al., 2010). Upon activation, LRRFIP1 interacts with β-catenin 
and promotes β-catenin activation, which would enhance recruitment of the 
p300-histone acteyltransferase complex to the Ifnb1 promoter through IRF3, 
leading to the transcription of Ifnb. LRRFIP1 has been shown to be 
upregulated in breast cancers and Burkitt lymphomas (Ariake et al., 2012; 
Rikiyama et al., 2003; Sjoblom et al., 2006) and it promotes colorectal cancer 
metastasis and liver invasion by regulating RhoA-induced cell adhesion, 
migration, and invasion of cancer cells (Rikiyama et al., 2003; Sjoblom et al., 
2006). LRRFIP1 is also one of the targets of the microRNA-21 (miR-21), 
which is overexpressed in many cancers such as glioblastoma (Li et al., 
2009b). Suppression of miR-21 could upregulate the expression of its 
LRRFIP1, which can inhibit NF-κB activation, and promotes the 
topoisomerase II inhibitor VM26-mediated cell death in glioblastoma 
multiforme cells (Li et al., 2009b). LRRFIP1 could contribute to resistance of 
cells to the topoisomerase II inhibitor VM-26 and the two genotoxic drugs 
cisplatin and doxorubicin (Li et al., 2009b; Shen et al., 2012). 
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HMGB1 is a highly versatile molecule that is involved in diverse 
functions such as recognition of cytosolic DNA, regulation of chromatin 
structure, transcription and DNA repair. It can bind both distorted and 
damaged DNA (Lange and Vasquez, 2009; Sims et al., 2010). HMGB1 
expression has been found to be upregulated in several tumors and tumor 
endothelium (van Beijnum et al., 2009). The metastatic potential of cancer 
cells was found to correlate with HMGB1 expression, possibly due to its 
ability to modulate the adhesion of cells, the extracellular matrix and 
angiogenesis (Brezniceanu et al., 2003; Chung et al., 2009; Ellerman et al., 
2007; Sparvero et al., 2009). HMGB1 can also promote endothelial cell 
proliferation in vitro and neovascularization in vivo (Schlueter et al., 2005). 
Consistent with a role for HMGB1 in cancer, inhibiting HMGB1 blocks 
proliferation of tumors and the ability to metastasize in a mouse model for 
lung cancer (Taguchi et al., 2000). In addition, HMGB1, which was released 
from tumor cells treated with different genotoxic agents, was found to enhance 
processing and cross-presentation of tumor antigens by dendritic cells (Apetoh 
et al., 2007).  
1.3.2 ZBP1 (Z-DNA-binding protein 1) 
ZBP1(Z-DNA-binding protein 1, also known as DNA-dependent 
activator of IRFs (DAI) or DLM1) is the first cytosolic DNA sensor identified 
(Takaoka et al., 2007). It has three DNA-binding domains in its N-terminal, 
Zα, Zβ and D3 (Figure 1.12). It shares similar DNA binding domains to 
ADAR1 (Adenosine deaminase acting on RNase 1), an RNA editing enzyme 
(Zα and Zβ) and the protein of vaccinia virus, E3L (Zα) (Vilaysane and 
Muruve, 2009). Its C-terminal contains multiple phosphorylation sites, which 
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may participate in various signal transduction pathways. ZBP1 is expressed 
ubiquitiously in various tissues such as the spleen, thymus, liver, lung and 
heart (Fu et al., 1999). Upon binding to dsDNA, ZBP1 would form a complex 
with TBK1 and IRF3 at its C terminal (Takaoka et al., 2007). IRF3 will be 
phosphorylated and it would form a dimer and translocate to the nucleus and 
induce the expression of type 1 interferons (IFNs) gene.  Recent studies have 
also shown that ZBP1  is involved in the activation of NF-κB through 
interaction with RIP1 (receptor interacting protein kinase 1) and RIP3 via their 
RHIM (RIP homotypic interaction motif) domains (Kaiser et al., 2008).  This 
result in the production of proinflammatory cytokines such as IL-6 and the 
induction of necrosis. ZBP1 could form a compex with RIP3 to mediate virus-
induced necrosis that is targeted by murine cytomegalovirus infection (Upton 
et al., 2012). ZBP1  recognises DNA irrespective of the sequences, but the 
induction of IFN requries a minimum length requirement of 100bp (Vilaysane 
and Muruve, 2009).  
ZBP1 is an interferon-inducible gene and the expression of ZBP1 can 
be upregulated by treatment with type I and II IFN (Takaoka and Taniguchi, 
2008) and PAMPs, which include dsDNA and lipopolysaccharides (LPS). 
ZBP1  mainly resides in the cytoplasm and forms stress granules when cells 
are exposed to stress such as oxidative stress, viral infection or UV radiation 
(Takaoka and Taniguchi, 2008).   
ZBP1 has been linked to autoimmune diesase. Expression of ZBP1 
was increased in SLE patients as well as in lupus mice (Zhang et al., 2013). In 
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addition, ZBP1 was reported to promote lupus nephritis by activating the 
calcium pathway (Zhang et al., 2013).  
 A link of ZBP1 to cancer was suggested by the finding that Zbp1 is 
highly upregulated in the peritoneal lining tissue of mice bearing ascites 
tumors (Fu et al., 1999). The role of ZBP1 in cancer still remains unclear and 
one of the aims of the study is to investigate the role of ZBP1 in the transgenic 
Eµ-Myc model, which developes spontaneous tumour.  
Figure 1.12 Schematic drawing of the main domains of ZBP1.  
 ZBP1 binds DNA via its Zα, Zβ and D3 domains. The RHIM domain interacts 
with RIP1 and RIP3. The carboxy-terminal of the protein is required for type1 
interferon pathways involing TBK1 and IRF3. Reprinted from (Vilaysane and 
Muruve, 2009) with permission from Elsevier. 
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1.4 Eμ-Myc mouse model 
 In the Eµ-Myc transgenic mouse model, the Eµ-Myc mice express c-
Myc on B cells under control of the immunoglobulin heavy chain enhancer 
(Eµ) and the mice develop Burkitt-like pre-B and B cell lymphomas (Adams 
et al., 1985). Myc is deregulated in 70% of all human malignancies (Meyer 
and Penn, 2008) and the genetics of the Eµ-Myc mice resembles that of acute 
lymphoblastic leukaemia (ALL) or non-Hodgkin's lymphomas in humans. 
Sustained expression of MYC has been shown to cause DNA damage in 
tumour cells through various mechanisms (Pusapati et al., 2006a; Ray et al., 
2006; Vafa et al., 2002a). DNA damage and the ensuing DDR have been 
proposed to represent an anticancer barrier in early tumorigenesis (Bartek et 
al., 2007; Bartkova et al., 2005; Gorgoulis et al., 2005a). 
 There are at least two types of DNA damage associated with Myc 
overexpression. ROS production, which has been shown to increase where 
Myc is deregulated, can increase oxidative damage (Vafa et al., 2002b).  
Another source of Myc-induced DNA damage is replication stress, which 
represents the generation of aberrant DNA replication intermediates that lead 
to the accumulation of DDR markers at sites of active DNA replication. Myc-
induced DDR are responsible for the genomic and chromosomal instability 
commonly linked with Myc hyper-activation. Various chromosomal 
abnormalities including translocations, dicentric chromosomes and tetraploidy 
have been reported upon Myc overexpression (Felsher and Bishop, 1999). 
ATM has been reported to regulate Myc-induced DDR (Maclean et al., 2007; 
Pusapati et al., 2006b; Reimann et al., 2007). Both DDR and apoptosis 
induced by Myc were reduced upon ATM loss, while tumorigenesis was 
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greatly accelerated in Eµ-Myc deficient in Atm. The role of ATM in regulating 
Myc-induced tumor suppressive DDR, was further confirmed in a mouse 
model of skin cancer suggesting that the relevance of this pathway in 
suppressing Myc-induced tumors suppression is not limited to hematological 
malignancies, but can be applied to solid tumors (Pusapati et al., 2006b). In 
support of these findings, genetic analysis of mice lacking wild-type p53-
induced phosphatase 1 (WIP1), a protein phosphatase that negatively regulates 
ATM, suggest that loss of WIP1 protect against Eµ-Myc induced lymphomas 
(Shreeram et al., 2006).  Similar results were reported for the haploinsufficient 
tumor suppressor histone acetyltransferase HTATIP (TIP60) (Gorrini et al., 
2007), a histone acetyl transferase (HAT) that has been associated in the 
regulation of the DDR via activation of ATM (Sun et al., 2005) and of DNA 
repair through a multifunctional complex with HAT and chromatin 
remodeling activities.  Loss of one TIP60 allele in Eµ-Myc transgenic mouse 
impaired ATM activation, p53 phosphorylation on Serine 18 and H2AX 
phosphorylation, thereby accelerating tumorigenesis.  
 Previous studies of Eµ-Myc mice demonstrated proliferating immature 
B cells appearing in the periphery after birth, followed by their disappearance 
after around 6 weeks of age and the appearance of B-cell lymphomas in 50% 
of mice by 15 to 20 weeks of age (Harris et al., 1988; Langdon et al., 1986; 
Sidman et al., 1993b). The mechanisms underlying their disappearance are 
poorly understood. Our lab has found that tumour cells in young Eµ-Myc mice 
undergo spontaneous rejection mediated by DNA-damage induced DNAM-1 
ligand expression and the rejection of tumour cells depends on natural killer 
cells and T cells (Croxford et al., 2013).   
 37 
1.5 Aims 
 Whether or how the DDR signaling pathway leading to NKG2D ligand 
expression intersects or interacts with signaling by PRRs has not been 
investigated in detail, though there are indications that PRRs can stimulate 
NKG2D ligand expression (Hamerman et al., 2004). One of the aims of the 
project is to investigate if molecules involved in the PRR can regulate 
NKG2D ligands. We would also like to investigate the role of one of the DNA 





Chapter 2: Materials and methods 
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2.1 Mice and cells  
C57BL/6 mice were purchased from the Centre for Animal Resources 
at the National University of Singapore. Eµ-Myc transgenic mice were 
purchased from Jackson Laboratory (USA) and Irf3-/- mice were purchased 
from Riken (Japan). Zbp1-/- mice (Zbp1tm1Aki) were kindly provided by Prof. 
K. Ishii (National Institute of Biomedical Innovation, NIBIO) and Prof. S. 
Akira (iFREC, Osaka University) (Ishii et al., 2008a). Mice were bred and 
housed according to the guidelines by the National University of Singapore. 
Zbp1-/- fibroblasts, TBK1-/-IKKε-/- and TBK1+/+IKKε+/+ mouse embryonic 
fibroblasts (MEFs) were generated as described in (Ishii et al., 2006a). BC2 
cells, which were derived from Eµ-Myc C57BL/6/129 mice, were a generous 
gift by L.M. Corcoran and EµM1 cells were generated from late stage Eµ-Myc 
C57BL/6 as described (Corcoran et al., 1999). Yac-1 cells were purchased 
from ATCC (USA). Cells were cultured in RPMI (Invitrogen, Carlsbad, USA) 
supplemented with 10% FCS (Thermo ScientificTM HyCloneTM, Waltham, 
USA), 50 µM 2-mercaptoethanol, 100 µM asparagine (for BC2 cells), 2mM 
glutamine (Sigma-Aldrich, St. Louis, USA) and 1% pen/strep (Invitrogen, 
Carlsbad,  USA).  
Cells derived from C57BL/6 such as EµM1, MEFs and tumor cells in 
Eµ-Myc mice express RAE1βδ and/or RAE1ε. In contrast, cells derived from 
other strains of mice including BC2 (C57BL/6 and 129) and Yac-1 (A/Sn) can 
express RAE1α, RAE1β, RAE1γ and RAE1δ.  
 
2.2 Reagents 
 Aphidicolin, CGK733, cytosine β-D-arabinofuranoside hydrochloride 
(Ara-C), DMSO, Poly A:U and Poly I:C were purchased from Sigma-Aldrich 
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(St Louis, USA). The ATM inhibitor KU55933 and KU60019 and the ATR 
inhibitor VE-821 were obtained from Tocris Bioscience (Bristol, UK) and 
Axon Medchem (Groningen, Netherlands) respectively.The murine TLR9 
ligand ODN1585, ODN1668 control (ssDNA) and LPS were purchased from 
InvivoGen (San Diego, USA). 8 µg of MSCV-IRES-GFP plasmid, genomic 
DNA or ODN1668 control were conjugated to AF488 using the Ulysis nucleic 
acid staining kit according to manufacturer’s instructions (Invitrogen, 
Carlsbad, USA). 4 µg labelled DNA was transfected into cells using 
TransFectinTM (Bio-Rad Laboratories Inc, Hercules, USA) according to 
manufacturer’s instructions. 
 
2.3 Flow cytometry  
2.3.1 Stainings of NKG2D ligands 
 Cells were stained for different NKG2D ligands using pan-Rae1-, 
Rae1αβγ-, Rae1βδ- and Rae1ε- (R&D Systems, Minneapolis, USA) and rat 
IgG-coupled to APC-specific antibodies (eBioscience, San Diego, USA). 
Stained cells were analyzed by multicolor flow cytometry using  FACSCalibur 
(BD Biosciences, San Jose, USA) and FlowJo. 8.8.6 (Treestar, Ashland, 
USA).  
2.3.2 Intracellular staining 
For intracellular staining, cells were fixed with 0.25% 
paraformaldehyde at 37°C for 10 min, followed by addition of -20°C methanol 
and incubation on ice for 20 min. After washing, cells were resuspended in 2% 
mouse serum and stained with 1/100 rabbit-anti-phospho-IRF3-Ser396 (Cell 
Signaling Technology Inc, Danvers, USA) and 1/25 AF647-conjugated anti-
phospho-TBK1-Ser172 antibodies (BD Biosciences, San Jose, USA) followed 
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by AF-488-coupled rabbit IgG-specific antibodies (Invitrogen, Carlsbad, 
USA). Some cells were treated with 2 U/µl λ-phosphatase (NEB, Ipswich, 
USA) at 37°C for 90 min. before staining. Stained cells were analyzed by 
multicolor flow cytometry using  FACSCalibur (BD Biosciences, San Jose, 
USA) and FlowJo. 8.8.6 (Treestar, Ashland, USA).  
2.3.3 Determination of tumour load and stainings of surface 
makers on T and B cells 
Blood was collected by facial bleeding and red blood cells were 
removed by red blood cells lysis. Fc receptors on blood cells were blocked by 
pre-incubating cells with CD16/CD32-specific antibodies for 10 min 
(eBioscience, San Diego, USA). Tumor cells were stained with combinations 
of anti-CD45R(B220), anti-IgM, anti-CD3, anti-CD4, anti-CD8  specific 
antibodies (eBioscience, San Diego, USA). Cells were stained for  MHC class 
I (H-2Kb), CD80, CD86, CXCR4 CD62L, ICAM-1 (eBioscience, San Diego, 
USA), DNAM-1 and CD155 (Biolegend, San Diego, USA). Tumour load was 
calculated as follows: ∑ (% IgM-B220low) x % B220+ + (IgM+B220low) x % 
B220+. Concentration of tumour cells in the blood was calculated by 
multiplying the lymphocyte count determined using a Scil Vet abc animal 
blood cell counter (Horiba, Kyoto, Japan) by the % of B220low cells in a 
FCS/SSC gate corresponding to lymphocytes as determined by flow 
cytometry. Stained cells were analyzed by multicolor flow cytometry using  
FACSCalibur (BD Biosciences, San Jose, USA) or LSRFortessa (BD 
Biosciences, San Jose, USA) and FlowJo. 8.8.6 (Treestar, Ashland, USA).  
2.3.4 Stainings of surface markers for NK cell maturation 
Spleen and bone marrow cells were harvested and red blood cells were 
removed by red blood cells lysis. Fc receptors were blocked by pre-incubating 
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cells with CD16/CD32-specific antibodies for 10 min. Cells were then stained 
with anti-CD122-eFluor®450, anti-CD43-FITC, anti-Cd11b-PerCP-Cy5.5, 
anti-CD49b/DX5-APC, anti-CD27, anti-CD3-eFluor®780, anti-NK1.1-PE-
Cy7. Stained cells were analyzed by multicolor flow cytometry using  
LSRFortessa (BD Biosciences, San Jose, USA) and FlowJo. 8.8.6 (Treestar, 
Ashland, USA).  
2.3.5 Proliferation and apoptosis assay 
For cell cycle analysis mice were injected i.p. with 1 mg BrdU (BD 
Pharmingen, San Jose, USA) and spleen and bone marrow were harvested and 
analyzed 18 hours later according to the manufacturer’s instructions. Briefly, 1 
x 106 cells were stained with B220-FITC and IgM-PE-Cy7 before fixing in BD 
Cytofix/Cytoperm buffer. Cells were then resuspended with BD Cytoperm 
Plus buffer and re-fixed with BD Cytofix/Cytoperm, after which cells were 
treated with DNase to expose incorporated DNA before staining with anti-
BrdU-APC. Finally, cells were resuspended in buffer containing 7AAD and 
analysed using LSRFortessa (BD Biosciences, San Jose, USA) and FlowJo. 
8.8.6 (Treestar, Ashland, USA). Cell aggregates or doublets were gated out 
from plot of width of 7AAD fluorescence signal against height of 7AAD 
fluorescence signal. 
 For ex vivo Annexin-V (eBioscience, San Diego, USA) staining, 
harvested splenocytes and bone marrow cells were cultured for 30 min to 
remove adherent cells before staining.  For in vitro staining, non-adherent cells 
were removed to a fresh flask and cultured at 37oC for 3 hours before 
Annexin-V staining according to the manufacturer’s instructions. Briefly, 1 x 
106 cells were stained with B220-FITC and IgM-PE-Cy7 before incubating 
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with Annexin-V-APC. Cells were then resuspended in buffer containing 
propidium iodide and analysed using LSRFortessa (BD Biosciences, San Jose, 
USA) and FlowJo. 8.8.6 (Treestar, Ashland, USA).  
2.4 shRNA retroviral constructs 
 Rig-I shRNA (5'-GCCCATTGAAACCAAGAAATT-3'), Tbk1 shRNA 
(5'-GAAGCCGTCTGGTGCAATA-3'), Ikke shRNA (5'-
CACTTCATCTACAAACAGT-3') and Irf3 shRNA (5'-
GCGGTTGGCTGTTGACAAT-3') target sequences were selected based on 
Dharmacon’s siRNA Design Center algorithm (Dharmacon, Lafayette, USA). 
Control shRNAs included scrambled versions of the Rig-I shRNA (5’-
GCCCATAGAAACCTAGAAATT-3’), Tbk1 shRNA (5’-GAAGCCGTG 
TGCTGCAATA-3’), and Irf3 shRNA (5'-GCGGTTCGTTGATGGCAAT-3'). 
The shRNAs constructs were subcloned in the MSCV/LTRmiR30-PIG vector 
(Open Biosystems Inc., Huntsville, USA) containing Gfp and the PuroMycinR 
gene according to manufacturer’s instructions. Irf3 (TRCN0000085239, 
TRCN0000085240, TRCN0000085241), Sting (V2MM_103338) and Zbp1 
(V2MM_47227)-specific shRNAs and the non-silencing control shRNAs were 
purchased from (Open Biosystems Inc, Huntsville, USA).  
The shRNA plasmids were transiently transfected into 293T cells using 
TransFectinTM according to the manufacturer's instructions (Bio-Rad 
Laboratories Inc, Hercules, USA). 48 h after transfection, BC2 or Yac-1 cells 
were transduced with the viral supernatant for 90 min at 34oC. The cells were 
then selected using puromycin (Sigma-Aldrich, St. Louis, USA) or sorted for 
GFP using MoFlo XDP (Beckman Coulter Inc., Brea, USA) at 48h post-
transduction. 
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2.5 Constructs and transduction of fibroblasts 
 Mouse Irf3, Tbk1 and IKKε were subcloned adjacent to the 
cytomegalovirus promoter in the pMSCV2.2-IRES-GFP proviral vector (gift 
of W. Sha, University of California, Berkeley). Human IRF3-EGFP and 
IRF3A7-EGFP were gifts of S. M. McWhirter (University of California, 
Berkeley). The chimeric constructs were subcloned into MSCV-IRES-GFP. 
Retroviral supernatants were generated as described (Diefenbach et al., 2003). 
WT and mutant Sting fibroblasts were kindly provided by Dr. R. Vance 
(University of California, Berkeley).  
2.6 Quantitative real-time RT-PCR 
 Total RNA was isolated using the nucleospin RNA II kit (Macherey- 
Nagel, Düren, Germany). Total RNA was reverse transcribed with random 
hexamers using M-MLV Reverse Transcriptase (Promega, Fitchburg, USA).  
Each amplification mixture (25 µl) contained reverse transcribed RNA, 5 µM 
forward primer, 5 µM reverse primer and 12.5 µl of iTaq SYBR Green 
Supermix with ROX (Bio-Rad Laboratories Inc, Hercules, USA). PCRs were 
performed in triplicates using the ABI PRISM® 7700 Sequence Detection 
System (Applied Biosystems, Foster City, USA). PCR thermocycling 
parameters were 50°C for 2 min, 95°C for 3 min, and 40 cycles of 95°C for 15 
sec and 60°C for 30 sec and 72°C for 45 sec. Samples were normalized to the 
signal generated from the housekeeping gene HPRT or GAPDH. The 
following primers were used: Hprt-5’: ctttgctgacctgctggatt; Hprt-3’: 
tatgtcccccgttgactgat; Irf3-5’: gccggacgtgtcaacctgga; Irf3-3’: 
cgcgcccctggagtcacaaa; Ifna-5’: tgacctcaaagcctgtgtgatg, Ifna-3’: 
aagtatttcctcacagccagcag; Ifnb-5’: aatttctccagcactgggtg, Ifnb-3’: 
tctcccacgtcaatctttcc; Ip-10-5’: gctgcaactgcatccatatc, Ip-10-3’: 
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tttcatcgtggcaatgatct; Ccl5-5’: accactccctgctgctttgc, Ccl5-3’: 
cacacttggcggttccttcg; Pkr-5’: ccaaagagaaaggcaggctcc, Pkr-3’: 
ttcctccctccctcctccattc; Sting-5’: tggaaatcctgtggggccctgtc; Sting-3’: 
ggcttctgaatggggagacagcag; Bcl2l12-5’: cccccacccacggagaagga, Bcl2l12-3’: 
gagttccacaaggcgggcga; Ku70-5’: attttgtggctttggtgccc, Ku70-3’ : 
tccgcttgtcatcggcataa; Hr23b-5’: agccagcttcaacaaccctg, Hr23b-3’: 
ggagttccagtactcacagcc; Rad54-5’ : tgtctccttttcggaagccc, Rad54-3’ : 
agcccaggggaccttgataa; Rad50-5’: tggatggttttgagcgtgga, Rad50-3’: 
tgtctgtcaggtcgctcaag; Mre11-5’: tctcagagaggccgagacac, Mre11-3’: 
gaaggctgttgtcgggtaga; Xrcc1-5’: tgtgcgtaaagagtgggtgc, Xrcc1-3’: 
ttttggggaagcttgggagc;  Brca1T1-5’: atagccactttcgggtgctg, Brca1T1-3’: 
gatgctcggtaaggaagtctca; Brca1T2-5’: gccggattacctaacacttcc, Brca1T2-3’: 
tctgaggaaagctcctcaaacc; Ku80-5’: gattgagaggcgttccatgc, Ku80-5’: 
tcttgcgtccacaactaccc; Wrn-5’: gggctttggttctcagtcctc, Wrn-3’: 
cgcaggccttttcttctgtag; Nbs1-5’: atgccaagcagcacaagaaac, Nbs1-3’: 
acatcaacaacgcaggttcc; LigaseIV-5’: gggactgatttcaggtggca, LigaseIV-3’: 
aaccctgccgaatgaaggag; c-Jun-5’: ttgctatgactgcaaagatggaaacgaccttc, c-Jun-3’ 
:tttcaaaacgtttgcaactgctgcgttagcatga ; TNF-α-5’: ccacgtcgtagcaaaccacc, TNF-
α-3’: ccttgtcccttgaagagaacc. Gapdh-5’: gaaggtcggtgtgaacgga, Gapdh-3’: 
gttagtggggtctcgctcct. Samples prepared without reverse-transcription served as 
negative control templates. 
2.7 Immunocytochemistry 
 IRF3-GFP or IF3A7-GFP expressing BC2 cells or Yac-1 cells were 
fixed with 4% formaldehyde for 10 min., rinsed once with 1 x PBS and 
incubated in 70% ethanol in PBS for 1 h at -20°C. For DNA stainings, cells 
were fixed according to manufacturer’s instructions (Merck Millipore, 
 46 
Billerica, USA), washed once with 1 x PBS before addition of 2 mg/ml RNase 
A (Sigma-Aldrich, St. Louis, USA) for 30 min at 37°C. For single-standed 
DNA (ssDNA) stainings, some cells were incubated with 1000 U/ml S1 
nuclease (Fermentas, Waltham, USA) for 1 h at 37°C. For double stranded 
DNA (dsDNA) stainings some cells were pretreated with 100 U/ml Dnase 
(Sigma-Aldrich, St. Louis, USA)  for 1 h at 37°C. After washing with 1 x 
PBS, cells were stained with ssDNA- (clone F7-26, Merck Millipore, 
Billerica, USA) or dsDNA- (MAB1293, Merck Millipore, Billerica, USA) and 
Cox IV (Abcam, Cambridge, UK)-specific antibodies, followed by anti-mouse 
IgG coupled to Cy3 (Merck Millipore, Billerica, USA), anti-rabbit IgG 
coupled to dylight 488 (Jackson ImmunoResearch Laboratories Inc, West 
Grove, USA) or anti-mouse IgM coupled to Cy3 (Merck Millipore, Billerica, 
USA) antibodies. Cytospins were prepared and slides were stained with DNA 
fluorochrome DAPI (0.05 mg/ml in PBS) (Dako, Glostrup, Denmark) for 10 
min. Slides were washed once in PBS before mounting with fluorescent 
mounting medium (Dako, Glostrup, Denmark).  
For γH2AX, RAD51 and cleaved CASPASE 3 staining, cells were 
cytospined and fixed with 4% formaldehyde for 15 min, rinse once with 1 x 
PBS and block with 1% bovine serum albumin and 2% goat serum for 1 hour. 
Cells were stained with γH2AX (Cell Signaling Technology Inc, Danvers 
USA), RAD51 (Santa Cruz Biotechnology Inc, Dallas, USA) or cleaved 
CASPASE 3 (Cell Signaling Technology Inc., Danvers USA) overnight at 4oC 
before incubating with anti-rabbit IgG-DyLight-488 (Jackson 
ImmunoResearch, West Grove, USA) antibodies. Cells were then stained with  
anti-CD45R(B220) (eBioscience, San Diego, USA) before incubating with 
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anti-rat IgG-AF647(Invitrogen, Carlsbad, USA). Cells were mounted in 
mounting medium containing 0.5 µg/ml DAPI (Dako, Glostrup, Denmark).  
Pictures of cells were taken using a Zeiss Axio Imager Z1 fluorescent 
microscope equipped with AxioVision 4.8 software (Carl Zeiss 
MicroImaging, Oberkochen, Germany) or a confocal TCS SP5 (Leica, 
Wetzlar, Germany). Pictures were analyzed using ImageJ 1.46 or Adobe 
Photoshop CS5 (Adobe, San Jose, USA). 
2.8 In vivo KU60019 injections 
 37-39 days of age Zbp1+/+Eµ-Myc or Zbp1-/-Eµ-Myc mice were 
separated into groups with similar tumor loads. Mice received 5 mg/kg i.p. 
KU60019 (Tocris Bioscience, Bristol, UK) or vehicle control at 37, 39, 47, 49, 
57, 59, 67 and 69 days of age. Blood tumor load was measured at 37, 44, 54, 
64 and 74 days of age. The mice were also tracked for survival.  
2.9 Microarray 
 Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, USA) 
and purified using RNAminelute  kit (Qiagen, Venlo, Netherlands) according 
to the manufacturer's instructions. The quality of total RNA was evaluated 
using Agilent Bioanalyzer (Agilent Technologies, Santa Clara, USA); only 
samples with RNA integrity number >7.5 were analyzed. Gene expression 
analysis was performed using Affymetrix GeneChip® Mouse Genome 430 2.0 
Array (Affymetrix, Santa Clara, USA). cRNA preparation, purification and 
labeling, array hybridization, and scanning were conducted as per the 
manufacturer's instructions. 
2.10 Western blot 
Whole cell extracts were prepared from purified B220+ cells (> 95% 
purity, CD19 positive selection kit (Stem Cell Technology, Vancouver, 
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Canada) from the spleen and bone marrow or from cell lines and 
electrophoresed in 10% SDS-PAGE or pre-cast gels, and blotted onto 
nitrocellulose membranes (Bio-Rad Laboratories Inc., Hercules, USA). For 
the preparation of whole-cell extracts, cells were lysed in Radio-
Immunoprecipitation Assay (RIPA) buffer consisting of 150 mM NaCl, 1 mM 
EDTA, 50 mM Tris-HCl (pH 7.4), 1% NP-40 and 1% sodium deoxycholate 
(Sigma-Aldrich, St. Louis, USA). In addition, protease inhibitor cocktail set 
III and phosphatase inhibitor cocktail set V (Merck KGaA, Darmstadt, 
Germany) were added to the lysis buffer according to the manufacturer’s 
instructions. Antibodies specific for phospho-H2AX-Ser139 (H2AX-P-
Ser139), phospho-ATM-Ser1981 (ATM-P-Ser1981), ATM, phospho-CHK1-
Ser345 (Chk1-P-Ser345), CHK1, CHK2, phospho-p53-Ser15 (p53-P-Ser15), 
p53, pRB, phospho-Rb-Ser608 (Rb-P-Ser608), CYCLIN D1, PUMA, c-MYC, 
IRF3, phospho-IRF3-Ser396 (IRF3-P-Ser396), TBK1, phospho-TBK1-Ser172 
(TBK1-P-Ser172), CASPASE3, CASPASE8, CASPASE7, NF-κB p65/RelA, 
phospho-NF-κB p65-Ser536 (NF-κB p65-P-Ser536) (Cell Signaling 
Technology Inc., Danvers, USA), CYCLIN A, BCL2L12 (clone E-13, Santa 
Cruz Biotechnology Inc., Dallas, USA), phospho-CHK2-Thr68 (CHK2-P-
Thr68) (Pierce Thermo Scientific, Waltham, USA) and GAPDH (Sigma-
Aldrich, St. Louis, USA) specific antibodies and horseradish peroxidase-
coupled second stage reagents were used to develop the blots (Thermo Fisher 
Scientific, Waltham, USA). Blots were exposed on X-ray film (Thermo Fisher 
Scientific, Waltham, USA) and densitometry analysis was performed using 
ImageJ 1.46. 
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2.11 Native PAGE and immunoblotting 
Dimerization of IRF3 was detected using Native PAGE using a 7.5% 
gel. The gel was pre-run with 25 mm Tris and 192 mm glycine, pH 8.4 with 
and without 1% deoxycholate (DOC) in the cathode and anode chamber, 
respectively, for 30 min at 40 mA. Samples in the native sample buffer (30 µg 
protein, 62.5 mm Tris-Cl, pH 6.8, 15% glycerol and 1% DOC) were applied to 
the gel and electrophoresed for 60 min at 25 mA. Immunoblotting was 
performed as described in 2.10. 
2.12 Measurement of NK cell activity 
2.12.1 CD107a degranulation assay 
Mouse NK cells were isolated from C57BL/6 mice spleens using an 
EasySep mouse NK cell enrichment kit following the manufacturer’s 
instructions (Stem Cell Technology, Vancouver, Canada). NK cells were 
cultured for another 4 days in 1 x 103 units/ml recombinant human IL-2 
(eBioscience, San Diego, USA) before co-incubation with target cells. NK cell 
purity was determined by flow cytometry to be >90% of NK1.1+CD3- cells. 
For the degranulation assays, 6 x 104 NK cells were incubated for 5 hours with 
2 x 104 Yac-1 tumor target cells in the presence of 4.0 µg/ml anti-CD107a-PE 
(eBioscience, San Diego, USA), 1.0 µg/ml GolgiPlug (BD Biosciences, San 
Jose, USA) and 2.0 µM GolgiStop (BD Biosciences, San Jose, USA) at 37oC. 
Cells were stained for anti-NK1.1 (eBioscience, San Diego, USA), anti-CD3 
(eBioscience, San Diego, USA) and intracellular IFN-γ (eBioscience, San 
Diego, USA) according to the manufacturer’s protocol (BD Pharmingen, San 
Jose, USA).  
2.12.2 In vitro activation of NK cells 
96-well plate was pre-coated with either 10 µg/ml of anti-mouse 
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NKG2D (MI6, eBioscience, San Diego, USA) or rat IgG2a κ isotype control 
(eBioscience, San Diego, USA) overnight at 4°C as previously described 
(Guerra et al., 2008). Freshly isolated splenocytes were harvested and added to 
each well. Some splenocytes were incubated with Leukocyte Activation 
Cocktail with Golgi Plug (BD Biosciences, San Jose, USA) to serve as 
positive control. In summary, 1 x 106 cells/well were stimulated for 5 hr at 
37°C in the presence of 1.0 µg/ml Golgi Plug (BD Biosciences, San Jose, 
USA) and 1 x 103 units/ml recombinant human IL-2 (eBioscience, San Diego, 
USA) before staining of surface markers and intracellular IFNγ as described 
above.  
2.13 ELISA 
The quantification of TNF-α was determined using ELISA kits (R&D 
systems, Minneapolis, USA), and quantification of IL-6 was determined using 
ELISA Ready Set Go kits (eBioscience, San Diego, USA) according to the 
manufacturer’s instructions. 
2.14 Statistical analyses 
 Mean percentages of tumor load between groups was compared using 
2-tailed unpaired t-tests (GraphPad Prism 5.0, La Jolla, USA). Survival was 
represented by Kaplan-Meier curves and statistical analysis of survival was 
performed with the log rank Mantel-Cox Test and Gehan-Breslow-Wilcoxon 






Chapter 3: TBK1 and IRF3 are necessary for 









3.1 IRF3 is activated upon DNA damage in BC2 cells 
IRF3 was previously shown to be activated in response to DNA 
damaging agents (Kim et al., 1999a; Servant et al., 2002). We therefore 
investigated the role of IRF3 in the expression of NKG2DLs in cells exposed 
to DNA damaging agents. Phosphorylation of serine 396 (serine 388 of mouse 
IRF3) has been shown to be critical for the activation of IRF3 (Hiscott et al., 
2003). Using flow cytometry to detect phosphorylation of IRF3S388, we 
observed increased phosphorylation of IRF3 after treatment with the DDR-
inducing agents Ara-C or aphidicolin in BC2 cells, a cell lined derived from 
Eµ-Myc (Figure 3.1a). The relatively late kinetics of IRFS388 phosphorylation 
was similar to the kinetics we previously observed for upregulation of 
NKG2DLs in response to DNA damage (Gasser et al., 2005). We also saw 
increase phosphorylation of endogenous IRF3 and formation of endogeneous 
IRF3 dimer in response to Ara-C treatment in BC2 cells (Figure 3.1b), 
although not to the same degree as LPS, a known inducer of IRF3 (Stein and 
Falck-Pedersen, 2012). Treatment of BC2 cells with Ara-C also induced 
activated IRF3 characterized by nuclear translocation of overexpressed 
chimeric IRF3-GFP (Figure 3.1c and d) consistent with previous reports (Kim 
et al., 1999a; Servant et al., 2002). No nuclear translocation was observed with 
a kinase-dead mutant of IRF3 (IRF3A7-GFP) that is unable to be activated 
(Figure 3.1c and d). The data suggest activation of IRF3 in response to DNA 
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3.2 IRF3 is required for RAE1 expression in response to DNA damaging 
agents in BC2 cells 
 
 To test if IRF3 is required for DDR-mediated upregulation of 
NKG2DLs, we transduced BC2 cells with an Irf3-specific shRNA. Compared 
to a control shRNA, the Irf3-specific shRNA significantly inhibited the 
upregulation of RAE1 ligands of NKG2D, in response to Ara-C (Figure 3.2). 
No consistent effects were observed for the NKG2DLs MULT-1 and H60.  
Figure 3. 1 IRF3 is activated by the DDR in BC2.  
(a) Kinetics of IRF3-S388 phosphorylation in BC2 cells treated with 10 μM Ara-
c, 4 μM aphidicolin, 10 μg/ml TLR3 agonist Poly I: C (red lines) or DMSO (blue 
line) detected by flow cytometry. Filled histograms depict isotype staining of Ara-
C treated cells. Median fluorescence intensity (MFI) ± SD of three independent 
experiments are shown. (b) Phosphorylation (left panel) and dimerization (right 
panel) of IRF3 in response to 14 hours of 10 μM Ara-C treatment detected by 
Western blotting and native gel respectively. For comparison, Raw 264.7 cells 
were treated with LPS, a known activator of IRF3 for 2 hours. Both the 
monomeric and dimeric IRF3 forms were detected by Western blotting using anti-
IRF3 antibody and are indicated by arrows. (c) 10 μM Ara-C induces nuclear 
localization of transduced IRF3-GFP in BC2 cells. Cells treated with 10 μg/ml 
Poly I: C served as a positive control. Kinase-dead IRF3A7-GFP failed to 
undergo nuclear localization. Some cells were treated with 10 μM of the 
ATM/ATR-specific inhibitor CGK733, which prevented IRF3 nuclear 
localization. FACS sorted GFP+ transductants were treated for 16 hours 9 days 
after transduction. Localization of IRF3 in DAPI stained cells was analyzed by 
confocal fluorescent microscopy. Representative image from 3 independent 
experiments are shown.(d) Quantification of DMSO, Ara-C and Ara-C with 
ATM/ATR inhibitor treated cells shown in (c). Nuclear (black), partial nuclear 
(grey) and cytoplasmic localization are indicated as stacked columns. >100 cells 
are counted for each treatment. Immunoblot data on phosphorylation of IRF3-
S388 were kindly provided by Dr Nina Le Bert. All experiments were repeated at 





3.3 IRF3 is activated constitutively in Yac-1 cells 
 
The DDR is constitutively activated in many tumor cell lines (Bartek 
and Lukas, 2003; Mills et al., 2003; Sieber et al., 2003). Activation of ATM 
and other components of the DDR pathway is also observed in precancerous 
lesions (Bartkova et al., 2005; Gorgoulis et al., 2005a). As a result many 
tumor cell lines constitutively express NKG2D ligands (Gasser and Raulet, 
2006c; Raulet, 2003). As expected if the DDR is activated in tumor cells and 
stimulates IRF3, S388-phosphorylated IRF3 was readily detected in Yac-1 
cells by intracellular staining (Figure 3.3a). The staining was specific for 
phosphorylated IRF3, because it was abrogated when the permeabilized Yac-1 
cells were pretreated with λ-phosphatase before staining. Inhibition of IRF3 
expression in Yac-1 cells by shRNA decreased the expression level of IRF3 
target genes (Figure 3.3b). IRF3-GFP, when transduced into Yac-1 cells, was 
frequently localised to the nucleus, indicating that IRF3 is often activated in 
Yac-1 cells (Figure 3.3c). In contrast, kinase-dead IRF3A7 exhibited an 
exclusively cytoplasmic localization pattern in Yac-1 cells. In summary, the 










Figure 3.2 IRF3-specific shRNA inhibits RAE1 expression in BC2 cells 
treated with 10 µM Ara-C for 16 hours. 	 
Cells were transduced with retroviral vectors encoding IRF3 shRNA and GFP 
(red line) or control shRNA and GFP (blue line), and cultured for 5 days 
before treatment. Gated GFP+ (transduced) cells were analyzed. DMSO-
treated IRF3 shRNA-transduced (dashed line) or control shRNA-transduced 
cells (dotted line) are also shown. Filled histograms depict isotype staining of 
Ara-C-treated BC2 cells. MFI ± SD of 3 independent experiments are 
indicated.  
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Figure 3. 3 IRF3 is activated constitutively in Yac-1 cells. 
 (a) Phosphorylation of IRF3-S388 in Yac-1 cells was detected by flow 
cytometry before (blue line) or after (red line) pre-treating the cells with λ-
phosphatase. The filled histogram shows isotype-staining of untreated Yac-1 
cells. MFI ± SD of 3 independent experiments are indicated. (b) Relative 
mRNA of indicated IRF3 target genes in Yac-1 cells transduced with different 
Irf3-specific shRNAs (grey and black bars) or control shRNA (white bar). 
mRNA levels of the indicated IRF3 target genes were analyzed by real-time 
PCR. Means ± SD of 3 independent experiments normalized to control 
shRNA-transduced cells are shown. p values are indicated as *p < 0.05 and 
**p < 0.01. Data was kindly provided by Dr Nina Le Bert. (c) Constitutive 
nuclear localization in Yac-1 cells of transduced IRF3-GFP but not IRF3A7-
GFP. DAPI-stained cells were examined by confocal microscopy 7 days after 
FACS sorting of GFP+ cells. Bottom panels shown without DAPI staining. 
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3.4 IRF3 is required for constitutive RAE1 expression in Yac-1 cells 
To test whether IRF3 plays a role in maintaining constitutive Rae1 
expression on tumor cell lines, we determined whether IRF3 shRNA inhibited 
ligand expression in these cells. Compared to control shRNA, the Irf3-specific 
shRNA caused a significant reduction in the amount of Rae1 displayed on the 
cell surface of Yac-1 cells (Figure 3.4).  The incomplete reduction in cell 
surface RAE1 by IRF3 shRNA may reflect in part incomplete turnover of 
preformed RAE1. These data suggest that IRF3 is constitutively activated in 
several tumor cell lines and that the optimal expression of RAE1 requires 











Figure 3.4 IRF3-specific shRNA inhibits constitutive RAE1 expression in 
Yac-1 cells.  
Cells transduced with vectors encoding GFP and IRF3-specific shRNA (red 
line) or control shRNA (blue line) were selected for 5 days in puromycin. 
Transduced cells were examined by gating on GFP+ cells. Isotype control 
staining of IRF3 shRNA (dotted line) or control shRNA (filled histogram) 
transduced cells is also shown. MFI ± SD of 3 independent experiments are 
indicated. 
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3.5 TBK1 is necessary for RAE1 expression in response to DNA damaging 
agents in BC2 cells 
IRF3 is activated by the two IKK-related serine/threonine kinases, 
TBK1 and IKKε (Fitzgerald et al., 2003; Pomerantz and Baltimore, 1999; 
Sharma et al., 2003; Shimada et al., 1999), prompting us to examine the role 
of TBK1 and IKKε in RAE1 expression. We initially tested whether TBK1 
was phosphorylated on serine 172 in response to DNA damage. Similar to 
results with IRF3, substantial TBK1 phosphorylation was detected after Ara-C 
or aphidicolin treatment, and phosphorylation occurred with relatively late 
kinetics over a 25-hour period (Figure 3.5). Induction of TBK1 
phosphorylation by Poly I: C occurred much more rapidly, as expected. We 






Figure 3.5 TBK1 is phosphorylated upon DNA damaging agents in BC2 cells.  
(a) BC2 cells were treated with 10 μM Ara-C, 4 μM aphidicolin, 10 μg/ml Poly I: 
C (bold lines) or DMSO (fine line) for the indicated time. Cells were stained for 
phosphorylation of S172 of TBK1. Filled histograms depict isotype staining of 
DMSO treated cells. MFI ± SD of 3 independent experiments are indicated. (b) 
Immunoblot analysis of TBK1S172 phosphorylation in BC2 cells treated with 10 μM Ara-C or DMSO for 14 hours. Raw 264.7 cells were treated with LPS for 4 

































          BC2 cells transduced with TBK1 shRNA had significant reduction in 
RAE1 cell surface expression compared to BC2 cells tranduced with control 
shRNA upon treatment with Ara-C (Figure 3.6a). Inhibition was observed 
compared to untransduced (GFP−) cells in the same cultures or compared to 
cells transduced with control shRNA (Figure 3.6a and data now shown). As an 
alternative approach, we employed mouse embryonic fibroblast (MEF) cell 
lines from mice in which both the TBK1 and IKKε genes were inactivated by 
gene targeting (Matsui et al., 2006). TBK1-/-IKKε-/- MEFs treated with Ara-C 
did not upregulate any of the NKG2D ligands tested (Figure 3.6bi). Genetic 
reconstitution of TBK1-/-IKKε-/- MEFs with either TBK1 or IKKε was 
sufficient to induce RAE1βδ and RAE1ε expression on a fraction of the cells 
(Figure 3.6bii and iii), and restore the capacity of the cells to upregulate RAE1 
further in response to DNA damaging agent Ara-C (Figure 3.6bii and iii). The 
induction of RAE1 without Ara-C treatment in some cells may reflect 
overexpression of TBK1 or IKKε, which has been shown to result in 
unregulated activation of the pathway in other contexts (Buss et al., 2004; 
Fensterl et al., 2005; Parvatiyar et al., 2010). In summary, these data suggest 
that TBK1 (and/or the similarly functioning IKKε) is required for normal 








































Figure 3.6 TBK1 is necessary for RAE1 expression in response to DNA 
damage.  
(a) Inhibition of RAE1 upregulation in response to DNA damage by TBK1 
shRNA. BC2 cells were transduced with retroviral vectors encoding TBK1 
shRNA and GFP (bold lines in histograms) or control shRNA and GFP (fine 
lines), cultured for 5 days and treated with 10 μM Ara-C for 16 hours. Rae1 
expression was determined by gating on transduced (GFP+) cells. Dotted line: 
DMSO treated cells expressing TBK1-specific (dashed line) or control shRNA 
(dotted line) stained with RAE1-specific antibodies. Filled histogram: Ara-C 
treated cells stained with isotype controls. (b) TBK1-/-IKKε-/- MEFs were 
transduced with the retroviral vectors encoding TBK1-IRES-GFP (ii), IKKε-
IRES-GFP (iii) or IRES-GFP (i). 8 days after selection cells were treated with 
DMSO (fine line) or 10 μM Ara-C for 18 hours (bold lines) and analyzed for 
indicated NKG2D ligand expression. Isotype staining of DMSO (filled 
histograms) or Ara-C treated (dashed line) is shown. MFI ±SD of 3 independent 
experiments are indicated. 
 62 
3.6 TBK1 is necessary for constitutive RAE1 expression in Yac-1 cells 
 Given the constitutive activation of IRF3 in Yac-1 cells, we next tested 
whether TBK1 or IKKε are constitutively active in Yac-1 cells. TBK1 
phosphorylated on serine 172 was readily detected in Yac-1 cells by 
intracellular staining (Figure 3.7a), which is to be contrasted with the 
undetectable level of phospho-TBK1 detected in unstimulated BC2 cells 
(Figure 3.6a).Treatment of the permeabilized Yac-1 cells with λ-phosphatase 
nearly abolished staining. Transduction of Yac-1 cells with TBK1 shRNA 




Figure 3.7 TBK1 is necessary for constitutive RAE1 expression in Yac-1 cells. 
(a) Phosphorylation on S172 of TBK1 was detected by flow cytometry (fine line). 
Some Yac-1 cells were pretreated with λ-phosphatase before staining (bold line). 
The filled histogram shows isotype-staining of untreated Yac-1 cells. (b) Yac-1 
cells were transduced with retroviral vectors encoding Tbk1-specific shRNA and 
GFP (bold line) or control shRNA and GFP (fine line) and cultured for 5 days. 
RAE1 expression was determined by gating on transduced (GFP+) cells. Isotype 
staining of Tbk1-specific shRNA (dashed lines) and control shRNA (filled 



















3.7 Phosphorylation of IRF3 and TBK1 in response to DNA Damage 
depends on ATR in BC2 cells 
Activation of ATR versus ATM depends on the nature of DNA 
damage to which a cell is exposed. Treatment of cells with Ara-C, a 
nucleoside analogue, results in ssDNA breaks leading to the preferential 
activation of ATR, which in turn activates CHK1 (Covey et al., 1986; 
D'Incalci et al., 1985; Wang et al., 2008b). To address the role of ATM and 
ATR in the activation of TBK1 and IRF3, we utilised different chemical 
inhibitors to block ATM and ATR function. Induction of RAE1 expression in 
BC2 cells by Ara-C was inhibited by the combined treatment of cells with 
specific ATM and ATR inhibitors (Figure 3.8a). Inhibition of ATM and ATR 
also inhibited TBK1 and IRF3 phosphorylation (Figure 3.8b and c) and 
nuclear localization of chimeric IRF3-GFP (Figure 3.1c and d) in Ara-C- 
treated BC2 cells. The effects of ATM or ATR inhibition on NKG2DL 
expression and phosphorylation of TBK1 and IRF3 were less pronounced 



















































































Figure 3.8 Phosphorylation of IRF3 and TBK1 in response to DNA Damage 
depends on ATR in BC2 cells.  
(a) Analysis of RAE1 expression in BC2 cells pretreated with 10 μM of the ATM 
inhibitor KU55933, 10 μM of the ATR inhibitor VE-821, 10 μM of KU55933 and 10 μM of VE-821 (red line) or DMSO (blue line) and further incubated with 10 μM Ara-
C for 16 hours. As controls, BC2 cells were pretreated with the same inhibitors 
(dashed line) or DMSO (fine line) before DMSO treatment for 16 hours. Filled 
histograms indicate isotype control staining. Phosphorylation of TBK1S172 (b) and 
IRF3S388 (c) in BC2 cells pretreated with 10 μM of the ATM inhibitor KU55933, 10 μM of the ATR inhibitor VE-821, 10 μM of KU55933 and 10 μM of VE-821 (red 
line) or DMSO (blue line) and further incubated with 10 μM Ara-C or DMSO for 16 
hours. As controls, BC2 cells were pretreated with the same inhibitors (dashed line) 
or DMSO (fine line) before DMSO treatment for 16 hours. Filled histograms indicate 
isotype control staining. MFI ± SD of 3 independent experiments are indicated. 
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3.8 Phosphorylation of IRF3 and TBK1 depends on ATR in Yac-1 cells 
The inhibition of ATR leads to a decrease in the constitutive RAE1 
expression and phosphorylation of TBK1 and IRF3 in Yac-1 cells (Figure 3.9a 
and b). Nuclear localization of IRF3-GFP in Yac-1 cells was also suppressed 
by inhibition of ATM and ATR (Figure 3.9c). Thus, activation of TBK1 and 
IRF3 in Yac-1 cells depends on ATR suggesting that constitutive single-
stranded (ss) DNA damage, which preferentially activates ATR (Sancar et al., 
2004a), is present in Yac-1 cells. 
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Figure 3.9 Phosphorylation of IRF3 and TBK1 depends on ATR in Yac-1 
cells.  
Yac-1 cells treated for 16 hours with ATM and/or ATR-specific inhibitors (red 
line) or DMSO (blue line) as indicated above and stained for RAE1 expression 
(a), TBK1pS172 (left panel) and IRF3pS388 (right panel) (b). Filled histograms 
depict isotype control staining.  MFI ± SD of 3 independent experiments are 
indicated. (c) Yac-1 cells transduced with chimeric IRF3-Gfp or IRF3A7-Gfp 
encoding retroviral vectors were treated with 10 μM of KU55933 and 10 μM of 
VE-821 or DMSO for 14 hours. IRF3 expression was analyzed by fluorescent 
microscopy. DAPI staining was removed for better visualization of IRF3 
expression in the lower panels. Representative image from 3 independent 
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  The data provide evidence that IRF3 and TBK1 are activated in 
response to DNA damage via ATR. Both constitutive and inducible 




Chapter 4: Accumulation of cytosolic DNA in 
response to DNA damage 
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4.1 DNA damaging agents induce accumulation of cytosolic DNA  
Recognition of cytosolic DNA by DNA sensors activates TBK1 and 
IKKε (Takeshita and Ishii, 2008; Yanai et al., 2009b). To test whether 
treatment of cells with DNA damaging agents leads to the accumulation of 
cytosolic DNA, we stained cells with antibodies specific for ssDNA or 
dsDNA. The specificity of DNA staining was determined by pretreating some 
cells with RNase and DNase to digest dsDNA or S1 nuclease to digest ssDNA 
before staining (Suzuki et al., 1997; Yang et al., 2007). In addition, we treated 
cells with RNase and stained for the mitochondrial marker COX IV to exclude 
mitochondrial DNA (Figure 4.1 and 4.2) (Khalimonchuk and Winge, 2008). 
Strikingly, we found that significant amounts of ssDNA and dsDNA 
accumulated in the cytosol after Ara-C treatment (Figure 4.1). Furthermore, 




Figure 4.1 DNA damage results in accumulation of cytosolic DNA in BC2 cells.  
(a) BC2 cells treated with 10 μM Ara-C or DMSO for 13 hours were fixed and stained 
with ssDNA or dsDNA-specific antibodies (red) and Cox-IV (green) in presence of 
RNase and DAPI (blue). Cells in the indicated panels were treated with S1 nuclease or 
DNase before staining. Representative image from 3 independent experiments are shown. 
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Figure 4.2 DNA damage results in accumulation of cytosolic DNA in Yac-1 cells.  
Yac-1 cells were fixed and stained with ssDNA or dsDNA-specific antibodies (red) 
and Cox-IV (green) in presence of RNase and DAPI (blue). Cells in the indicated 
panels were treated with S1 nuclease or DNase before staining. Representative image 
from 3 independent experiments are shown. 
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4.2 Expressions of RAE1 is dependent on DNA 
The finding that DNA accumulates in the cytosol of cells exposed to 
DNA damage, coupled with the data showing that mediators that relay signals 
from DNA sensors (IRF3 and TBK1) are required for induction of NKG2D 
ligands, suggested that DNA sensors may play a role in the induction of 
NKG2D ligands. To test whether cytoplasmic DNA can induce RAE1 
expression in BC2 cells we transfected cells with AF488-labelled plasmid 
DNA, genomic DNA or ssDNA. AF488-positive BC2 cells upregulated 
expression of NKG2D ligands, although to a lesser degree than cells treated 
with the DNA damaging agent Ara-C (Figure 4.3). The findings that DNA 
accumulates in the cytoplasm of cells subjected to DNA damage and that 
DNA introduced into cells induces NKG2D ligands provide additional 
evidence that links the DNA sensing pathway to NKG2D ligand expression 































Figure 4.3 RAE1 expression is induced by DNA.  
BC2 cells were transfected with 4 µg AF488-labelled MSCV-IRES-GFP, 
C57BL/6 genomic DNA or ssDNA (non-stimulatory control for ODN 1668). As 
controls, cells were treated with 10 µM Ara-C or DMSO. 18 hours after 
transfection or treatment, BC2 cells were stained for the indicated NKG2D 
ligands and analyzed by flow cytometry. Ara-C treated or gated DNA-transfected 
cells (AF488+) are shown as bold lines. Control gated AF488- cells are indicated 
as dotted lines. DMSO treated cells are depicted as fine lines. Isotype staining of 
Ara-C treated or AF488+ cells is shown as dashed lines. Filled histograms indicate 
DMSO treated cells stained with isotype controls. MFI ± SD of 3 independent 
experiments are indicated. 
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4.3 Expressions of RAE1 is dependent on STING 
The presence of DNA in the cytosol activates endoplasmic reticulum-
resident transmembrane protein stimulator of IFN genes (STING)-dependent 
DNA sensors leading to the activation of TBK1 and IRF3 (Ishikawa and 
Barber, 2008). We therefore tested whether STING is necessary for RAE1 
expression induced in cells exposed to genotoxic stress. WT MEFs 
upregulated RAE1βδ in response to Ara-C, but this was abrogated in MEFs 
with a loss of function Sting mutation (Figure 4.4) (Burdette et al., 2011). 
Reconstitution of Sting expression by transduction resulted in restored 
inducibility of RAE1 in the cells. As another approach, BC2 cells expressing a 
Sting-specific shRNA showed reduced RAE1 induction by Ara-C as well 
(Figure 4.5a). Furthermore, Sting inhibition in Yac-1 cells resulted in reduced 
constitutive RAE1 expression levels (Figure 4.5b). These data support the 
conclusion that the STING-dependent DNA sensor pathway is necessary for 
induction of NKG2D ligands. 
We next tested the requirement in RAE1 induction for one candidate 
STING-dependent DNA sensor that activates IRF3, ZBP1 (Takaoka et al., 
2007). Knockdown of Zbp1 partly inhibited the upregulation of RAE1αβγ in 
response to Ara-C, but had little effect on RAE1βδ (Figure 4.5a). In contrast, 
knockdown of Zbp1 modestly inhibited RAE1βδ, but not RAE1αβγ, 
expression in Yac-1 cells (Figure 4.5b). Inhibition of Rig-I, a RNA sensor that 
may indirectly mediate responses to cytosolic DNA, had no effect on RAE1 
expression in BC2 or Yac-1 cells (Figure 4.5). It is likely, therefore, that DNA 
sensors other than ZBP1 participate in inducing RAE1 expression in response 
to DNA damage, in line with other evidence suggesting the existence of DNA 
sensors redundant with ZBP1 (Ishii et al., 2008a). Taken together these data 
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suggest that cytosolic nucleic acid sensors regulate NKG2D ligand expression 
























Figure 4.4 Expressions of RAE1 is dependent on STING.  
WT MEFs or MEFs lacking functional STING were transduced with retroviral 
vectors encoding Sting-IRES-Gfp or IRES-Gfp and cultured for 5 days before 
treating with 10 μM Ara-C for 16 hours. RAE1 expression was determined by 
gating on transduced (GFP+) cells. Ara-C treated (bold) and DMSO-treated 
(thin) cells were stained with the different RAE1 isoforms. Isotype controls 
for Ara-C treated (filled histogram) and DMSO-treated (dotted) cells were 







































Figure 4.5 Knockdown of Sting, Zbp1 and Rig-I in BC2 and Yac-1 cells.  
(a) BC2 cells were transduced with Sting, ZBP1 and Rig-I-specific shRNAs 
(bold line) or control shRNAs (fine line) and treated with 10 µM Ara-C for 16 
hours. As a control, BC2 cells were transduced with shRNA specific for the 
nucleic acid sensors (Dashed line) or control shRNAs and treated with DMSO 
(dotted line). NKG2D ligand expression was analyzed by flow cytometry. 
Isotype control stainings are shown as filled histograms. (b) Yac-1 cells were 
transduced with Sting, Zbp1 and Rig-I-specific shRNAs (bold line) or control 
shRNAs (fine line). Isotype control staining of nucleic acid sensor-specific 
shRNA (dashed line) or control shRNA (filled histogram) is shown. MFI ± 
SD of 3 independent experiments are indicated. 
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4.4 Accumulation of cytosolic DNA in leukaemic B cells of Eµ-Myc mice 
Our previous data suggested that cytosolic DNA may lead to the 
immune mediated rejection of immune cells. To study this in vivo, we used the 
Eµ-Myc murine model or B cell lymphoma (Harris et al., 1988).  Eµ-Myc mice 
over-express murine c-Myc under the control of the Ig heavy chain enhancer 
region (Eµ), analogous to human Burkitt lymphoma (Harris et al., 1988). 
Early-stage Eµ-Myc disease is characterized by immature B cell leukaemia, 
which progresses to lymphoma terminal-stage disease (Harris et al., 1988). 
The tumour cells in Eµ-Myc mice can be identified in the blood by their 
surface expression markers B220 and IgM (Figure 4.6). Tumour cells in Eµ-
Myc mice spontaneously regress at around day 40 of age and the regression is 
dependent on immune cells (Croxford et al., 2013). Myc-induced replication 
stress was shown to induce DNA damage in Eµ-Myc mice (Croxford et al., 
2013; Reimann et al., 2007). Furthermore, NKG2D was reported to play a role 
in tumour surveillance in the Eµ-Myc mice (Guerra et al., 2008). To test if B 
cell tumors express ssDNA as a consequence of Myc expression, we stained B 
cells for the presence of cytosolic DNA. In agreement with our in vitro 
findings, we observed ssDNA in the cytoplasm of ex vivo leukaemic B cells 
purified from the spleen of young (< d42) Eµ-Myc mice (Figure 4.7a). 
Quantification analyses showed that 23.0 ± 1.4 % of the total B220 cells 
accumulate ssDNA (Figure 4.7b). This is in contrast to wild type B cells, 
which do not show cytosolic DNA.  
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Figure 4.7 Ex vivo leukemia B cells accumulate ssDNA.  
 (a) Accumulation of ssDNA in early Eµ-Myc tumour cells compared to WT cells. 
Data is representative of 3 independent experiments. (b) Quantification of the 
percentage of total B220+ cells with ssDNA. Error bar indicating SD was too small to 
be seen. > 100 cells were counted for each genotype. 
Figure 4.6 Tumour populations in Eµ-Myc and WT mice.  
Cells derived from the peripheral blood were stained for anti-B220 and anti-
IgM antibodies, and were subsequently assessed by flow cytometry. B220low 
populations in Eµ-Myc mice were identified by the oval gates. Adapted from 









































% without ssDNA 







4.5 Summary  
 
We observed accumulation of cytosolic DNA in response to DNA 
damaging drugs in BC2 and constitutive expression of cytosolic DNA in Yac-
1 cells. In addition, cytosolic DNA is also present in ex vivo tumour B cells 
from Eµ-Myc mice. We also showed that the expression of NKG2DLs is 






Chapter 5: Decreased survival of Eµ-Myc mice 
deficient in Irf3  
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5.1 Decreased survival of Eµ-Myc mice heterozygous for Irf3  
Our data raise the possibility that IRF3-dependent NKG2D ligand 
expression plays a critical role in immune surveillance of tumours. To analyse 
the effect of IRF3 on the progression of B cell lymphomas, Irf3-deficient mice 
were crossed with the Eµ-Myc mice. Survival analysis showed that Irf3+/-Eµ-
Myc mice (n= 17; median survival= 62 days) experienced a significantly 
reduced survival rate compared to Irf3+/+Eµ-Myc mice (n= 25; median 
survival= 116 days) (***p<0.001 by Log-Rank test or by Gehan-Breslow-
Wilcoxon Test) (Figure 5.1). No difference in survival rate between Irf3-/- or 
Irf3+/+ non-Eµ-Myc mice was observed (n= 25; median survival= >250 days) 
(Figure 5.1). We were not able to generate Irf3-/-Eµ-Myc mice because Irf3+/-
Eµ-Myc mice failed to breed. 
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Figure 5.1 Accelerated onset of Myc-driven lymphomas in heterozygous IRF3 
Eμ-Myc mice. 
 Irf3+/-Eμ-Myc mice (thick line) exhibit decreased survival compared to Irf3+/+Eμ-
Myc (thin line) or non-transgenic Irf3+/+ (dashed line) or Irf3-/- mice (dotted line). 
Kaplan-Meier analysis of survival of Irf3+/+Eμ-Myc mice (n= 25; median 
survival= 116 days), Irf3+/-Eμ-Myc mice (n= 17; median survival= 62 days) and 
Irf3+/+ or Irf3-/- mice (n= 25; median survival= >250 days). ***p < 0.0001 by 
Log-Rank test or by Gehan-Breslow-Wilcoxon Test. Data were kindly provided 
by Dr John Ludovic Croxford and Ms Pan Meng Fei. 
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            In addition, heterozygosity of Irf3 in Eµ-Myc mice resulted in a 2.5-
fold lower levels of IRF3 and reduced expression of IRF3 target genes in 
splenic B cell lymphomas when compared to Irf3+/+Eµ-Myc mice (Figure 5.2).  
 
 
Figure 5.2 Reduced expression of IRF3 target genes. 
Relative mRNA levels of indicated IRF3 target genes in purified tumor cells 
of Irf3+/-Eμ-Myc (white) and Irf3+/+Eμ-Myc (black) mice were measured by 
real-time PCR and normalized with HPRT. Error bar denotes SD. Data were 























































5.2 Lower expressions of RAE-1 isoforms in Irf3+/-Eµ-Myc mice 
  
 To determine if the reduced IRF3 amounts impaired NKG2D ligand 
expression in Eµ-Myc mice we stained tumor cells for expression for RAE1ε, 
the only RAE1 family member detected on Eµ-Myc tumor cells (Unni et al., 
2008). In Eµ-Myc mice, tumor cells exhibit the phenotypes of IgM-B220low 
and IgM+B220low cells in the blood or spleen (Figure 4.5) (Harris et al., 1988; 
Langdon et al., 1986; Sidman et al., 1993a; Yukawa et al., 1989), allowing 
them to be distinguished from normal B cells (IgM+B220high). RAE1ε 
expression was significantly reduced in tumor cells of Irf3+/-Eµ-Myc (n = 3) 











Figure 5.3  RAE1ε  expression in tumor cells of Irf3+/-Eμ-Myc mice. 
B220low tumor cells in blood of moribund Irf3+/-Eμ-Myc (bold line) and 
Irf3+/+Eμ-Myc (fine line) mice were stained for indicated NKG2DL 
expression. Filled histogram depicts isotype staining of B220low tumor in 
Irf3+/+Eμ-Myc mice. Flow histograms from 3 different mice are shown.	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 5.3 Altered survival curve in Irf3/Bcl2l12+/-Eµ-Myc is due to decreased 
expression of IRF3, rather than changes in BCL2L12 expression 
The null mutation introduced into the Irf3 allele also resulted in the 
functional inactivation of the neighboring Bcl2l12 gene (Nakajima et al., 
2009). BCL2L12 was shown to promote or suppress tumorigenesis depending 
on the cellular context (Stegh et al., 2007). However, in contrast to IRF3, 
heterozyogosity of the gene-targeted locus did not result in reduced BCL2L12 
protein levels (Figure 5.4).  
 
 
To compare apoptosis rate in tumor cells of Irf3+/-Eµ-Myc and 
Irf3+/+Eµ-Myc mice, we cultured tumor cells for 2-4 hours in vitro (Figure 
5.5a). We found no difference in the apoptosis rate of tumor cells derived from 
Irf3+/-Eµ-Myc mice and Irf3+/+Eµ-Myc mice. Tumor cells in Irf3+/- and 
Irf3+/+Eµ-Myc mice also incorporated similar amounts of BrdU suggesting the 
proliferation rate of tumor cells is not changed by heterozygosity in the Irf3 
locus (Figure 5.5b).  
Figure 5.4 Reduced IRF3 but not BCL2L12 protein levels in Irf3+/-Eµ-
Myc.  
(a) Immunoblot analysis of purified splenic B cell lymphomas (> 78% purity) 
from Irf3+/-Eμ-Myc, Irf3+/+Eμ-Myc, Irf3+/+WT, Irf3+/-WT and Irf3-/-WT 
probed with antibodies for IRF3, BCL2L12 and GAPDH (left panel). (b) 
Densitometry of immunoblot analysis of IRF3, BCL2L12 expression in 
splenic B cells lymphomas from Irf3+/-Eμ-Myc and Irf3+/+Eμ-Myc mice. Mean 
± SD of 3 mice are normalized to GAPDH levels. p values are indicated as 































































































In BC2 and EµM1 cells, overexpression of Bcl2l12 had no effect on 
proliferation or NKG2D ligand expression (Figure 5.6a and b). The rate of 
apoptosis was not also changed in BC2 cells overexpressing Bcl2l12 when 
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Figure 5.5 Rate of apoptosis and proliferation is not changed in tumors of 
Irf3+/-Eµ-Myc mice.  
(a) Tumor cells derived from the blood of day 27 of age Irf3+/-Eµ-Myc (white) 
and Irf3+/+Eµ-Myc (black) mice were cultured for 2 to 4 hrs before staining 
with B220, IgM, Propodium Iodide (PI) and Annexin-V. Annexin-V and PI 
positive cells were considered apoptotic. Data is represented as mean ± SD of 
4 different mice for each genotype. (b) 37 days of age Irf3+/+Eμ-Myc (black) 
and Irf3+/-Eμ-Myc (white) mice were injected with 1 mg BrdU i.p. 18 hrs 
before B220low blood cells were analysed for IgM expression and BrdU 
incorporation. Percentage of BrdU positive B220lowIgM- (left panel) and 
B220lowIgM+ (right panel) in the blood of mice is shown.  Data is represented 
as mean ± SD of 3 different mice for each genotype. 
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apoptosis in EµM1 cells (Figure 5.6c). In EµM1 cells, the percentage of 
Annexin V+PI+ cells was significantly higher in cells transduced with Gfp 
control (mean ± SD = 7.850 ± 0.752 %, n = 4)  compared to cells transduced 
with Bcl2l12 (mean ± SD = 5.213 ± 0.607 %, n = 4) (P = 0.0116). These data 
support the conclusion that the altered survival curve in Irf3/Bcl2l12+/-Eµ-Myc 




























































































































Figure 5.6 Overexpression of Bcl2l12 in BC2 or EµM1 cells has little or no 
effect on RAE1 expressions, apoptosis or proliferation rate.  
BC2 or EμM1 cells were transduced with retroviral vectors encoding Bcl2l12-
IRES-Gfp (red line) or IRES-Gfp (blue line). (a) 3 days post transduction 
expression of indicated RAE1s was determined by flow cytometry. Filled 
histograms show isotype staining of Bcl2l12-IRES-Gfp transduced cells. Fine line 
indicates the isotype staining of IRES-Gfp expressing cells. (b) 0.5 x 105/ml 
MSCV-Bcl2L12 (open symbol) or MSCV-GFP (filled symbol) transduced BC2 
cells (left panel) or EμM1 (right panel) were plated and living GFP+ cells were 
counted every 24 hours for the next 5 days. Data is represented as means ± SD of 
3 independent experiments. (c) The percentage of Annexin-V+/PI+ cells MSCV-
Bcl2L12 (open symbol) or MSCV-GFP (filled symbol) transduced BC2 cells 
(circle) or EμM1 (black) was determined by flow cytometry. Statistical analyses 
were performed using student’s t test. *p<0.05. Data represents means ± SD of 4 
independent experiments. 
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5.4 Characterization of NK cells maturation and activity in Irf3+/-Eµ-Myc 
mice  
 Our previous data showed that NK cells and T cell contribute to 
immunosurveillance in Eµ-Myc mice (Croxford et al., 2013). Irf3 deficiency 
has no impact on NK and T cell numbers (Sato et al., 2000). To address if 
there is any difference in NK cells activation in the Irf3+/-Eµ-Myc mice, we 
performed a CD107a degranulation assay. Several studies had established that 
degranulation of CD107a in NK cells correlate with its cytotoxicity activity 
and could be used as a sensitive marker for NK cell activity (Aktas et al., 
2009; Alter et al., 2004). Besides being expressed on nearly all cytokine-
secreting cells, CD107a was also expressed on a large subset of NK cells that 
did not secrete cytokine following stimulation. Thus, this facilitates 
identification of a large fraction of activated NK cells that may degranulate 
without cytokine secretion. We did not observe any difference in percentage 
of CD107a+ NK cells between Irf3+/-Eµ-Myc (n = 9, mean ± SD = 21.489 ± 
4.589%) and Irf3+/+Eµ-Myc mice (n = 7, mean ± SD = 23.400 ± 7.528%) 
when co-incubation with Yac-1 in a 3:1 target to effector ratio (Figure 5.7a). 
Similarly, the percentage of IFNγ+ NK cells were not significantly different 
between Irf3+/- Eµ-Myc (n = 9, mean ± SD = 4.901 ± 1.371%) and Irf3+/+Eµ-
Myc mice (n = 7, mean ± SD = 4.751 ± 2.288%) (Figure 5.7a). 
To investigate if there is any difference in NK cells activity upon 
stimulation of the NKG2D receptor, we took freshly isolated splenocytes and 
stimulated in vitro for 5 hours on plates pre-coated with anti-NKG2D or 
isotype control antibody. We did not observe any difference in percentage of 
IFNγ+ NK cells between Irf3+/- Eµ-Myc (n = 4, mean ± SD = 20.350 ± 
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6.360%) and Irf3+/+Eµ-Myc mice (n = 4, mean ± SD = 28.625 ± 12.156%) 
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Figure 5.7 NK cells from Irf3+/- Eµ-Myc and Irf3+/+Eµ-Myc showed similar 
activation. 
 (a) IL-2–activated NK cells derived from Irf3+/-Eμ-Myc (white squares, n= 8) 
and Irf3+/+Eμ-Myc (black circles, n= 7) mice were incubated with Yac-1 cells 
at an effector: target ratio of 3:1. After 4 hrs, the percentage of CD107a and 
IFN-γ-expressing NK1.1+CD3- cells was determined by flow cytometry (left 
and right panel). (b) Freshly isolated splenocytes of Irf3+/-Eμ-Myc (white 
squares, n= 4) and Irf3+/+Eμ-Myc (black circles, n= 4) mice were stimulated in 
vitro for 5 hrs on plates coated with NKG2D-specific antibodies (MI-6, 10 μg/ml), or isotype control (10 μg/ml) in the presence of GolgiPlug and 1 x 103 
units/ml recombinant human IL-2 before staining and analysis. Intracellular 
IFN-γ was detected by flow cytometry on electronically gated NK1.1+CD3- 
cells. Data is represented as mean ± SD. 
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In addition, we did not observe a significant difference in the 
development of NK cells from Irf3+/-Eµ-Myc and Irf3+/+Eµ-Myc mice (Figure 
5.8). NKG2D deficiency increases the tumor load of Eµ-Myc mice, but has not 
impact on the survival (Guerra et al., 2008). Hence, it is possible that 
additional Irf3-mediated effects are responsible for the shortened survival of 







0.290 ± 0.198 0.243±0.107 













































































Irf3+/+ Eµ-Myc Irf3+/- Eµ-Myc Irf3+/- Eµ-Myc 
Figure 5.8 NK cell development is preserved in Irf3+/-Eµ-Myc mice. 
Analysis of NK subsets in the bone marrow (n= 4; left panel) and spleen (n= 
4; right panel) of Irf3+/+Eμ-Myc mice (left columns) and Irf3+/-Eμ-Myc mice 
(right columns). The top groups represent gated CD3- cells, whereas the 
remaining panels represent gated NK1.1+CD3- cells. The numbers represent 





Eµ-Myc mice heterozygous for Irf3 exhibit decreased survival and 
reduced expression of RAE1ε. The null mutation introduced into the Irf3 allele 
also resulted in the functional inactivation of the neighboring Bcl2l12 gene. 
Bcl2l12 in BC2 or EµM1 cells has little or no effect on RAE1 expressions, 
apoptosis or proliferation rate, thus suggesting that the altered survival curve 
in Irf3/Bcl2l12+/-Eµ-Myc is due to decreased expression of IRF3, rather than 
changes in BCL2L12 expression. The activity and maturation of NK cells are 




Chapter 6: Increased survival of Eµ-Myc mice 
deficient in Zbp1      
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6.1 Increased survival of Eµ-Myc mice deficient in Zbp1  
 To study the potential role of cytosolic DNA sensors in tumorigenesis, 
we bred mice deficient for Zbp1 (Zbp1-/-) to Eµ-Myc mice. Surprisingly, the 
survival of complete knockout of Zbp1-deficient Eµ-Myc mice (Zbp1-/-Eµ-
Myc) showed a significant increase in survival (median survival of 174 days, n 
= 57) when compared to Zbp1+/+Eµ-Myc (median survival of 111 days, n = 38) 
(P = 0.003 by Log-Rank(Mantel-Cox) Test or  P = 0.016 by Gehan-Breslow-
Wilcoxon Test) and Zbp1+/-Eµ-Myc mice (median survival of 111 days, n= 32) 
(P < 0.001 by Log-Rank (Mantel-Cox) Test or  P = 0.008 by Gehan-Breslow-







Figure 6.1 Survival is increased in Eµ-Myc mice deficient in Zbp1. 
Zbp1-/-Eµ-Myc mice (dark grey) exhibit increased survival compared to 
Zbp1+/-Eµ-Myc (light grey) and Zbp1+/+Eµ-Myc mice (black) using Kaplan-
Meier analysis of survival. **p < 0.010 or *** p< 0.001 by Log-Rank 






















6.2 Eµ-Myc mice deficient in Zbp1 had reduced tumour load 
The tumour cells in Eµ-Myc mice can be identified in the blood by 
their surface expression markers B220 and IgM (Figure 4.5). The prolonged 
survival of Zbp1-/-Eµ-Myc mice correlated with a lower blood tumor load in 
the blood between day 21-40 (n = 152, mean tumor load ± SD = 39.570 ± 
12.020%) and day 41-65 (n = 106, mean tumor load ± SD = 25.860 ± 
15.800%) (P < 0.001) (Figure 6.2a and b). However, we did not observe 
similar regression in Zbp1+/+Eµ-Myc between day 21-40 (n = 120, mean 
tumour load ± SD = 39.410 ± 26.280%) and day 41-65 (n = 80, mean tumour 
load ± SD = 37.540 ± 24.220%) (Figure 6.2a and b). Similarly, Zbp1+/-Eµ-Myc 
mice showed no significant decrease in blood tumour load between day 21-40 
(n = 173, mean tumour load ± SD = 45.940 ± 14.980%) and day 41-65 (n = 
127, mean tumour load ± SD = 36.460 ± 21.030%) (Figure 6.2a and b). 
Expectedly, the tumour load of WT mice remains low (mean tumour load< 
20%).  
 At day 41-65, the tumour load for Zbp1-/-Eµ-Myc mice (n = 106, mean 
tumor load ± SD = 25.860 ± 15.800%) was significantly lower than Zbp1+/- 
Eµ-Myc (n = 80, mean tumour load ± SD = 37.540 ± 24.220%) (P < 0.001) 
and Zbp1+/+Eµ-Myc mice (n = 80, mean tumour load ± SD= 37.540 ± 
24.220%) (P < 0.001) (Figure 6.2a and b). At greater than 65 days of age, the 
tumour load for Zbp1+/+ Eµ-Myc mice (n = 88, mean tumor load ± SD = 
39.580 ± 29.950%) was significantly higher than Zbp1-/-Eµ-Myc mice (n = 
215, mean tumor load ± SD = 24.830 ± 21.500%) (Figure 6.2a and b).  
 We also measured the absolute number of B220low cells in the blood by 
multiplying the number of blood lymphocytes measured by scil Vet abc with 
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percentage of blood tumor load assessed by flow cytometry. We observed a 
significant decreease in the number of B220low cells in the blood between day 
31-40 (n = 14, mean ± SD = 2.597 ± 1.649 x 103 cells per µl) and day 51-65 (n 
= 14,  mean ± SD = 1.395 ± 0.187 x 103 cells per µl) (P = 0.0187) in Zbp1-/-
Eµ-Myc mice (Figure 6.2c). We did not observe a difference in the number of 
B220low cells in the blood between day 31-40 (n = 15, mean ± SD = 2.646 ± 
1.379 x 103 cells per µl) and day 51-65 (n = 15,  mean ± SD = 2.490 ± 2.681 x 
103 cells per µl) in Zbp1+/+Eµ-Myc mice (Figure 6.2c).   	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Figure 6.2 Eµ-Myc mice deficient in Zbp1 had reduced tumour load.  
(a) and (b) Longitudinal analysis of tumor load in peripheral blood of Eµ-Myc 
or WT mice by flow cytometric analysis. Each point (·) represents percentage 
of B220low cells in the blood of individual Eµ-Myc mice. Mice were sacrificed 
after developing signs of disease. Diamond represents mean tumor load per 
time-point and 95% confidence limit. Mean percentage of B220low cells in the 
blood of WT mice is represented by black line. Summary of data in (a) is 
shown in (b). Data represent average tumour cells ± SD. Statistical analyses 
were performed using one-way ANOVA. *** p<0.001. (c) Number of B220low 
cells in the peripheral blood of Zbp1-/-Eµ-Myc (black circle) and Zbp1+/+Eμ-
Myc mice (white square) is calculated by multiplying the number of blood 
lymphocytes measured by scil Vet abc with percentage of blood tumor load 
assessed by flow cytometry. Data represent mean tumor load per time-point ± 
SD. Statistical analyses were performed using student’s t test. *p<0.05. 
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6.3 Difference in regression was not due to altered trafficking of tumour 
cells 
A similar decrease was observed in the tumor load in the spleen and 
lymph nodes at 41-65 days of age in the Zbp1-/-Eµ-Myc mice (Figure 6.3). In 
the spleen of Zbp1-/-Eµ-Myc mice, there was a significant decrease in the 
percentage of IgM- B220low cells from day 21-40 (n = 39, mean ± SD = 48.350 
± 14.831%) to day 41-65(n = 10, mean ± SD = 24.518 ± 24.939%) (P < 0.001) 
(Figure 6.3). However, in the spleen of Zbp1+/+Eµ-Myc mice, the percentage of 
IgM- B220low cells from day 21-40 (n = 32, mean ± SD = 47.241 ± 16.923%) 
to day 41-65(n = 15, mean ± SD = 39.654 ± 29.086%) remains relatively 
constant.  
In the lymph nodes of Zbp1-/-Eµ-Myc mice, there was a significant 
decrease in the percentage of IgM- B220low cells from day 21-40 (n = 22, mean 
± SD = 42.145 ± 17.682%) to day 41-65(n = 7, mean ± SD = 14.454 ± 
25.382%)  (P = 0.003) (Figure 6.3). However, in the spleen of Zbp1+/+Eµ-Myc 
mice, the percentage of IgM- B220low cells from day 21-40 (n = 19, mean ± 
SD = 43.053 ± 16.733%) to day 41-65(n = 11, mean ± SD = 37.818 ± 
32.657%) remains relatively constant (Figure 6.3). The percentage of tumor 
cells in the bone marrow in both Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc was 
comparable and was roughly constant at all stages of disease (Figure 6.3).  
No tumor cell invasion of the thymus was detected except at the very 
late stage of disease in mice older than 120 days of age. As expected, no 
tumors were detected in WT mice (background staining was < 20%) ((Figure 
6.3). Our data suggest that the decrease of tumor cells in the blood was not a 
consequence of altered trafficking of tumor cells to other organs.   







Figure 6.3 Difference in regression was not due to altered trafficking of 
tumour cells.  
Longitudinal analysis of the B220low cells in spleen, thymus, bone marrow and 
lymph node of Zbp1-/-Eµ-Myc (light grey column) and Zbp1+/+Eµ-Myc mice 
(dark grey column). Mean percentage ± SD of IgM-B220low (grey bars), 
IgM+B220low (white bars) cells in the indicated organs of Zbp1-/- Eµ-Myc mice 
(n≥ 7 per time-point) before 41 days of age (early), between 41 and 65 days of 
age (regression) and post 65 days of age (late) are shown. Statistical analyses 
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6.4 B220low cells from Zbp1+/+Eμ-Myc and Zbp1-/-Eμ-Myc mice showed 
similar rate of proliferation 
KI-67 protein is present during all active phases of the cell cycle (G 
(1), S, G (2), and mitosis), but is absent from resting cells (G (0)), thus, its 
expression is strictly associated with cell proliferation (Gerdes, 1990). Anti-
KI-67 protein antibodies had been used in diagnostics of human tumours and 
the fraction of KI-67-positive tumor cells or the KI-67 labeling index often 
correlates with the clinical course of the disease (Gerdes, 1990; Scholzen and 
Gerdes, 2000). Therefore, we compared the percentage of KI-67 positive 
b220low tumour cells in the blood of Zbp1-/-Eµ-Myc, Zbp1+/+Eµ-Myc, Zbp1-/- 
and Zbp1+/+ mice by intracellular flow cytometry. As expexted, pre-regression 
B220low cells from both Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice expressed 
high levels of KI-67 compared to WT cells (Figure 6.4). However, we did not 
observe any difference in the percentage of KI-67 high cells between B220low 
cells from both Zbp1-/-Eµ-Myc (n = 9, mean ± SD = 67.678 ± 9.910%) and 

































Figure 6.4 Similar levels of KI-67 in B220low cells from Zbp1-/-Eµ-Myc and 
Zbp1+/+Eµ-Myc mice. 
(a) B220low cells from blood of Zbp1+/+ (black bold) and Zbp1-/- (grey bold) mice were 
assessed for intracellular KI-67 expression. Isotype controls for Zbp1+/+ (filled grey) 
and Zbp1-/-(black) were as shown. Representative FACS histograms with gatings for 
KI-67high cells are shown. (b) Mean percentage of B220low cells that were KI-67high ± 
SD for each genotype (≥ 4n each) were plotted. Statistical analyses were performed 
using student’s t test and *** denotes p < 0.001. 
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We also compared the proliferation rate of the tumour cells by BrdU 
incorporation and DNA content. Analysis of BrdU incorporation and DNA 
content revealed that pre-regression (before 40 days of age) B220low cells of 
Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc mice incorporated similar amount of BrdU 
in both the spleen and the bone marrow (Figure 6.5). As expected, the rate of 
proliferation was higher for Zbp1+/+Eµ-Myc compared to Zbp1+/+ and for Zbp1-
/-Eµ-Myc compared to Zbp1-/- in both the spleen and bone marrow (Figure 6.5). 
In the bone marrow, the percentage of B220low cells in S-phase was higher for 
Zbp1+/+Eµ-Myc  (n = 5, mean ± SD = 55.940 ± 10.650%) compared to Zbp1+/+ 
(n = 3, mean ± SD = 25.333 ± 1.604%) (P = 0.0402) and for Zbp1-/-Eµ-Myc (n 
= 9, mean ± SD = 48.633 ± 11.745%) compared to Zbp1-/-  (n = 4, mean ± SD 
= 24.675 ± 4.577%) (P = 0.0026) (Figure 6.5). In the spleen, the percentage of 
B220low cells in S-phase was higher for Zbp1+/+Eµ-Myc  (n = 5, mean ± SD = 
33.320 ± 12.747%) compared to Zbp1+/+ (n = 5, mean ± SD = 9.652 ± 7.113%) 
(P = 0.0067) and for Zbp1-/-Eµ-Myc (n = 5, mean ± SD = 27.500 ± 10.487%) 




































































Figure 6.5 B220low cells from Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice 
displayed similar proliferation rate. 
Spleen (bottom panel) and bone marrow (BM) (top panel) from day 31-40 were 
analysed for BrdU incorporation and DNA content. Data represent mean 
percentages of B220low cells in S-phase ± SD. Statistical analyses were performed 
using Student’s t test. * denotes p < 0.05 and ** denotes p < 0.01. n ≥ 3 mice were 
analysed for each genotype. 
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As expected for tumor cells, proteins important for S-phase entry such 
as CYCLIN D1, CYCLIN A, phosphorylated pRB and CDK2 were 
upregulated in B220low cells of Eµ-Myc mice when compared to WT cells 
(Figure 6.6). However, we did not observe a significant difference in the 
expression levels of S-phase associated proteins in pre- regression B220low 
cells between Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc (Figure 6.6). This support 
the conclusion that proliferation rate might not account for the difference in 
regression.  
Figure 6.6 Immunoblot of cell cycle proteins.  
Expression levels of cell cycle-related proteins in purified splenic B220+ cells 
of Zbp1+/+Eμ-Myc, Zbp1-/-Eμ-Myc, Zbp1+/+ and Zbp1-/- from 31-40 days of 


















6.5 B220low cells from Zbp1-/-Eµ-Myc mice have higher apoptosis rate than 
Zbp1+/+Eµ-Myc mice  
         To compare the rates of apoptosis, we analyzed pre-regression (before 
40 days of age), regression (between 41-65 days of age) and WT B220low cells 
for Annexin-V expression and propidium iodide (PI) uptake. The percentage 
of apoptotic cells (Annexin-V+ and/or PI+) was significantly increased in 
B220low cells from 41-65 day of age bone marrow of Zbp1-/-Eµ-Myc mice (n = 
8, mean ± SD = 84.454 ± 6.655%) compared to Zbp1+/+Eµ-Myc mice (n = 7, 
mean ± SD = 70.000 ± 15.443%) (P = 0.0276), Zbp1+/+ mice (n = 4, mean ± 
SD = 55.225 ± 9.944%) (P < 0.001) or Zbp1-/- mice (n = 4, mean ± SD = 
50.351 ± 8.829%) (P < 0.001) after 3 hours in culture (Figure 6.7b). The rate 
of apoptosis in B220low cells from bone marrow of Zbp1+/+Eµ-Myc mice (n = 
7, mean ± SD = 70.000 ± 15.443%) was significantly higher than Zbp1-/- mice 
(n = 4, mean ± SD = 50.351 ± 8.829%) (P = 0.039) but not significant when 
compared to Zbp1+/+ mice (n = 4, mean ± SD = 55.225 ± 9.944%)(Figure 
6.7b). This could be due to insufficient number of mice. 
          The percentage of apoptotic cells was significantly increased in B220low 
cells from 41-65 day of age bone marrow of Zbp1-/-Eµ-Myc mice (n = 8, mean 
± SD = 84.454 ± 6.655%)compared to 31-40 days of age bone marrow (n = 7, 
mean ± SD = 51.858 ± 26.801%) (P = 0.005) (Figure 6.7b). This is consistent 
with the observation that regression of B220low occurs after day 41 in Zbp1-/-
Eµ-Myc mice.  
 We did not observe any significant difference in percentage of 
apoptotic cells in ex vivo B220low cells from the spleen or bone marrow and in 
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Figure 6.7 Increase apoptosis of B220low cells from the bone marrow of 
Zbp1-/-Eµ-Myc.  
Annexin-V staining of B220low cells from spleen (right panel) or bone marrow 
(left panel) of Zbp1+/+Eμ-Myc (black columns), Zbp1-/-Eμ-Myc (white 
column), Zbp1+/+ (light grey column) and Zbp1-/- (dark grey column)(≥ 4n 
each). Annexin-V staining was done on ex vivo cells (a) or cells kept in culture 
for 3 hours (b). Data were represented as mean percentage of Annexin V+ 
cells ± SD. Student’s t test was used to perform statistical analysis and p 





Caspases play a major role in the apoptotic response (Shi, 2002; 
Thornberry and Lazebnik, 1998). Caspases are cysteine proteases that cleave 
after an aspartate residue in their substrates and belong to a conserved family 
of enzymes that irreversibly commit a cell to die (Riedl and Shi, 2004). There 
are two classes of apoptotic caspases: the initiator caspases, which include 
caspase-2, -8, -9 and -10 and the effector caspases, which include caspases-3, -
6 and -7 in mammals (Riedl and Shi, 2004). All caspases exist in cells as 
catalytically inactive precursor and must undergo proteolytic activation during 
apoptosis. The activation of an effector caspase is carried out by an initiator 
caspase through cleavage at specific internal Asp residues that would produce 
the large (~p20) and small (~p10) subunits. By contrast, the initiator caspases 
are auto-activated in a tightly regulated process.  
To investigate if there are differences in the activation of caspases, we 
purified B cells from the mice and performed an immunblot analysis using 
antibodies specific for CASPASE7 and CASPASE3. We observed presence of 
cleaved CASPASE 7 in all 3 Zbp1-/-Eµ-Myc mice but only 1 out of 3 Zbp1+/+ 
Eµ-Myc mice showed presence of cleaved CASPASE 7 (Figure 6.8a). 
Similarly, we saw presence of cleaved CASPASE 3 in all 3 Zbp1-/-Eµ-Myc 
mice but only 1 out of 3 Zbp1+/+Eµ-Myc mice showed presence of cleaved 
CASPASE 3 (Figure 6.8a). The ratio of the relative intensity of cleaved 
CASPASE 3 to CASPASE 3 was significantly higher in Zbp1-/-Eµ-Myc mice 
(n = 3, mean ± SD = 1.446 ± 0.747) compared to Zbp1+/+ Eµ-Myc mice (n = 3, 
mean ± SD = 0.140 ± 0.150) (P = 0.041) (Figure 6.8b). Similarly, the ratio of 
the relative intensity of cleaved CASPASE 7 to CASPASE 7 was significantly 
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higher in Zbp1-/-Eµ-Myc mice (n = 6, mean ± SD = 0.660 ± 0.490) compared 
to Zbp1+/+ Eµ-Myc mice  (n = 6, mean ± SD = 0.157 ± 0.246) (P = 0.049) 
(Figure 6.8b). The data is in line with the finding that B220+ cells in Zbp1-/-
Eµ-Myc mice have increased apoptosis. 
Figure 6.8 Increased activation of CASPASE7 and CASPASE3 in B220+ cells 
of Zbp1-/-Eµ-Myc mice. 
(a) Expression levels of CASPASE7, cleaved CASPASE7, CASPASE3 and 
cleaved CASPASE3 in purified bone marrow B220+ cells of Zbp1+/+Eμ-Myc, 
Zbp1-/-Eμ-Myc, Zbp1+/+ and Zbp1-/- mice. Representative blots from 3 independent 
experiments are shown. (b) The ratio of the intensity of cleaved caspase to 
procaspase from the immunoblot in (a) was plotted as mean ± SD. n ≥ 3 mice 
were analysed for each genotype. Student’s t test was used to perform statistical 






































































 Using immunocytochemistry, we used antibody specific for cleaved 
CASPASE 3 to probe for activated CASPASE 3 in the bone marrow and 
spleen of Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice. We observed more B220+ 
cells with cleaved CASPASE3 in the bone marrow of Zbp1-/-Eµ-Myc 
compared to the bone marrow of Zbp1+/+Eµ-Myc mice (Figure 6.9). We 
observed presence of cleaved CASPASE 3 in the spleen of 2 out of 3 Zbp1-/-
Eµ-Myc mice in contrast to only 1 out of 3 Zbp1+/+Eµ-Myc mice/Zbp1+/-Eµ-
Myc mice (Figure 6.9).  
These data support the conclusion that Zbp1-/-Eµ-Myc tumor cells were 
more prone to apoptosis possibly due to increased levels of p53 upregulated 
modulator of apoptosis (PUMA) (Figure 6.6) and increases in cleaved 
CASPASE 3 and cleaved CASPASE 7 (Figure 6.8 and 6.9). In summary, our 
analysis revealed that differences in cell intrinsic apoptosis pathways might 






6.6 No difference in expressions of T cells activation markers in Zbp1-/-Eµ-
Myc and Zbp1+/+Eµ-Myc mice  
We have previously reported that regression of tumour cells in the 
peripheral is dependent on T and NK cells (Croxford et al., 2013). Regression 
correlated with upregulation of the DNAM-1 ligand CD155 and the 
downregulation of H-2Kb on tumour cells and the downregulation of CD62L 
on T cells.  
CD62L/L-selectin is a marker found on naïve T cells and further 
differentiates central memory (Tcm, CD62L+) from effector memory (Tem, 
CD62L−) T cells (Yang et al., 2011). CD62L is shed from the cell membrane 
following T cell activation and it can be used as a marker for T cell activation 
(Yang et al., 2011). The percentage of CD62Llow CD4+ T cells was not 
significantly different between Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice 
during 21-40 days of age (n = 10, mean ± SD = 17.591 ± 11.382% versus n = 
10, mean ± SD = 17.584 ± 12.500%) and during 41-65 days of age (n = 10, 
mean ± SD = 21.165 ± 10.504% versus n = 10, mean ± SD = 27.770 ± 
11.700%) (Figure 6.10a). Furthermore, we did not observe any significant 
difference in CD62Llow CD8+ T cells between Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-
Myc mice during 21-40 days of age (n = 10, mean ± SD = 13.069 ± 11.679% 
versus n = 10, mean ± SD = 12.874 ± 9.436%) and during 41-65 days of age 
Figure 6.9 Immunocytochemistry of cleaved CASPASE 3 in bone marrow 
and spleen.  
Splenocytes and bone marrow cells from 40-65 days of age Zbp1-/-Eμ-Myc 
(n=3) mice or Zbp1+/+Eμ-Myc mice/Zbp1+/-Eμ-Myc mice (n=3) were 
cytospined and probed for antibody specific for cleaved CASPASE3 (red), 
B220+(green) and DAPI (blue). Arrows point to cells positive for both B220 
and cleaved CASPASE 3. For each cytospun slides, 5 different fields were 
observed under the microscrope and >100 cells were being examined. 
Representative immunofluorescence images are shown for each mouse. 
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(n = 10, mean ± SD = 19.084 ± 14.177% versus n = 10, mean ± SD = 23.847 ± 
15.767%) (Figure 6.10a).  
DNAM-1 is an adhesion molecule involved in the cytolytic function of 
T lymphocytes (Shibuya et al., 1996). We did not observe any significant 
difference in DNAM-1 expressions on CD4+ T cells from Zbp1-/-Eµ-Myc and 
Zbp1+/+Eµ-Myc mice during 21-40 days of age (n = 10, mean MFI ± SD = 
4.805 ± 0.887 and n = 10, mean MFI ± SD = 5.033 ± 0.974 respectively) and 
during 41-65 days of age (n = 10, mean MFI ± SD = 3.478 ± 1.126 and n = 10, 
mean ± SEM MFI = 3.455 ± 2.701 respectively) (Figure 6.10b). There was no 
significant difference in DNAM-1 expressions on CD8+ T cells from Zbp1-/-
Eµ-Myc and Zbp1+/+Eµ-Myc mice during 21-40 days of age (n = 10, mean 
MFI ± SD = 27.940 ± 3.199 and n = 10, mean MFI ± SD = 30.085 ± 3.706 
respectively) and during 41-65 days of age (n = 10, mean MFI ± SD = 20.389 
± 8.087 and n = 10, mean MFI ± SD = 21.597 ± 12.618 respectively) (Figure 
6.10b). 
The observations are in contrast to previous report from our lab that 
implicates the role of T cells and NK cells in spontaneous regressions 
(Croxford et al., 2013). As tumour-specific T cells might only constitute a 
small percentage of the total population, it would be difficult to detect any 
significant difference in T cells activation between Zbp1-/-Eµ-Myc and 
Zbp1+/+Eµ-Myc mice, thus explaining the discrepancies in observations.  
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Figure 6.10 Flow cytometry analysis of activation makers on CD8+ and CD4+ T 
cells from the blood.  
(a) Top panel: Representative FACS plot showing CD62L levels on CD4+ and CD8+ 
T cells from the blood of regression mice (d41-d65) from both Zbp1+/+Eμ-Myc (bold 
lines) and Zbp1-/-Eμ-Myc (thin lines). Isotype control for Zbp1+/+Eμ-Myc (filled 
histogram) and Zbp1-/-Eμ-Myc (dashed lines) and gates indicating CD62Llow and 
CD62Lhigh populations are also shown. Bottom panel: Mean percentage ± SD of 
CD62L low cells on CD4+ or CD8+ T cells from blood of Zbp1+/+Eμ-Myc (black) and 
Zbp1-/-Eμ-Myc (white) from pre-regression (d21-40) and regression (d41-65) mice. n= 
10 for each genotype. (b) Top panel:  Representative FACS plot showing DNAM-1 
levels on CD4+ and CD8+ T cells from the blood of regression mice (d41-d65) from 
both Zbp1+/+Eμ-Myc (bold lines) and Zbp1-/-Eμ-Myc (thin lines). Isotype control for 
Zbp1+/+Eμ-Myc (filled histogram) and Zbp1-/-Eμ-Myc (dashed lines) Bottom panel: 
mean MFI ± SD of DNAM-1 levels on CD4+ or CD8+ T cells from blood of 
Zbp1+/+Eμ-Myc (black) and Zbp1-/-Eμ-Myc (white) from pre-regression (d21-40) and 
regression (d41-65) mice. n= 10 for each genotype. Statistical analyses were 
performed using Student’s t test.  
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6.7 Similar expressions of co-stimulatory molecules on B220low cells from 
Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice  
 
Poliovirus receptor (CD155) and Nectin-2 (CD112) have been 
identified as ligands for DNAM-1, with CD155 appearing to have a major role 
in inducing DNAM-1-dependent responses (Bottino et al., 2003). CD155 is 
widely expressed on normal cells and overexpressed on many tumor types 
(Bottino et al., 2003; Carlsten et al., 2007; Castriconi et al., 2004; El-Sherbiny 
et al., 2007; Pende et al., 2006; Reymond et al., 2004; Sloan et al., 2005). The 
DNAM-1/CD155 interaction is important for recognition and elimination of 
tumour cells by NK cells (Carlsten et al., 2007). We did not observe any 
significant difference in CD155 expressions on B220low cells from Zbp1-/-Eµ-
Myc and Zbp1+/+Eµ-Myc mice during 21-40 days of age (n = 10, mean MFI ± 
SD = 2.241  ± 1.719 and n = 10, mean MFI ± SD = 1.913 ± 1.137 
respectively) and during 41-65 days of age (n = 10, mean MFI ± SD = 2.683 ± 
1.195 and n= 10, mean MFI ± SD = 3.191 ± 1.368 respectively) (Figure 6.11a 
and b). We also did not see any significant difference in CD155 expressions 
when we compare Zbp1-/-Eµ-Myc or Zbp1+/+Eµ-Myc between 21-40 days of 
age and 41-65 days of age.   
Engagement of CD28 on naive T cells by either CD80 or CD86 
ligands on antigen-presenting cells provides a strong costimulatory signal to T 
cells activated through their T cell receptor (Carreno and Collins, 2002). This 
leads to induction of IL-2 transcription, expression of CD25, proliferation and 
provides critical survival signals to the T cells. We did not observe any 
significant difference in CD80 expressions on B220low cells from Zbp1-/-Eµ-
Myc and Zbp1+/+Eµ-Myc mice during 21-40 days of age (n = 10, mean MFI ± 
SD = 0.264  ± 0.403 and n = 10, mean MFI ± SD = 0.130 ± 0.172 
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respectively) and during 41-65 days of age (n= 10, mean MFI ± SD = 0.096 ± 
0.166 and n= 10 and mean MFI ± SD = 0.125 ± 0.297 respectively) (Figure 
6.11a and b). Similarly, we did not observe any significant difference in CD86 
expressions on B220low cells from Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice 
during 21-40 days of age (n = 10, mean MFI ± SD = 1.365  ± 0.243 and n = 
10, mean MFI ± SD = 1.463 ± 0.561 respectively) and during 41-65 days of 
age (n= 10, mean MFI ± SD = 1.082 ± 0.578 and n= 10 and mean MFI ± SD = 
1.689 ± 1.525 respectively) (Figure 6.11a and b). We also did not see any 
significant difference in CD80 or CD86 expressions when we compare Zbp1-/-
Eµ-Myc or Zbp1+/+Eµ-Myc between 21-40 days of age and 41-65 days of age.  
ICAM-1 is an integral membrane glycoprotein possessing an 
extracellular domain containing five tandem Ig-like domains, a 
transmembrane domain, and a short cytoplasmic tail (Staunton et al., 1988). 
ICAM-1 provides enough costimulatory signals to induce T cell activation and 
IL-2 gene expression in a CD28-independent mechanism, and is the main, 
essential costimulatory molecule required for the activation of T cells in the 
absence of B7/CD28 costimulation (Salomon and Bluestone, 1998; 
Zuckerman et al., 1998). We did not observe any significant difference in 
ICAM-1 expressions on B220low cells from Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-
Myc mice during 21-40 days of age (n = 10, mean MFI ± SD = 21.223  ± 
5.601 and n = 10 and mean MFI ± SD = 20.801 ± 7.513 respectively) and 
during 41-65 days of age (n = 10, mean MFI ± SD = 18.905 ± 6.222 and n= 10 
and mean MFI ± SD = 21.678 ± 10.103 respectively) (Figure 6.11a and b). We 
also did not observe any significant difference in ICAM-1 expressions when 
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we compare Zbp1-/-Eµ-Myc or Zbp1+/+Eµ-Myc between 21-40 days of age and 
41-65 days of age.  
The chemokine receptor type 4 (CXCR4), which binds to the 
chemokine stromal cell-derived factor (SDF)-1 (CXCL12), is involved in 
lymphocyte trafficking. CXCR4 had also been found to be a prognostic 
marker in different cancers, including leukemia and breast cancer. There is 
increasing evidence that CXCR4 expression and function in hematopoietic 
malignancies have an important role on disease progression. CXCR4 levels 
are significantly increased in B-cell chronic lymphocytic leukemia (Mohle et 
al., 1999), B-cell but not T-cell acute lymphoblastic leukemia (Bradstock et 
al., 2000; Dialynas et al., 2001), multiple myeloma (Hideshima and Anderson, 
2002), and acute myeloid leukaemia (Tavor et al., 2004). We observe a 
significant decrease in CXCR4 expressions on B220low cells from Zbp1-/-Eµ-
Myc between 21-40 days of age (n = 10, mean MFI ± SD = 14.244  ± 8.232) 
and 41-65 days of age (n = 10, mean MFI ± SD = 6.49  ± 1.33) (P = 0.016) 
(Figure 6.11a and b). However, expressions of CXCR4 on B220low cells 
remain high in Zbp1+/+Eµ-Myc mice during 21-40 days of age (n = 10, mean 
MFI ± SD = 12.147 ± 8.587) and during 41-65 days of age (n = 10, mean MFI 
± SD = 18.580 ± 26.613) (Figure 6.11a and b). These correlated with the 
increased in malignancy of the tumours, as CXCR4/CXCL12 signaling is 
critically involved in the survival and trafficking of normal and malignant B-
lymphocytes. 
It had been reported that tumour cells could lose MHC class 1 
molecules through a variety of mechanisms, resulting in escape from immune 
surveillance (Khong and Restifo, 2002). Consistent with the earlier report by 
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Croxford et al. (2013), we saw a similar decrease in expressions of MHC class 
I H-2Kb molecules on B220low cells in the blood in Zbp1-/-Eµ-Myc mice 
between 21-40 days of age (n = 22, mean MFI ± SD = 70.160 ± 22.093) and 
41-65 days of age (n = 19, mean MFI ± SD = 49.422 ± 22.295) (P = 0.005) 
(Figure 6.11a and b). We also observe a significant decrease in MFI intensity 
in Zbp1+/+Eµ-Myc mice between 21-40 days of age (n = 16, mean MFI ± SD = 
62.801 ± 18.575) and 41-65 days of age (n = 15, mean MFI ± SD = 44.663 ± 
20.042) (P = 0.014) (Figure 6.11a and b). However, when we compare the 
MFI of H-2Kb of Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice within each age 
group, we did not observe any significant difference, suggesting that the 
expression levels of H-2Kb were similar for Zbp1-/-Eµ-Myc and Zbp1+/+Eμ-
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Figure 6.11 Flow cytometry analysis of surface makers on B220low cells 
from the blood of Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice.  
(a) Representative FACS plot showing expressions of CD80, CD86, CD155, 
ICAM-1, CXCR4 and H-2Kb in both Zbp1+/+Eμ-Myc (black bold lines) and 
Zbp1-/-Eμ-Myc (black dash lines) on B220low cells from the blood of pre-
regression (d31-40) and regression mice (d41-65). Isotype controls were either 
tinted (Zbp1+/+Eμ-Myc) or dashed (Zbp1-/-Eμ-Myc). b) Mean MFI ± SD of 
CD80, CD86, CD155, ICAM-1, CXCR4 and H-2Kb on both bp1+/+Eμ-Myc 
(black) and Zbp1-/-Eμ-Myc (white) in B220low cells from the blood.  n= 10 
each for Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc.  Statistical analyses were 




  Eµ-Myc mice deficient in Zbp1 had increased survival and reduced 
tumour load. The reduced tumour load is not due to altered trafficking of the 
tumour cells to other organs or dicrepancies in proliferation rate. Eµ-Myc mice 
deficient in Zbp1 had higher expressions of cleaved CASPASE3 and cleaved 
CASPASE7 and increased apoptosis rate which might account for the reduced 






Chapter 7: Increased DNA damage in Eµ-Myc 
mice deficient in Zbp1 
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7.1 Whole genome microarray revealed increase expression of genes 
involved in the DNA repair pathways in Zbp1-/-Eµ-Myc  
We performed a whole genome microarray on sorted B220low cells 
from pre-regression spleens of both Zbp1+/+Eµ-Myc (n= 3) and Zbp1-/-Eµ-Myc 
(n= 3)  mice. Interestingly, we saw upregulation of various genes involved in 
the DNA damage repair pathways in B220low cells in the Zbp1-/-Eµ-Myc mice 
compared to the Zbp1+/+Eµ-Myc mice (Figure 7.1). This is consistent with our 
previous study which indicated that DDR plays a role in tumorigenesis 
(Croxford et al., 2013) . 
Key genes invovled in HRR such as Brca2, Rad50, Rad54 were 
upregulated in all 3 Zbp1-/-Eµ-Myc mice compared to Zbp1+/+Eµ-Myc  mice; 
Mre11 and Nbs1 were upregulated in 2 out of 3 Zbp1-/-Eµ-Myc mice compared 
to Zbp1+/+Eµ-Myc mice from the microarray analyses (Figure 7.1a). We 
validated these genes using real time PCR and we observed slightly higher 
fold change of Brca2 transcript variant 1 (n = 3, mean fold change ± SD = 
1.689 ± 0.432), Brca2 transcript variant 2 (n = 3, mean fold change ± SD = 
1.536 ± 0.444), Rad54 (n = 3, mean fold change ± SD = 2.659 ± 0.680) and 
Nbs1 (n = 3, mean fold change ± SD = 1.410 ± 1.342) in B220low cells from 
Zbp1-/-Eµ-Myc mice  compared to Zbp1+/+Eµ-Myc (Figure 7.1b). However, we 
did not observe much difference in the fold change of Rad50 (n = 3, mean fold 
change ± SD = 1.071 ± 0.230) and Mre11 (n = 3, mean fold change ± SD = 
0.910 ± 0.141) (Figure 7.1b). 	 
In the NER pathway, Hr23b, Xpg and Csa were upregulated in all 3 
Zbp1-/-Eµ-Myc mice compared to Zbp1+/+Eµ-Myc mice from the microarray 
results (Figure 7.1a). We validated Hr23b with real time PCR as Hr23b was 
one of the top few genes that were upregulated in Zbp1-/-Eµ-Myc mice. 
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Consistent with the microarray analyses, we observed significantly higher fold 
change of Hr23b (n = 3, mean fold change ± SD = 2.133 ± 0.198) (P = 0.010) 
in real time PCR in B220low cells from Zbp1-/-Eµ-Myc mice compared to 
Zbp1+/+Eµ-Myc  mice (Figure 7.1b).  
From the microarary analyses, Ku70, Dna ligase ΙΙ, Atm from the 
NHEJ pathway were upregulated in all 3 Zbp1-/-Eµ-Myc mice while Ku80, 
Xrcc1, Dna ligase ΙV and Wrn were upregulated in 2 out of 3 Zbp1-/-Eµ-Myc 
mice (Figure 7.1a). In the real-time PCR analyses, we observed significantly  
higher fold change of Ku70 (n = 3, mean fold change ± SD = 1.635 ± 0.177) 
(P = 0.025), Ku80 (n = 3, mean fold change ± SD = 1.461 ± 0.101) (P = 0.016)  
and Xrcc1 (n = 3, mean fold change ± SD = 1.171 ± 0.051) (P = 0.029)   in 
B220low cells from Zbp1-/-Eµ-Myc mice compared to Zbp1+/+Eµ-Myc mice 
(Figure 7.1b). We observed slightly higher fold change of Atm (n = 3, mean 
fold change ± SD = 1.531 ± 0.365), Dna ligase IV (n = 3, mean fold change ± 
SD = 1.671 ± 1.197) and Wrn (n = 3, mean fold change ± SD = 1.556 ± 0.788) 
in B220low cells from Zbp1-/-Eµ-Myc mice compared to Zbp1+/+Eµ-Myc 
mice(Figure 7.1b).  
c-Jun , which had role in apoptosis and cell cycle, was one of the top 
genes that were downregulated in Zbp1-/-Eµ-Myc mice from the microarray 
results (Figure 7.1a). From the real-time PCR, we also observed significant 
downregulation of c-Jun (n = 3, mean fold change ± SD = 0.477 ± 0.082) (P = 
0.0081) in B220low cells from Zbp1-/-Eµ-Myc mice (Figure 7.1b). TNF-α is a 
major inflammatory cytokine that was first identified to induce rapid 
haemorrhagic necrosis of experimental cancers (Balkwill, 2009). TNF-α can 
be pro- or anti- tumour and it is important in cancer biology. From the 
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microarray results, Tnf-α was upregulated in 2 out of 3 Zbp1-/-Eµ-Myc mice 
(Figure 7.1a). Consistent with the microarray results, we observed higher fold 
change of Tnf-α (n = 3, mean fold change ± SD = 1.998 ± 0.486) in B220low 
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Figure 7.1 Increased expression of genes involved in the DNA 
repair pathways.  
(a) Whole genome microarray using sorted B220low cells from spleens 
of Zbp1-/-Eµ-Myc mice (n= 3) and Zbp1+/+Eµ-Myc mice (n= 3) were 
performed. The table represents fold change of Zbp1-/-Eµ-Myc mice 
compared to Zbp1+/+Eµ-Myc mice. (b) Real-time PCR of selected 
genes using the same samples from the microarray. The mean fold 
change ± SD of B220low cells from Zbp1-/-Eµ-Myc mice (n= 3) over 
Zbp1+/+Eµ-Myc mice (n= 3) was plotted. Statistical analysis was 
performed using paired Student’s t test. *p<0.05 and **p<0.01. 
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7.2 Enhanced DDR in tumour cells from Zbp1-/-Eµ-Myc mice 
Most proteins in the DDR pathway are phosphorylated upon 
activation; therefore, we investigated the phosphorylation status of some of the 
key molecules in the DDR pathway. B220+ splenocytes of Zbp1-/-Eµ-Myc mice 
expressed higher levels of phosphorylated H2AX (γH2AX), a DNA damage 
marker, when compared to Zbp1+/+Eµ-Myc mice (n = 3) (Figure 7.2). Western 
blot analysis of B cells from the spleen revealed higher levels of 
phosphorylated p53, phosphorylated CHK1, phosphorylated CHK2 and 
phosphorylated ATM in Zbp1-/-Eµ-Myc mice compared to the Zbp1+/+Eµ-Myc 
mice, providing further evidence that the loss of Zbp1 potentiates the DDR 
(Figure 7.2). The presence of γH2AX acts as a sensitive marker for DNA 
double-strand breaks (DSBs) (Bonner et al., 2008), which are predominantly 
repaired by NHEJ or HRR. Both the Western blot data and the microarray data 
are consistent with the suggestion that there are persistent DSB breaks in the 





Figure 7.2 Enhanced DNA damage response in tumour cells from Zbp1-/-
Eµ-Myc mice.  
Immunoblot analysis of splenic B220+ cells (> 98% purity) from day 31- 40 
Zbp1+/+, Zbp1-/-, Zbp1+/+Eμ-Myc, and Zbp1-/-Eμ-Myc mice were probed with 
antibodies for indicated DNA damage response markers. Representative blots 































 In an alternative approach, we stained blood cells of mice with γH2AX 
and B220 specific antibodies and DAPI (nuclear stain). Immunofluorescence 
microscopy provided further evidence that there were significantly higher 
number of tumour cells of Zbp1-/-Eµ-Myc mice (n = 3, mean ± SD = 93.110 ± 
9.602%) with γH2AX as compared to Zbp1+/+Eµ-Myc mice (n = 4, mean ± SD 
= 14.020 ± 11.080%) (P < 0.001) (Figure 7.3a). 
Additionally, we stained for RAD51, a molecule that acts to transduce 
DNA damage signals to promote DSB repair via HRR (Suwaki et al., 2011). 
In addition, a recent study has identified RAD51 as a potential tumour 
suppressor gene (Bric et al., 2009). As expected, we observed accumulation of 
higher number of RAD51 foci in the nucleus of B cells in Zbp1-/-Eµ-Myc mice. 
Quantitative analysis of microscopy data showed that there was significantly 
higher percentage of B cells in Zbp1-/-Eµ-Myc mice (n = 3, mean ± SD = 
83.460 ± 19.40%) with more than three foci as compared to Zbp1+/+Eµ-Myc 
mice (n = 3, mean ± SD = 14.010 ± 12.37%) (P = 0.0064) (Figure 7.3b). The 
greater activation of RAD51 observed in Zbp1-/-Eµ-Myc mice indicated higher 
levels of DNA repair occurring through HRR, which probably exert a greater 




Figure 7.3 Increased γH2AX and RAD51 foci in B220+ cells of Zbp1-/-Eµ-
Myc mice.  
Costaining of B cells from blood of Zbp1+/+ (n=2), Zbp1-/- (n=2), Zbp1+/+Eμ-
Myc (n≥3) and Zbp1-/-Eµ-Myc (n=3) mice for expression of γH2AX (a) and 
RAD51 (b) and the B cell marker B220 (red) in presence of DAPI (blue). The 
percentage of B220+ that are positive for γH2AX (a, bottom panel) and having 
more than 3 RAD51 foci (b, bottom panel) were plotted. Statistical analyses 
were performed using Student’s t test and error bar denotes SD. **p<0.01 and 
***p<0.001. Representative images from 3 independent experiments are 
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7.3 Enhanced DNA damage in in vitro cell lines derived from Zbp1-/-Eµ-
Myc mice 
Late stage Eµ-Myc mice developed enlarged lymph nodes. We derived 
an in vitro cell line, EµM1, from enlarged lymph nodes from late stage 
Zbp1+/+Eµ-Myc (Zbp1+/+ EµM1) and Zbp1-/-Eµ-Myc (Zbp1-/- EµM1) mice (see 
Materials and methods section 2.1). We saw higher expression of γH2AX in 
DMSO treated Zbp1-/- EµM1 compared to Zbp1+/+ EµM1 (Figure 7.4). There is 
no significant difference in γH2AX levels in Zbp1-/- EµM1 cells treated with 
Ara-C compared to Zbp1+/+ EµM1 cells (Figure 7.4). This is consistent with 
the findings that tumour cells in the Zbp1-/-Eµ-Myc mice had enhanced DNA 
damage. Cell cycle analysis of Zbp1-/- EµM1 cells revealed that these cells 
contain more than 2n DNA (Figure 7.5a), which might explain why these cells 










Figure 7.4 Enhanced DNA damage in in vitro cell lines derived from Zbp1-/-
Eµ-Myc mice.  
Zbp1+/+ EµM1 cells and Zbp1-/- EµM1 cells were treated with DMSO or 10 µM 
Ara-C for 16 hours and probed for γH2AX. Representative blots from 3 








7.4 Zbp1-/- EµM1 cells and Zbp1+/+ EµM1 cells showed no difference in 
proliferation and apoptosis rate 
 
 We compared the proliferation rate of Zbp1-/- EµM1 cells compared to 
Zbp1+/+ EµM1 cells by BrdU incorporation (Figure 7.5). We did not find any 
significant difference in percentage of cells that were BrdU+ in Zbp1-/- EµM1 
cells (n = 3, mean ± SD = 61.050 ± 8.839%) and Zbp1+/+ EµM1 cells (n = 3, 




Figure 7.5 No difference in proliferation rate in Zbp1-/- EµM1 cells compared 
to Zbp1+/+ EµM1 cells.  
(a) Cell cycle analysis of Zbp1-/- EµM1 cells compared to Zbp1+/+ EµM1 cells using 
BrdU incorporation. The population of cells with >2n DNA were indicated. 
Results in (a) were quantified as percentage of BrdU+ cells in (b). Statistical 
comparisons were conducted using Student’s t test and the results were expressed 






















 We also investigated the apoptosis rate of Zbp1-/- EµM1 cells compared 
to Zbp1+/+ EµM1 cells by Annexin V and PI staining. We did not find any 
significant difference in early apoptotic cells, defined as being Annexin V+ 
and PI- between Zbp1-/- EµM1 cells (mean ± SEM= 5.10 ± 0.710%) and 
Zbp1+/+ EµM1 cells (mean ± SEM= 7.24 ± 0.66%) (Figure 7.6). We also did 
not find any significant difference in Annexin V+ and PI+ between Zbp1-/-
EµM1 cells (mean ± SEM= 1.95 ± 0.210%) and Zbp1+/+EµM1 cells (mean ± 
SEM= 1.99 ± 0.025%) (Figure 7.6). 	 
Although we observed higher γH2AX in Zbp1-/-EµM1 cells compared 
to Zbp1+/+EµM1 cells, we did not observe any difference in apoptosis or 
proliferation. This could likely be because these cells are derived from late 
stage tumour that might have been selected for their ability to circumvent the 
tumour suppressor effects of the DDR pathways.  
Figure 7.6 No difference in apoptosis rate in Zbp1-/-EµM1 and Zbp1+/+EµM1 
cells.  
Cell cycle analysis of Zbp1-/- EμM1 cells compared to Zbp1+/+ EμM1 cells using 
Annexin V/PI staining. Data are represented as mean percentage of cells ± SD of 


















7.5 Knockdown of Zbp1 increased γH2AX in BC2 cells 
To address the relationships between Zbp1 and the DDR, Zbp1 
expression was knocked down using shRNA in BC2 cells. Inhibition of Zbp1 
expression by shRNA in BC2 cells increased the expression of γH2AX 
(Figure 7.7). The expression of γH2AX in Zbp1-expressing BC2 was 
comparable to the γH2AX expression in BC2 cells treated with the DNA-
damage-inducing agents Ara-C and Aphidicolin (Figure 7.7a). This further 
suggests that higher levels of DDR activation were seen in BC2 cells with 
Zbp1 knockdown.  
To address if ZBP1 could directly regulate the DDR, we reconstituted 
Zbp1 in Zbp1-/- EµM1 cells and treated the cells with Ara-C or DMSO for 16 
hours before performing an intracellular flow staining of γH2AX. However, 
Zbp1-/- EµM1 cells reconstituted with Zbp1-Gfp or Ctrl-Gfp showed similar 
response to DMSO or Ara-C treatment (Figure 7.7b).  This suggests that ZBP1 
might be inhibiting an irreversible form of damage in the cells, which could 










Figure 7.7 Knockdown of Zbp1 increased γH2AX. 
(a) Immunoblot analysis of BC2 cells transduced with retroviral vectors encoding 
Zbp1 shRNA and Gfp or control shRNA and Gfp, and cultured for 5 days before 
treatment with DMSO, 10 µM Ara-C or 4 µM aphidicolin. Data were kindly 
provided by Ms Munirah. Representative immunoblots from 3 indpendent 
experiments are shown. (b) Zbp1-/- EµM1 cells were transduced with retroviral 
vectors encoding Zbp1-Gfp (blue line) or with Ctrl-Gfp (red line). 5 days after 
transduction, cells were treated with 10 µM Ara-C (right panel) or DMSO (left 
panel) for 16 hrs and analyzed for the expression of γH2AX on GFP+ cells. 
Isotype stainings of Zbp1-/- EµM1 cells transduced with Zbp1-Gfp (black line) or 
Ctrl-Gfp (filled histogram) are shown. Representative histograms from 3 
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7.6 Regression is dependent on ATM in Zbp1-/-Eµ-Myc mice 
 We have previously shown that the ATM-dependent DNA damage 
contributes to the regression of B220low tumor cells in the blood of Eµ-Myc 
mice (Croxford et al., 2013). To establish if ATM-dependent DNA damage 
contributes to the regression of B220low tumor cells in the Zbp1-/-Eµ-Myc mice, 
we injected both Zbp1+/+Eµ-Myc mice and Zbp1-/-Eµ-Myc mice with the ATM 
inhibitor, KU60019, or DMSO control. We observed earlier survival in the 
Zbp1-/-Eµ-Myc mice in the KU60019 group (n = 8, median age = 106) 
compared to the DMSO group (n = 5, median age = undefined) (P = 0.029 by 
Log-rank (Mantel-Cox) Test and P = 0.401 by Gehan-Breslow-Wilcoxon 
Test) (Figure 7.8a). In contrast, the survival of Zbp1+/+Eµ-Myc mice in the 
KU60019 group (n =10, median age = 115.5) was not significantly different 
from the DMSO group (n = 6, median age = 138.5) (Figure 7.8a). In the 
DMSO control group of Zbp1-/-Eµ-Myc mice, there is a significant decrease in 
the absolute number of B220low cells in the blood between day 21-40 (n = 5, 
mean ± SD = 2.607 ± 0.925 103 per µl) and day 61-70 (n = 5, mean ± SD = 
0.927 ± 0.515 103 per µl) (P = 0.008) and between day 21-40 and day 71-80 (n 
= 5, mean ± SD = 0.356 ± 0.185 103 per µl) (P < 0.001) (Figure 7.8b). In 
contrast, in the KU60019 group of Zbp1-/-Eµ-Myc mice, the absolute number 
of B220low cells in the blood remains relatively constant and we did not 
observe a decrease in B220low cells in the blood between the different age 
groups (Figure 7.8b). In the Zbp1+/+Eµ-Myc mice, there was no significant 
difference in the absolute number of B220low cells in the blood between the 
KU60019-treated and DMSO-treated mice within each age group (Figure 
7.8b). The data support the importance of ATM-dependent DDR pathway in 




Figure 7.8 Regression is dependent on ATM in Zbp1-/-Eμ-Myc mice. 
Zbp1-/-Eμ-Myc (left panel) and Zbp1+/+Eμ-Myc mice (right panel) were injected 
i.p. with 5 mg/kg of the ATM inhibitor, KU60019 (bold) or DMSO (thin) at 37, 
39, 47, 49, 57, 59, 67 and 69 days of age. The survival of the mice was plotted 
using Kaplan-Meier survival analysis (a) and the number of B220low cells in the 
blood was measured at 37, 44, 54, 64 and 74 days of age (b). Statistical 
comparisons were conducted using Log-rank (Mantel-Cox) Test and Gehan-
Breslow-Wilcoxon Test (a) and Student’s t test (b). In (b), the results are 
expressed as mean ± SD. At least 5 mice were analysed for each treatment. *** p 
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7.7 Enhanced NF-κB activation in Zbp1-/-Eµ-Myc mice 
  p65/RelA is a member of the NF-κB family that includes other proteins 
such as c-Rel, RelB, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). 
Heterodimers of RelA/p65 and p50 are the most common in most cells, and 
the term NF-κB is frequently used to refer to this complex (Janssens and 
Tschopp, 2006). NF-κB can be activated in response to genotoxic stress via a 
highly regulated process involving ATM, NF-κB essential modulator (NEMO) 
and IKK (Wu et al., 2006). Western blot analyses revealed higher levels of 
phosphorylated NF-κB p65/RelA in B220+ cells from the spleen of Zbp1-/-Eµ-
Myc compared to Zbp1+/+ Eµ-Myc mice (Figure 7.9), which is consistent with 





              Several NF-κB target genes, including the pro-inflammatory 
cytokines TNF-α and IL-6, are associated with tumor development and 
progression in humans and mice (Karin and Greten, 2005). We measured the 
serum levels of IL-6 and TNF-α in Zbp1+/+, Zbp1-/-, Zbp1+/+Eµ-Myc and Zbp1-
/-Eµ-Myc mice.  
Figure 7.9 Enhanced activation of NF-κB in Zbp1-/-Eµ-Myc mice. 
Splenic B220+ cells (> 98% purity) from day 31-40 Zbp1+/+, Zbp1-/-, Zbp1+/+Eμ-
Myc and Zbp1-/-Eμ-Myc mice were probed with antibodies for phosphorylated 
NF-κB p65 subunit and NF-κB p65 subunit. Representative blots from 3 











            We did not observe any significant difference in serum IL-6 levels 
between Zbp1+/+Eµ-Myc (n = 13, mean ± SD = 52.283 ± 80.564 pg/ml) and 
Zbp1-/-Eµ-Myc (n = 13, mean ± SD = 122.429 ± 206.522 pg/ml) mice in 31-40 
days of age (Figure 7.10a). In mice bearing lymphomas, we did not observe 
any significant difference in serum IL-6 levels between Zbp1+/+Eµ-Myc (n = 7, 
mean ± SD = 141.100 ± 115.522 pg/ml) and Zbp1-/-Eµ-Myc (n = 6, mean ± SD 
= 44.727 ± 45.683 pg/ml) mice (Figure 7.10a). Serum IL-6 levels in 
lymphomas bearing Zbp1+/+Eµ-Myc was siginificantly higher than Zbp1+/+ (n 
= 5, mean ± SD = 12.757 ± 10.435 pg/ml) (P = 0.035) and Zbp1-/- (n = 7, mean 
± SD = 14.618 ± 15.573 pg/ml) (P = 0.014)  (Figure 7.10a). 
            We were unable to detect serum TNF-α levels in Zbp1+/+, Zbp1-/-, 
Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc mice during 31-40 days of age. Serum 
levels of  TNF-α was not significantly different between Zbp1+/+Eµ-Myc (n = 
5, mean ± SD = 29.465 ± 15.415 pg/ml) and Zbp1-/-Eµ-Myc (n = 5, mean ± SD 

















Figure 7.10 Serum levels of IL-6 and TNF-α.  
(a) ELISA of serum levels of IL-6 in Zbp1+/+ (n =	 5), Zbp1-/-(n = 7), Zbp1+/+Eµ-Myc 
(n = 13) and Zbp1-/-Eµ-Myc (n = 13) mice in early stage of the disease (31-40 days of 
age) and Zbp1+/+Eµ-Myc (n = 7) and Zbp1-/-Eµ-Myc (n = 6) mice bearing lymphomas. 
Statistical comparisons were conducted using Student’s t test and data are represented 
as means ± SD. * denote p < 0.05. (b) ELISA of serum levels of TNF-α in Zbp1+/+Eµ-
Myc (n = 5) and Zbp1-/-Eµ-Myc (n = 5) mice bearing lymphomas. 
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            The effects of cytokines on tumour cells could occur in the tumour 
microenvironment. In an alternative method, we sorted B220low cells from 
lymphoma bearing Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc mice and performed 
real-time PCR to determine the expression levels of TNF-α levels. The mRNA 
level of TNF-α was significantly higher in Zbp1-/-Eµ-Myc (n = 3, mean ± SD = 
1.329 ± 0.680) compared to Zbp1+/+Eµ-Myc (n = 3, mean ± SD = 0.091 ± 
0.045) (P = 0.035) (Figure 7.11). This is consistent with the data that there are 










Figure 7.11 Higer mRNA expressions of Tnf-α  in  Zbp1-/-Eµ-Myc. 
Real-time PCR of TNF-α levels in sorted B220low cells from lymphoma bearing 
Zbp1+/+Eμ-Myc (n = 3) and Zbp1-/-Eμ-Myc (n = 3) mice. Data were normalised 
to B220low cells in WT bone marrow. Gapdh was used as internal control. 
Statistical comparisons were conducted using Student’s t test and the results are 




















7.8 Increased cleaved CASPASE 8 in Zbp1-/-Eµ-Myc mice  
We observe higher expressions of Tnf-α in sorted B220+ cells of the 
Zbp1-/-Eµ-Myc mice compared to Zbp1+/+Eµ-Myc mice in both microarray 
(Figure 7.1) and real-time PCR (Figure 7.11). TNF-α produced may bind to 
TNFR1 on the tumour cells and activate caspase-8 which could result in 
apoptosis (Balkwill, 2009). To investigate presence of TNF-α mediated 
apoptosis, we performed an immunoblot using purified B220+ cells from bone 
marrows of day 41-65  Zbp1+/+, Zbp1-/-, Zbp1+/+Eµ-Myc,  and Zbp1-/-Eµ-Myc  
mice. We observed an increase in cleaved CASPASE 8 in Zbp1-/-Eµ-Myc mice 
compared to Zbp1+/+Eµ-Myc mice (Figure 7.12). The data is consistent with 
the idea that tumour cells in the Zbp1-/-Eµ-Myc mice produced more TNF-α 
leading to apoptosis triggered by caspase-8 activation.  
 
 
Figure 7.12 Increased cleaved CASPASE 8 in Zbp1-/-Eµ-Myc mice. 
 Bone marrow B220+ cells (> 98% purity) from day 41-65 Zbp1+/+, Zbp1-/-, 
Zbp1+/+Eμ-Myc and Zbp1-/-Eμ-Myc mice were probed with antibodies for 












7.9 Overexpression of ZBP1 in human cancer cells 
According to the data deposited in the ZBP1 gene expression profile 
database from Oncomine Research, the mRNA levels of  ZBP1 are 
significantly higher in human leukemia and head and neck cancer samples 
compared to normal samples (Figure 7.13). This is consistent with the 
potential role of ZBP1 as a tumour promoter from our data. As loss of  ZBP1 
might potentiate the DDR leading to apoptosis in the tumour cells, tumour 
cells might undergo selection pressure to upregulate ZBP1 expressions. 
However, more experiments had to be performed to verify the expression 
status of ZBP1 in various human cancer samples.  22/5/13 19:16 PMOncomine Main
Page 1 of 2https://www.oncomine.org/resource/main.html#a%3A1840%3Bac%3A7936%2C4604%3Bcso%3AsizeSmallL…200001287%3Bpg%3A1%3Bpvf%3A3066%2C39654%2C150004%3Bscr%3Adatasets%3Bss%3Aanalysis%3Bv%3A15
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Figure 7.13 Overexpression of ZBP1 in human cancer cells.  
ZBP1 mRNA expression in B cell leukemia samples (left panel) and in head and 
neck cancer samples (right panel) compared to normal human sample. The graphs 
were derived from published data available through the ONCOMINE database 




 Zbp1-/-Eµ-Myc mice had enhanced DDR response based on data from 
microarray, immunoblotting and immunocytochemistry analyses. In vivo 
inhibition of ATM shortened the survival and reversed the regression in Zbp1-
/-Eµ-Myc mice. In vitro cell lines derived from late stage Zbp1-/-Eµ-Myc mice 
displayed enhanced DNA damage. Knockdown of Zbp1 using shRNA 
increased the expressions of γH2AX. Consistent with enhanced DDR in Zbp1-
/-Eµ-Myc mice, we observed enhanced activation of NF-κB and increased 
expression of TNF-α in Zbp1-/-Eµ-Myc mice. The presence of cleaved 
CASPASE 8 suggested a role of TNF-α signalling in mediating apoptosis in 
Zbp1-/-Eµ-Myc mice. Deposited data from Oncomine Research suggest 






Chapter 8: Discussions and future perspectives 
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8.1 Summary of key findings  
  In the present study, we investigated the pathway linking the DDR to 
the induction of NKG2D ligands. The results show that the DDR is associated 
with the accumulation of DNA in the cytoplasm of affected cells, the 
phosphorylation of TBK1 and IRF3, nuclear localization of IRF3 and the 
production of interferon and certain cytokines in damaged cells. Furthermore, 
ligand induction by the DDR requires the action of TBK1 and IRF3, and 
transfection of undamaged cells with cytoplasmic DNA induces the expression 
of NKG2D ligands. Mice heterozygous for IRF3 had shortened survival and 
reduced levels of RAE1ε expressions. We proposed a model based on our 




Figure 8.1 Proposed model of regulation of NKG2D ligands.  
Genotoxic stress results in increased nuclear DNA damage, which would activate 
the ATM/ATR pathway. The increased nuclear DNA damage might result in 
accumulation of cytosolic DNA, which would be sensed by DNA sensors. This 
would activate STING, which would in turn activate TBK1/IKKε, leading to 
phosphorylation of IRF3. Activated IRF3 would increase NKG2D ligands 
expressions on tumor cells, facilitating the killing of the tumour cells by NK cells 
and T cells.  
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 To investigate the in vivo function of DNA sensors in 
lymphomagenesis, we cross mice deficient in Zbp1 with Eµ-Myc mice, a 
mouse model for Burkitt lymphomas. We made the surprising discovery that 
loss of ZBP1 prolongs the survival of Eµ-Myc mice significantly. In the 
absence of ZBP1, tumor cells accumulate DNA damage in the nucleus leading 
to the activation of ATM and the downstream DDR. Consequently, tumour 
cells deficient in ZBP1 undergo apoptosis, resulting in suppression of 
tumorigenesis and contributes to the increased survival of Zbp1-/-Eµ-Myc 
mice. Our findings reveal a novel role for ZBP1 in Eµ-Myc malignancy.  
8.2 Linkage of DNA sensing pathway with regulation of NKG2D ligands 
8.2.1 Regulation of NKG2D ligands by STING/TBK1/IRF3 
Our previous results provided evidence that genotoxic stress provides 
signals that induce NKG2D ligands and thus activate immune responses. As 
genotoxic stress is associated with both infections and cancer, these findings 
suggested a new scheme exploited by the immune system to discriminate 
between diseased or normal tissues or cells from normal ones. Although 
ATR/ATM and CHK1 were shown to play a role in the induction of NKG2D 
ligands downstream of DNA damage, little else was known about the 
pathway. 
The results herein link the DDR to the STING/TBK1/IRF3 signaling 
molecules, which constitute critical components of a major pathway common 
to many innate immune receptors, including TLRs and sensors that detect the 
cytosolic DNA and RNA introduced into cells by pathogens (Palm and 
Medzhitov, 2009; Takeuchi and Akira, 2010). The convergence of signaling 
by these pattern recognition receptors and the DDR enables diverse signals 
associated with disease, specifically pathogen constituents and disease-
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induced stress pathways, to provide a common output for immune activation. 
Previous studies provided indications that the DDR could induces IRF3 
phosphorylation and that certain Toll-like receptor ligands could induce Rae1 
gene expression in peritoneal macrophages (Hamerman et al., 2004; Kim et 
al., 1999b) (though not in several other cell types tested, data not shown), but 
the linkage of these pathways had not been explored.  
Previous studies demonstrated that many tumor cell lines and 
precancerous lesions exhibit constitutive activation of the DDR. The data 
herein demonstrated that Yac-1 tumor cells contain detectable cytosolic DNA 
and exhibit constitutive activation of TBK1/IRF3, thus providing at least a 
partial explanation for the constitutive expression of NKG2D ligands by these 
and other tumor cell lines. Whereas IRF3 activation is necessary for optimal 
cell surface expression of RAE1, it is unlikely to be sufficient, because we 
failed to observe reproducible cell surface expression in macrophages or 
dendritic cells exposed to various TLR agonists that activate IRF3 (data not 
shown).  
A key question is how the DDR induces TBK1 and IRF3. A most 
interesting finding in the present study was that cells subjected to DNA 
damaging agents accumulate DNA in the cytoplasm, suggesting that cytosolic 
DNA is a trigger leading to DNA damage-dependent activation of TBK1/IRF3 
and ultimately the expression of NKG2D ligands. It is well established that 
DNA sensor pathways activate STING/TBK1/IRF3 (Stetson and Medzhitov, 
2006; Takaoka et al., 2007; Yang et al., 2010). Additional support for the 
interpretation that cytoplasmic DNA induces RAE1 comes from the finding 
that transfection of DNA into cells resulted in the induction of RAE1 on the 
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cell surface. Most striking was the finding that NKG2D ligand expression 
critically depended on expression of Sting, a crucial mediator of DNA sensors 
(Goubau et al., 2010). Finally, induction of RAE1 by Ara-C partially relied on 
ZBP1. ZBP1 is a candidate sensor that is reported to activate TBK1/IRF3 
(Takaoka et al., 2007). However, additional TBK1-activating DNA sensors 
exist since MEFs from Zbp1-/--deficient mice mount a normal type-I IFN 
response to DNA (Ishii et al., 2008b; Takaoka et al., 2007). These sensors may 
be required for constitutive NKG2D ligand expression in Yac-1 cells. Hence, 
unidentified DNA sensors may play a predominant role in Yac-1 cells, or may 
function redundantly with ZBP1, in the induction of RAE1. How DNA 
damage and the DDR influence the accumulation of DNA in the cytosol and 
the subsequent biological response remains to be elucidated and worked out in 
detail, though it is possible that some of the cytosolic DNA corresponds to 
products of DNA repair, which is enhanced in cells in which the DDR is 
activated.  
It remains uncertain whether cytoplasmic DNA sensing is the sole 
mechanism for the activation of TBK1 and IRF3 in cells subjected to DNA 
damage. It is possible that the DDR contributes more directly to TBK1 or 
IRF3 activation by phosphorylating critical residues in these molecules. 
Although TBK1 and IRF3 were not identified as DDR-induced ATR or ATM 
substrates in a recent large-scale proteomic analysis (Matsuoka et al., 2007), it 
remains possible that CHK1 or another DDR effector kinases downstream of 
ATR will play such a role. 
Taken together, the in vitro study suggests that DNA damaging agents 
or tumorigenesis leads to the accumulation of cytoplasmic ssDNA and 
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dsDNA, one or both of which are recognized by DNA sensor pathways that 
activate STING/TBK1/IRF3. STING/TBK1/IRF3 activation, in turn, induces 
interferon and other cytokines and is required for the optimal expression of 
NKG2D ligands such as RAE1. RAE1 displayed on tumor cells or damaged 
cells can trigger the activation of innate immune cells, particularly NK cells, 
and enhance the responses of various T cell subsets.  
8.2.2 Nature of the cytosolic DNA in tumour cells 
Cytosolic DNA has been shown to accumulate in cells upon viral and 
bacterial infection or the uptake of apoptotic host cells (Ishii and Akira, 2006). 
Our data show the presence of cytosolic DNA in uninfected tumor cells. An 
intriguing question is where cytosolic DNA originates from and the 
mechanism leading to cytosolic DNA accumulation in tumor cells.  
 There are several reports that suggest the release of mitochondrial 
DNA (mtDNA) in the cytoplasm during cellular stress. Oxidized mtDNA 
released during apoptosis could activate the NLRP3 inflammasome, resulting 
in the production of IL-1β (Shimada et al., 2012). IL-5- or IFN-γ–primed 
eosinophils could release mitochondrial DNA in a reactive oxygen species 
(ROS)–dependent manner, but independent of eosinophil death and the release 
of DNA happened rapidly in a catapult-like manner (Yousefi et al., 2008). 
Neutrophils were also found to release mitochondrial DNA in a similar 
manner (Yousefi et al., 2009). 
It is also possible that the cytosolic DNA is derived from the genome. 
Cytosolic dsDNA could be generated during the DDR-dependent DNA repair 
of retroelements that can result in deletion of genomic DNA (Hedges and 
Deininger, 2007). Finally, it is possible that long tandem repeats, 
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retrotransposon elements and inverted repeats cause replication fork stalling 
resulting in dsDNA breaks, repair and the accumulation of cytosolic DNA 
(Brown et al., 2012). It is unclear if such deletions of DNA from the genome 
would result in increase genomic instability and if these DNA would integrate 
back into the genome as the constant removal of portions of the genome might 
be deleterious to the cell.    
It would be interesting to clone and sequence the DNA from the 
cytoplasm to verify its origins as outlined by the method in (Stetson et al., 
2008). This might provide insights in the mechanism leading to cytosolic 
DNA accumulation in tumour cells. Current literature suggests that the 
recognition of DNA in the cystoplasm occurs in a sequence independent but 
length dependent manner (Hornung and Latz, 2010). However, the sequence 
of the DNA might affect the efficiency of transcription of type 1 IFNs. The 
homo-copolymer poly (dA: dT) was the stongest activator of IRF3 
transcription while other homo-copolymers such as poly (dG: dC) or poly (dI: 
dC) were much less potent IFN inducers (Ishii et al., 2006a). As such, 
determining the length and sequence of the cytosolic DNA might provide 
information on the efficiency of IRF3 activation.  
The exact nature of the DNA ligand that is recognised by cells during 
an innate immune response is not known. DNA isolated from viruses, bacteria 
or mammals appears to be recognised equally well when transfected into 
responsive cells, so long as the DNA fragments are of sufficient length 
(Ablasser et al., 2009; Ishii et al., 2006b; Unterholzner et al., 2010b). An 
exception is the dsDNA mimic poly (dA-dT), which is specifically transcribed 
to dsRNA by RNA polymerase III (Ablasser et al., 2009; Chiu et al., 2009; 
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Unterholzner et al., 2010b). While all the cytosolic DNA sensors have been 
shown to bind DNA, only a handful have well-described DNA binding 
specificities. The crystal structure of the IFI16 HINb domain in a complex 
with DNA corresponds well with the observed sequence-independence of 
DNA recognition, as the binding occurs speficificty with the sugar-phosphate 
backbone of the DNA (Jin et al., 2012). A similar sequence-independent 
interaction has been seen in the structure of cGAS with DNA (Civril et al., 
2013; Gao et al., 2013). However, this does not provide further insights into 
why a mimumum length of dsDNA fragments are needed to elicit an IFN 
response in cells. 
Nucleic acids, especially DNA ligand, are emerging as key activators 
of the innate immune system in several situations beside viral infection. 
Intracellular DNA is a crucial PAMP during infection with intracellular 
bacteria, such as Mycobacterium tuberculosis (Manzanillo et al., 2012), 
Listeria monocytogenes (Rathinam et al., 2010; Stetson and Medzhitov, 2006; 
Stockinger et al., 2004), and Francisella tularensis (Atianand et al., 2011; 
Jones et al., 2010; Rathinam et al., 2010), and the protozoan Plasmodium 
falciparum (Sharma et al., 2011). DNA can also act as endogenous ‘danger’ 
signal during conditions of sterile inflammation and in autoimmune diseases 
such as SLE (Ablasser et al., 2013). It is thought that DNA from dead cells 
that is not effectively cleared by DNases, DNase I in the extracellular space, 
DNase II in lysosomes and TREX1 (three prime repair exonuclease 1) in the 
cytoplasm, could activate the DNA sensing pathways. DNA from dying cells 
has also been shown to be a ‘danger’ signal during the immune response to the 
vaccine adjuvant alum (Marichal et al., 2011). The proper 
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compartmentalization of DNA is important for the survival of the cell as the 
presence of DNA, both foreign and self, in the cytoplasm would trigger an 
innate immune response. Our data suggest that presence of cytosolic DNA in 
the tumour cells could act as endogenous “danger” signal that might trigger an 
immune response.  
8.2.3 Role of STING/TBK1/IRF3 in cancer 
STING is a transmembrane protein that is expressed in the 
endoplasmic reticulum and interacts with SSR2 signal sequence receptor 2 
(SSR2), a member of the translocon-associated protein (TRAP) complex 
(Ishikawa and Barber, 2008, 2011) that is associated with the exocyst complex 
(Heider and Munson, 2012). In the presence of cytosolic DNA, STING 
relocalizes with TBK1 from the endoplasmic reticulum to perinuclear vesicles 
that contain the exocyst component Sec5A (Ishikawa et al., 2009). STING 
could function as an adaptor in the DNA-induced IFN response, but as a 
receptor in the recognition of bacterial signalling molecules such as cyclic di-
AMP and di-GMP (Burdette et al., 2011). The role of STING in tumorigenesis 
has not been elucidated, but STING was found to induce apoptosis and 
possibly inhibit proliferation of B cell lymphoma cells (Jin et al., 2008). Many 
cancer cells have elevated cellular levels of ROS and it was reported that ROS 
could inhibit STING induction of IFNβ (Jin et al., 2010). Given the crucial 
role of STING in the activation of type I IFN in a variety of DNA virus 
infections, it is possible that STING may act as a tumor suppressor by 
preventing infection of cells by oncoviruses (Heiber and Barber, 2012).  
We have established a role of STING in regulating the expressions of 
NKG2D ligands. As mentioned in the introduction, NKG2D ligands were 
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thought to play an important role in immunesurveillance of tumours. Our data 
suggest that STING might play a role in regulating the immunesurveillance of 
tumours through regulation of NKG2D ligands expressions. Further 
experiments have to be done to investigate the relationship of STING in 
cancer. One possible experiment would be to cross mice deficient in Sting to 
Eµ-Myc mice. 
Both TBK1 and IKKε have been implicated in cancer.  Recent findings 
suggest a role for TBK1 and IKKε in RAS-induced transformation of cells 
(Chien et al., 2006; Clement et al., 2008; Ou et al., 2011). TBK1 is recruited 
and activated by a RalB-Sec5 effector complex that is needed for RAS-
mediated transformation. In addition, TBK1 was necessary to inhibit apoptosis 
in response to RAS activation possibly by activating the v-akt murine 
thymoma viral oncogene homolog (AKT) survival pathway (Barbie et al., 
2009; Chien et al., 2006; Chien and White, 2008; Ou et al., 2011). IKKε was 
identified as an effector of the phosphatidylinositol 3-kinase (PI3K)-AKT 
pathway and works with MAP kinase-ERK kinase (MEK) to promote 
transformation. siRNA-mediated inhibition of IKKε expression blocked 
proliferation, adhesion, and invasiveness of several tumor cell lines (Hsu et al., 
2012; Qin and Cheng, 2010). In patients with prostate cancer, there was a 
correlation between IKKε expression levels and malignancy of the cancer 
(Peant et al., 2011).  
We have established a role of TBK1/IKKε in regulating the 
expressions of NKG2D ligands. This additional function of TBK1/IKKε might 
contribute to their implicated roles in cancer. TBK1/IKKε has been previously 
thought to influence cancer progression through their effects on cell intrinsic 
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survival pathway, however, our results hint that TBK1/IKKε might also play a 
role in immunesurveillance of tumours through regulation of NKG2D 
expressions.  
IRF3 is one of the main regulators of type I IFN production needed for 
an effective anti-viral response (Taniguchi et al., 2001). Upon phosphorylation 
by TBK1 or IKKε in the cytoplasm, IRF3 forms a homodimer, translocate into 
the nucleus, and form part of an IFN enhanceosome consisting of IRF3, NF-
κB and activating transcription factor 2 (ATF2)-c-JUN heterodimers that 
recruit the histone acetyltransferase CREB-binding protein (CBP) to the IFNB 
promoter (Barber, 2011; Falvo et al., 2000; Merika et al., 1998). IRF3 also 
binds to the IFNA promoter in humans and Ifna4 promoter in mice (Civas et 
al., 2006).  
 IRFs and IFNs have been implicated in eliciting anti-tumor effects 
(Taniguchi et al., 2001). Expression of a dominant-negative mutant form of 
IRF3 in tumor cells increased their ability to form tumors in nude mice, while 
overexpression of IRF3 inhibited cell proliferation and increased apoptosis 
due to activation of p53 (Kim et al., 2007b) and possibly secretion of type I 
IFNs (Kim et al., 2003). 5,6-dimethylxanthenone-4-acetic acid (DMXAA), 
which was found to activate the TBK1-IRF3 pathway (Roberts et al., 2007), is 
currently in clinical trials for use as a chemotherapeutic drug against lung, 
ovarian and prostate cancer activates. However, some human lung cancer 
express constitutively activated IRF3 (Tokunaga et al., 2010). A study using 
high throughput screening of genes to identify factors that would stimulate 
human umbilical vein endothelial cell (HUVEC) proliferation, found that the 
TBK1-IRF3 axis was involved in the production of factors such as chemokine 
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(C-C motif) ligand 5 (CCL5) and IL-8 that can promote angiogenesis and 
tumor growth (Korherr et al., 2006).  
 Consistent with the proposed tumour suppressor effects of IRF3, we 
observed shortened survival of Eµ-Myc mice heterozygous for IRF3. Although 
the Irf3 mutation also suppresses expression of the neighboring Bcl2l12 gene, 
numerous experiments we performed argued that heterozygosity of that locus 
did not account for the observed effects. IRF3 is known to have tumor 
suppressor activities that are linked to its effect on apoptosis by transactivating 
genes, such as Isg56, Trail, and Noxa in a p53-independent manner 
(Grandvaux et al., 2002; Guo et al., 2000; Kirshner et al., 2005; Lallemand et 
al., 2007; Weaver et al., 2001). We observed no difference in the rates of 
apoptosis or proliferation comparing the WT and heterozygous tumor cells. 
These data support the conclusion that the accelerated tumorigenesis of 
heterozygous Irf3/Bcl2l12 Eµ-Myc mice is not due to effects of IRF3 or 
BCL2L12 on cell intrinsic apoptosis or proliferation. In addition, we observed 
lower expressions of IRF3 target genes in Irf3+/-Eµ-Myc mice compated to 
Irf3+/+Eµ-Myc mice, suggesting reduced activation of IRF3 and its tartget 
genes in Irf3+/-Eµ-Myc mice. This might contribute to the quickened survival 
in Irf3+/-Eµ-Myc mice due to less efficient removal of tumours.  
8.3 Role of ZBP1 in tumourigenesis 
8.3.1 A novel role of ZBP1 in B cell cancer 
Having established a role for STING/TBK1/IRF3 in cancer using in 
vitro system, we would like to investigate the potential role of the cytosolic 
DNA sensing pathway in vivo. We crossed mice deficient in Zbp1 to the Eµ-
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Myc and found that the loss of ZBP1 in Eµ-Myc mice promotes survival of the 
mice significantly.   
ZBP1 was the first cytoplasmic DNA sensor to be identified through 
studies done using in vitro system (Takaoka et al., 2007). However, cells 
derived from Zbp1-deficient mice responded normally to poly (dA: dT) and 
plasmid DNA and they did not display defects in immune function after 
infection with a DNA virus (Ishii et al., 2008a; Wang et al., 2008a). ZBP1 was 
also reported to interact with RIP3 to induced necrosis upon murine 
cytomegalovirus infection. Most of the studies done on ZBP1 were in the 
context of pathogen recognition and it is unclear if it plays a role in other 
systems. The only link of ZBP1 to cancer was suggested by the finding that 
ZBP1 is highly upregulated in the peritoneal lining tissue of mice bearing 
ascites tumors (Fu et al., 1999). Here, we provided evidence of a novel role of 
ZBP1 as loss of ZBP1 prolongs the survival of Eµ-Myc mice, a mouse model 
for Burkitt lymphomas, significantly.  
Although there are some reports that suggested an association between 
DNA sensors and tumorigenesis, much remains to be done to elucidate the 
physiological relationships as most of the study was performed using in vitro 
cell lines, transplantable tumours or induced tumour mice models (Chen et al., 
2006; Liao et al., 2011; Ludlow et al., 2005; Mazibrada et al., 2010). In 
addition, the exact mechanism of how these DNA sensors promote 
tumorigenesis remains to be elucidated. 
Activation of the intracellular DNA sensing pathways lead to the 
production of type I IFNs, which have both antiviral and antitumour activities. 
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Type I IFNs, which are pleiotropic in nature, consist of IFN-α, IFN-β, IFN-ω, 
IFN-ε and IFN-κ. Type 1 IFNs have been linked to suppression of 
tumorigenesis in both hematological and solid tumors (Dunn et al., 2006). 
Ifnar1-deficient mice are more susceptible to carcinogen-induced tumors and 
transplanted syngeneic tumors (Dunn et al., 2005). The inactivation of IFN-
consensus-sequence binding protein (ICSBP), a transcription factor involved 
in the regulation of IFN-stimulated genes, results in a chronic myeloid 
leukemia (CML)-like disease and many patients with untreated CML have low 
ICSBP levels (Schmidt et al., 1998). In addition, type I IFNs can enhance cells 
susceptibility to p53-mediated apoptosis (Takaoka et al., 2003). The 
production of endogenous IFN-α/β has been shown to reject tumour formation 
of sarcomas and carcinogen-induced tumours in immunocompetent mice (Kim 
et al., 2007a). IFN-α/β has also been shown to increase NK cells cytotoxic 
activity through activation of tumour necrosis factor related apoptosis-
inducing ligand (TRAIL) (Swann et al., 2007). In addition, it can also activate 
dendritic cells (DCs). Furthermore, tumour cells that express IFN-α induce 
anti-tumour immunity whereby it prevents apoptosis of tumour-specific T 
cells after stimulation.  
Activation of the intracellular DNA sensing pathways could activate 
NF-κB, which is a major transcription factor responsible for inflammation and 
driving the expression of various cytokines, chemokines and receptors needed 
for antigen presentation or immune recognition (Pahl, 1999).  Deregulation of 
NF-κB plays an important role in supporting pro-survival properties of tumor 
cells. The classical and non-canonical pathway can activate NF-κB. In the 
classical pathway, bacterial and viral infections, as well as pro-inflammatory 
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cytokines, activate the IKK complex and target IκBα for proteasomal 
degradation, releasing NF-κB dimers that are made up of REL-A/p65, REL/c-
REL and p50 subunits to translocate to the nucleus and mediate transcription 
of target genes (Karin and Greten, 2005). Certain TNF-family members can 
activate the non-canonical pathway leading to the phosphorylation of p100 by 
IKK-α and the degradation of its carboxy-terminal half by the proteasome in 
an IKK-β- independent and IKK-γ-independent manner (Karin and Greten, 
2005). This results in nuclear translocation of p52/REL-B dimers. The role of 
the classical pathway in cancer is more extensively studied than the alternate 
pathway. Somatic copy number alteration analysis of multiple human cancer 
samples identified NF-κB regulators such as TRAF6, IKBKB, IKBKG, and 
RIPK1 to be amplified (Beroukhim et al., 2010), consistent with its emerging 
importance in tumorigenesis. Studies have shown that NF-κB is constitutively 
activated in various tumor cells and inhibition of NF-κB in tumor cells induces 
apoptosis (Sovak et al., 1997).  
It remains unclear if these pathways are deregulated in Zbp1-/-Eµ-Myc. 
However, the anti-tumour activities of type 1 IFNs contrasted with the 
increased survival that we observed in Zbp1-/-Eµ-Myc. In addition, we reported 
a decreased in survival of the Irf3+/-Eµ-Myc mice compared to the Irf3+/+Eµ-
Myc mice, which is opposite to the phenotype we saw in Zbp1-deficient Eµ-
Myc mice. It is unknown why there is a divergent in the phenotypes observed 
for Zbp1-/-Eµ-Myc and Irf3+/-Eµ-Myc mice. It is likely that ZBP1 might be 
involved in other functions in addition to its IFN-dependent antiviral role. In 
addition, redundancy in the DNA sensors suggests that other sensors could 
play a role in mediating the phenotype observed in Irf3+/-Eµ-Myc mice. It 
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would be interesting to investigate the role of STING, which is a key adaptor 
molecule in the DNA sensing pathway, in Eµ-Myc lymphomagenesis. 
It remains to be investigated if ZBP1 has a unique role in B cell cancer 
or if it plays a crucial role in other forms of cancer. In addition, the other DNA 
sensors have not been crossed with Eµ-Myc mice and it remains to be seen if 
other DNA sensors also play a similar role as ZBP1 in Eµ-Myc 
lymphomagenesis. 
8.3.2 Role of ZBP1 in DDR 
Constitutive DNA damage and DDR signalling is found in most 
tumour cells including those of the bladder, breast and colon (Bartkova et al., 
2005). In the Eµ-Myc mouse model, expression of c-Myc in B cells under 
control of the immunoglobulin heavy chain enhancer (Eµ) results in a 
sustained Myc expression, which promotes DNA damage in tumour cells by 
increasing ROS production and replication stress, thus resulting in more DNA 
DSB (Pusapati et al., 2006a; Ray et al., 2006; Vafa et al., 2002a). 
We found that Zbp1-/-Eµ-Myc mice showed higher levels of γH2AX in 
splenocytes from B cells using two separate techniques, thus indicating 
sustained DNA DSB.  In addition, there was a corresponding increase in 
RAD51 foci in tumour B cells of Zbp1-/-Eµ-Myc mice. RAD51 is involved in 
DSB repair via homologous recombination and presence of its distinct foci 
indicates ongoing DNA repair (Suwaki et al., 2011). In addition, a recent 
study has identified Rad51 as a potential tumour suppressor gene (Bric et al., 
2009). As such, an increased RAD51 foci in Zbp1-/-Eµ-Myc mice, indicates 
higher levels of DNA repair occurring through HRR and which might 
contribute in suppressing tumours.  
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There are hints of a link between viral infection, DNA damage and the 
innate immune response based on previous reports on the ability of DNA 
viruses to induce and regulate the DDR (Weitzman et al., 2010), and the 
finding that DNA damage can result in the production of IFNs (Karpova et al., 
2002; Kim et al., 1999b; Weitzman et al., 2010). However, several molecules 
involved in the DDR such as the catalytic subunit of DNA-PK (DNA-PKcs), 
its binding partners KU70 and KU80 and ATM were shown to be dispensable 
for the IFN response to intracellular DNA in murine bone marrow-derived 
macrophages (Stetson and Medzhitov, 2006). Since then, other molecules in 
the DDR have been implicated in the STING-dependent response to 
intracellular DNA in other cell types. 
During DNA damage, a complex consisting of DNA-PKcs, KU70 and 
KU80 binds to DNA breaks and activates cell cycle arrest and the repair of 
damaged DNA. In addition, DNA-PKcs, KU70 and KU80 have been 
implicated in the IFN-dependent anti-viral response. KU70 has been linked to 
the DNA-induced production of IFN-λ (Zhang et al., 2011a). DNA-PKcs, 
KU70 and KU80 are required for the production of IFN-β following DNA 
transfection into mouse and human fibroblasts (Ferguson et al., 2012). 
Furthermore, DNA-PKcs, KU70 and KU80 were also involved in the response 
to the DNA viruses HSV-1 and Modified Vaccinia Ankara (MVA) in mouse 
embryonic fibroblasts (MEFs) and in mouse intradermal infection models in 
vivo.  
Recently, MRE11, an important molecule in the DDR, has been 
implicated in the sensing of cytosolic DNA (Kondo et al., 2013). MRE11 and 
the DNA-PKcs/KU70/KU80 complex are involved in HRR and NHEJ, which 
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are the two major repair pathways for dsDNA breaks. MRE11 was shown to 
be required for the DNA-induced IFN response in mouse bone marrow 
derived dendritic cells, MEFs and in a human cell line lacking MRE11 (Kondo 
et al., 2013). MRE11 was specifically involved in the detection of transfected 
dsDNA, but not in the recognition of pathogens such as HSV-1 and Listeria 
(Kondo et al., 2013). The physiological role of MRE11 during infection with 
other pathogens or during conditions of sterile inflammation remains to be 
investigated. 
ZBP1 had not been implicated in the DNA repair pathways. ZBP 
might have an effect on the two major repair pathways for dsDNA breaks in 
addition to its role as intracellular DNA sensor. Interestingly, ZBP1 is 
predominantly cytosolic and it is unclear how it could affect the nuclear DDR.  
In IFN or leptomycin B (LMB)-treated cells, ZBP1 can form foci in the 
nucleus that overlap with PML oncogenic domains or nuclear bodies (Pham et 
al., 2006). It remains to be seen if ZBP1 could translocate to the nucleus of the 
cell upon DNA damage and if it does, the exact role of ZBP1 in the nucleus. 
One of the cytosolic DNA sensors, IFI16, had been reported to shuttle 
between the nuclear and the cytoplasm (Unterholzner, 2013). Alternatively, 
there is increasing evidence for a cytoplasmic pool of ATM or extranuclear 
shuttling of ATM (Boehrs et al., 2007; Kim et al., 2010; Li et al., 2009a; Lim 
et al., 1998; McCool and Miyamoto, 2012; Watters et al., 1999). Loss of ATM 
could also affect various cytoplasmic signalling pathways, such as calcium 
and potassium ion mobilization (Chiesa et al., 2000; Famulski et al., 2003; 
Rhodes et al., 1998). In addition, in response to DNA damage, ATM was 
reported to regulate de novo synthesis of ceramide, which occurs in the 
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endoplasmic reticulum (Liao et al., 1999). It is possible that ZBP1 could 
interact with ATM in the cytoplasm and the relationship between ZBP1 and 
ATM remains to be investigated.  
8.3.3 Cell intrinsic versus cell extrinsic factors 
Oncogenic stress created by sustained MYC expression was shown to 
induce DNA damage in tumors cells of Eµ-Myc transgenic mice through DNA 
DSB and increased ROS, leading to cell cycle arrest or apoptosis. Previous 
study reported that B220+ cells in Eµ-Myc mice underwent apoptosis 
(Jacobsen et al., 1994; Sidman et al., 1993b), which could be triggered via cell 
intrinsic or cell extrinsic pathways. Our data shows increase activation of the 
DDR and the subsequent activation of p53 and PUMA in Eµ-Myc mice 
deficient in ZBP1, suggesting that changes in cell intrinsic pathways trigger 
the induction of apoptosis in these mice. 
In line with this idea, we observed an increase in apoptosis of B220low 
cells from bone marrow of Zbp1-/-Eµ-Myc mice from 41-64 days of age after 
incubating them in culture for 3 hours. We also observed increase activation of 
CASPASE 3, 7 and 8 in tumour cells of Zbp1-/-Eµ-Myc mice by immunoblot 
analysis. Because of the speed with which apoptotic cells are cleared by 
resident phagocytes in vivo, the analysis of Annexin V+/PI+ or PI- by flow 
cytometry can give only a semi-quantitative comparison of the true magnitude 
of apoptosis among B-lineage cells. Western blot analyses of cleaved 
CASPASE 3, 7 and 8 suggest that apoptosis may occur in higher frequency in 
vivo. This may explain why we did not observe any significant differences in 
apoptosis in both ex vivo bone marrow and spleen by Annexin V+/PI+ or PI- 
assay. 
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We observed a more pronounced activation of CASPASE 7 compared 
to CASPASE 3 by immunoblot analysis. Caspases-3 and -7 are activated by 
the same upstream activators and share overlapping substrate specificity. It is 
not clear the extent to which caspase-3 and caspase-7 share functions. 
However, there are some differences in their regulation, probably due to their 
divergent amino-terminal sequences. Removal of the amino terminus 
sequences of caspase-7 present only in the pro-enzyme and not the mature 
enzyme seem to potentiate caspase-7 activity. The authors speculate that these 
residues may play an undefined role in sequestering the enzyme from its 
upstream activators (Denault and Salvesen, 2003). Therefore, it is currently 
unknown why caspase-7 may be preferentially activated in Zbp1-/-Eµ-Myc 
mice. 
In addition, we did not find any significant differences in proliferation 
in both the bone marrow and spleen by immunoblot analysis of key cell cycle 
proteins, intracellular KI-67 staining and BrdU incorporation. These data 
support the finding that tumour cells from Zbp1-/-Eµ-Myc mice have increased 
DNA damage and thus are more prone to apoptosis either through ATM-
dependent apoptosis or TRAIL-induced apoptosis. Increase in apoptosis of 
tumour B cells in the bone marrow may lead to decrease in tumour load in the 
periphery, which is consistent with the observed regression of tumour cells.  
We have previously reported a role of T and NK cells in mediating 
regression in the Eµ-Myc mice (Croxford et al., 2013). We did not observe any 
difference in T cells activation markers in Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc 
and in co-stimulatory molecules important for T cells activation in Zbp1-/-Eµ-
Myc and Zbp1+/+Eµ-Myc mice. The percentage of tumour specific T cells 
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could be less than 1%; therefore it might be difficult to observe any significant 
difference in Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice. While we could not 
conclude that the immune system does not play a role in mediating the 
difference between Zbp1-/-Eµ-Myc and Zbp1+/+Eµ-Myc mice, our data suggest 
that differences in the cell intrinsic pathway might play a dominant role in the 
phenotype that we observed for Zbp1-/-Eµ-Myc mice. To conclusively 
delineate the effects of the immune system, one could perform a bone marrow 
chimera experiment (Iwasaki, 2006). It would also be useful to perform a 
transfer experiment where we transfer tumour cells from the Eµ-Myc mice to 
the severe combined immunodeficiency (SCID) common γ chain-/- mice 
(Bosma and Carroll, 1991), which lack functional T and B cells, and monitor 
survival of the mice. If T cells play a role, there should be no difference in 
survival of the SCID injected with tumour cells from either Zbp1-/-Eµ-Myc 
mice or Zbp1+/+Eµ-Myc mice. 
8.3.4 DNA-damaged induced NF-κB activation 
ZBP1 could interact with RIP1 and RIP3 to activate NF-κB (Kaiser et 
al., 2008; Rebsamen et al., 2009), but we did not observe an increase in NF-
κB activation in tumour cells from Zbp1-/-Eμ-Myc mice. In contrast, we saw 
higher phosphorylated p65/RELA in tumour cells from Zbp1-/-Eμ-Myc mice, 
which are most likely activated as part of the DDR (Wu et al., 2006). NF-κB is 
usually thought of as a pro-survival factor; however, recent papers suggest that 
NF-κB can contribute to genotoxic stressed-induced apoptosis (Bian et al., 
2001; Campbell et al., 2001; Campbell et al., 2004; Kaltschmidt et al., 2000; 
Ryan et al., 2000; Wang et al., 2002). Genetic activation of the NF-κB 
pathway could induce apoptosis in mouse and human c-MYC transformed 
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lymphomas (Klapproth et al., 2009). Overexpression of c-MYC could 
sensitize cells to NF-κB-induced apoptosis, and persistent inactivity of NF-κB 
signaling is a prerequisite for Myc-induced tumorigenesis (Klapproth et al., 
2009). 
The tumour suppressor status of a cell plays a decisive role in the 
functional outcome of NF-κB, thereby explaining the apparent dual role of 
NF-κB (Rocha et al., 2003a; Rocha et al., 2003b; Webster and Perkins, 1999). 
As NF-κB is a pro-survival factor and promote cellular proliferation, and p53 
induces cell cycle arrest or apoptosis, mechanisms that integrate the activities 
of both pathways in conditions when they are activated simultaneously must 
exist (such as genotoxic stress treatment). p53 could oppose NF-κB function 
by blocking its transcriptional activity through competition for coactivators or 
through conversion of Rel members from activators to repressors (Culmsee et 
al., 2003; Ravi et al., 1998). p53 could promote a switch from p52–Bcl-3 
activator complexes to p52–HDAC1 complexes (Rocha et al., 2003b) and 
another tumour suppressor gene ARF could induce phosphorylation of Thr505 
on RelA, resulting in its association with HDAC1, thereby inhibiting its 
transcriptional activity (Rocha et al., 2003a).  Both effects could explain why 
p53-induced NF-κB activation is not transcriptionally active and leads to 
apoptosis, most likely through p53-mediated repression of NF-κB induced 
antiapoptotic gene expression (Ryan et al., 2000). In addition, other p53-
independent mechanisms must exist to play a role in NF-κB ’s proapoptotic 
functions (Campbell et al., 2004).  
Several NF-κB target genes, including the pro-inflammatory cytokines 
TNF-α and IL-6, are associated with tumor development and progression in 
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humans and mice (Karin and Greten, 2005). These cytokines can promote 
proliferation, survival or apoptosis of tumor cells in an auto- and paracrine 
fashion (Grivennikov et al., 2010). 
IL-6 was found to promote or inhibit lymphoma progression depending 
on their development stage (Gilbert and Hemann, 2012). In the bone marrow, 
IL-6 signaling suppresses the development of B cell lymphomas by promoting 
differentiation of B cells, while IL-6 stimulates survival of transformed B 
cells. IL-6 also supports the survival of colitis-associated cancers in mice and 
promotes the growth of hepatocellular carcinomas (HCCs) (Bollrath et al., 
2009; Grivennikov et al., 2009; Naugler et al., 2007). In humans, serum levels 
of IL-6 predict the HCC development in patients with chronic hepatitis B 
(Wong et al., 2009). We did not find any difference in IL-6 between 
Zbp1+/+Eµ-Myc and Zbp1-/-Eµ-Myc mice, suggesting that the effects of IL-6 
might not explain the phenotype observed.  
 Low concentrations of TNF-α released from tumor-associated 
inflammatory cells augment tumor proliferation and progression, while high 
concentrations of TNF can induce necrosis of tumor cells (Karin and Greten, 
2005; Luo et al., 2004). In vivo the latter function of TNF-α may be more 
relevant as Tnfa-deficient mice and Tnfr1-deficient mice are resistant to 
carcinogen-induced tumors (Arnott et al., 2004; Moore et al., 1999). TNF-α 
could have pro- or anti- tumour effect depending on the status of the cell. The 
default pathway is induction of genes involved in inflammation and cell 
survival.  Upon binding to TNF-α, the activated TNFR1 induces a range of 
inflammatory mediators and growth factors through the AP1 transcription 
factors or IKKs which would activate NF-κB (Balkwill, 2009). Notably, NF-
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κB activation induces negative regulators of apoptosis such as FLIPL (also 
known as CFLAR), BCL-2 and superoxide dismutase. If NF-κB activation is 
insufficient, apoptosis occurs through caspase-8 and, through accumulation of 
intracellular reactive oxygen, sustained Jun amino-terminal kinase (JNK) 
activation and mitochondrial pathways (Balkwill, 2009). Apoptosis is a late 
response to TNF, unlike the rapid apoptosis that is induced by other members 
of the TNF superfamily such as FAS ligand (FASL) and TRAIL (also known 
as TNFRSF10C).   
Consistent with the notion that there are increased DNA damage and 
increased NF-κB activation in the Zbp1-/-Eµ-Myc mice, we observed an 
increase in mRNA expressions of Tnf-α in Zbp1-/-Eµ-Myc mice and increased 
in caspase-8 activation in Zbp1-/-Eµ-Myc mice. This suggests that TNF-α 
induced apoptosis that is mediated through caspase-8 may contribute to the 
increase in apoptosis seen in Zbp1-/-Eµ-Myc mice. However, further 
experiments had to be done to determine the importance of this pathway in 
Zbp1-/-Eµ-Myc lymphomagenesis. We could inhibit TNF-α in vivo using 
antibodies or small molecule inhibitors and obrserve the effects on regression 
or survival. In addition, we could cross mice deficient in TNF-α with Eµ-Myc 
mice and monitor disease progression. 
8.4 Future work 
In light of the phenotype that we observed for Zbp1-/-Eµ-Myc and 
Irf3+/-Eµ-Myc, it would be worthwhile to cross mice deficient in STING with 
Eµ-Myc. STING is an important adaptor molecule that links signals from the 
cytosolic DNA sensors to downstream effectors such as TBK1 and IRF3. In 
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addition, STING could act as a direct sensor of cyclic di-GMP (Burdette et al., 
2011).  
 An outstanding question is the mechanism of actions of ZBP1 in 
potentiating the DDR in Eµ-Myc lymphomagenesis. It would be interesting to 
identify potential interacting partners of ZBP1 by performing a co-
immunoprecipitate experiment with antibody against ZBP1. This might 
provide insights on the mechanism of actions of ZBP1 and if it interacts 
directly with any of the proteins that are involved in the DDR. In addition, it 
would be interesting to investigate the role of ZBP1 in other mouse models of 
cancer. Genome instability is one of the hallmarks of cancer (Hanahan and 
Weinberg, 2011). If ZBP1 could affect the DDR response, ZBP1 could 
presumably play an important role in different contexts of cancer.  
 It would be worthwhile to investigate if loss of ZBP1 could potentiate 
the DDR in human cancer cell lines. With the advent of clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 
system as an efficient gene-targeting technology (de Souza, 2013; Jinek et al., 
2012), it might be possible to utilise the system to generate ZBP1 knockout 
human cells and test if it affects the DDR in these cells. 
8.5 Conclusion 
Together our findings link genotoxic stress to cytoplasmic DNA sensor 
pathways and the induction of NKG2D ligands. The response to cytoplasmic 
DNA could provide a common trigger for NKG2D ligand induction in 
cancerous and infected cells, linking together protective NKG2D-mediated 
responses to infections, malignant transformation and cells with genomic 
damage (Gasser and Raulet, 2006c; Weitzman et al., 2004). We also link IRF3 
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and ZBP1, which are involved in the intracellular DNA sensing pathway, to B 
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